

CITATION REPORT

List of articles citing

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

DOI: 10.1126/science.272.5265.1167
Science, 1996, 272, 1167-70.

Source: <https://exaly.com/paper-pdf/26882889/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2244	Effects of collection, processing, and storage on RNA detection and quantification. 1999 , 26, 43-59		
2243	Antiretroviral therapy. 1996 , 80, 1263-82		2
2242	Viral quasi-species and recombination. 1996 , 263, 1577-1584		77
2241	Will killing the last HIV1 particle cure AIDS patients? Doesn't CMV activation and/or a graft-versus-host component of the disease, also have to be considered? I. First of two parts. 1996 , 50, 185-206		4
2240	AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue. 1996 , 50, 220-7		12
2239	Antiretroviral drugs for AIDS. 1996 , 348, 800-3		69
2238	Changing the natural history of HIV disease. 1996 , 348, 239-46		102
2237	Contribution of cohort studies in understanding HIV pathogenesis: introduction of the GRIV cohort and preliminary results. 1996 , 50, 480-7		23
2236	Antiretroviral Therapy in the 1990's: Recent Advances. 1996 , 15, 43-46		
2235	Viral counts count in HIV infection. <i>Science</i> , 1996 , 272, 1124-5	33.3	187
2234	Quantitative image analysis of HIV-1 infection in lymphoid tissue. <i>Science</i> , 1996 , 274, 985-9	33.3	522
2233	Treatment of HIV infection and its complications. 1996 , 17, 647-63		
2232	Perspective: research highlights of the University of Alabama at Birmingham Center for AIDS Research. Paradigm shifts, translational research, and CFARs. 1996 , 12, 1301-3		2
2231	Pediatric HIV infection: a primer for pharmacists. 1996 , NS36, 580-95		
2230	Efficacy measures: surrogates or clinical outcomes?. 1996 , 36, 767-70		18
2229	New strategies to combat HIV drug resistance. 1996 , 31, 47-50, 53-8		6
2228	Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals. 1996 , 93, 13125-30		76

2227	Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. 1996 , 93, 15323-8	96
2226	Development of HIV vectors for anti-HIV gene therapy. 1996 , 93, 11395-9	118
2225	Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. <i>Science</i> , 1996 , 273, 1856-62	33.3 2024
2224	Inhibition of complete development of <i>Cryptosporidium parvum</i> in Caco-2 cells. 1996 , 15, 897-900	3
2223	Viral load in relation to clinical outcome in HIV-infected children. 1996 , 15, 900	1
2222	Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment. 1996 , 24, 419-25	12
2221	Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. 1996 , 50, 293-302	83
2220	Wissenschaft. 1996 , 26, 300-302	
2219	Macaque models for AIDS vaccine development. 1996 , 8, 554-60	37
2218	HIV causes AIDS: Koch's postulates fulfilled. 1996 , 8, 613-8	23
2217	Intérêt de l'analyse en cytométrie en flux des sous-populations lymphocytaires chez les patients infectés par le VIH. 1996 , 1996, 53-57	
2216	HIV viral load markers in clinical practice. 1996 , 2, 625-9	448
2215	The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. 1996 , 2, 1240-3	1201
2214	Host factors and the pathogenesis of HIV-induced disease. 1996 , 384, 529-34	753
2213	The clinical utility of viral load monitoring in HIV infection: strengths and limitations. 1996 , 72, 393-5	1
2212	AIDS in 1996 Much Accomplished, Much to Do. 1996 , 276, 155	7
2211	Antiretroviral Therapy for HIV Infection in 1996. 1996 , 276, 146	261
2210	Vancouver: optimism, but at a cost. 1996 , 7, 385-7	1

2209 Making drugs work against HIV. **1996**, 31, 11, 15-6

2208 Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. **1996**, 335, 1350-6

397

2207 Major advances in the treatment of HIV-1 infection. **1997**, 35, 25-9

8

2206 Antiretroviral therapies in HIV-1 infection. **1997**, 6, 1049-61

9

2205 Assays for HIV with improved sensitivity and specificity. **1997**, 6, 965-83

2

2204 Energy expenditure in human immunodeficiency virus infection. **1997**, 336, 70-1

63

2203 Viral load and combination therapy for human immunodeficiency virus. **1997**, 336, 958-9; author reply 960

3

2202 Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. **1997**, 336, 1337-42

462

2201 Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. **1997**, 13, 857-63

62

2200 Psychological Aspects of the AIDS Epidemic. **1997**, 33, 89-107

2

2199 Preliminary findings of an in vitro human spleen mononuclear cell culture system for primary isolates of HIV type 1. **1997**, 13, 967-77

3

2198 Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. **1997**, 337, 734-9

1610

2197 The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. **1997**, 175, 1029-38

221

2196 Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for. **1997**, 73, 216-8

1

2195 Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study. **1997**, 176, 1161-7

57

2194 Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. **1997**, 176, 798-800

34

2193 Antiretroviral Therapy for HIV Infection in 1997. **1997**, 277, 1962

358

2192 Human immunodeficiency virus (HIV) RNA in plasma as the preferred target for therapy in patients with HIV infection: a critique. **1997**, 24, 116-22

9

2191	Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts 5 years. 1997 , 176, 665-71	22
2190	Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. 1997 , 175, 172-5	119
2189	HIV and aging as a model for immunosenescence. 1997 , 52, M261-3	9
2188	The clinical evaluation of antiviral agents. Report of a Working Party of the British Society for Antimicrobial Chemotherapy and the Society of Pharmaceutical Medicine. 1997 , 40 Suppl B, I-X, 1-67	
2187	Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. 1997 , 13, 393-9	20
2186	An approach to the validation of markers for use in AIDS clinical trials. 1997 , 24, 764-74	59
2185	Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. 1997 , 53-70	1
2184	Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. 1997 , 11, 1-17	171
2183	Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 x 10(6)/l. 1997 , 11, 53-7	32
2182	HIV-1 and the thymus. 1997 , 11, 403-14	55
2181	Viral load—Not yet the holy grail. 1997 , 73, 218-220	
2180	Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques. 1997 , 13, 635-45	70
2179	Study of spontaneous apoptosis in HIV+ patients: correlation with clinical progression and T cell loss. 1997 , 13, 1501-8	32
2178	Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. 1997 , 336, 1487-93	345
2177	A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. 1997 , 25, 2979-84	258
2176	Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and nondemented patients with acquired immunodeficiency syndrome. 1997 , 3, 299-303	26
2175	Law and Medicine. 1997 , 277, 1866	4
2174	Infectious Diseases. 1997 , 277, 1865	1

2173	Acute Primary HIV Infection. 1997 , 278, 58	61
2172	New approaches to using antiretroviral therapy for the management of HIV Infection. 1997 , 31, 228-36	10
2171	Correlates of latent and productive HIV type-1 infection in tonsillar CD4(+) T cells. 1997 , 94, 9332-6	21
2170	New Anti-CMV Strategies. 1997 , 21, 229-238	
2169	Primary HIV infection--a public health opportunity. 1997 , 87, 1928-30	43
2168	Janus considers the HIV pandemic--harnessing recent advances to enhance AIDS prevention. 1997 , 87, 10-2	14
2167	Annotation: wanted--a simple and meaningful HIV staging system. 1997 , 87, 546-8	1
2166	New Advances in the Pharmacological Treatment of Human Immunodeficiency Virus (HIV) Infection: Focus on Protease Inhibitors. 1997 , 10, 20-51	2
2165	Overview of protease inhibitors. 1997 , NS37, 543-51	5
2164	Selecting and validating biologic markers for drug development. 1997 , 37, 355-62	33
2163	Extracorporeal whole body hyperthermia treatment of HIV patients, a feasibility study. 1997 , 13, 577-86	8
2162	Quantification of HIV in semen. 1997 , 11, 987-993	123
2161	Enhancing antibodies in HIV infection. 1997 , 115 Suppl, S127-40	60
2160	Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. 1997 , 11, 169-75	21
2159	Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma. 1997 , 11, F47-52	64
2158	Early and late HIV-1 RNA level and its association with other markers and disease progression in long-term AIDS-free homosexual men. 1997 , 11, 1383-8	24
2157	Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. 1997 , 11, F113-6	193
2156	Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. 1997 , 11, 477-83	49

2155	Implications of HIV variability for transmission. 1997 , 11, 1???15	6
2154	Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. 1997 , 11, 895-901	52
2153	Subtype-specific problems with quantification of plasma HIV-1 RNA. 1997 , 11, 859-65	118
2152	AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. 1997 , 11, 1799-806	127
2151	CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. 1997 , 66, 273-311	86
2150	Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. 1997 , 126, 929-38	205
2149	The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. 1997 , 94, 254-8	229
2148	Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. 1997 , 126, 939-45	192
2147	Association between CCR5 genotype and the clinical course of HIV-1 infection. 1997 , 127, 882-90	197
2146	Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. 1997 , 13, 555-61	15
2145	Branched DNA for quantification of viral load. 1997 , 26, 9-13	19
2144	Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment. 1997 , 8, 243-9	
2143	Polymorphisms within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type 1-seropositive persons. 1997 , 175, 188-90	41
2142	AIDS and ophthalmology: a period of transition. 1997 , 124, 227-33	128
2141	Immunology of HIV and pregnancy. The effects of each on the other. 1997 , 24, 821-31	14
2140	Antiretroviral agents. Current usage. 1997 , 15, 319-29	7
2139	Sexual transmission of HIV. 1997 , 336, 1072-8	823
2138	Natural history of HIV infection in women. 1997 , 24, 743-58	15

2137	Pediatric HIV-1 infection. 1997 , 24, 911-24		1
2136	Recent advances in the management of human immunodeficiency virus infection. 1997 , 72, 854-8; quiz 859		7
2135	Pathogenesis of HIV infection in children. 1997 , 7, 19-31		1
2134	Antiretroviral therapy in the pregnant woman. 1997 , 24, 833-54		2
2133	Progressive immunodeficiency in a patient with IgA deficiency. 1997 , 79, 297-301		19
2132	HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient. 1997 , 96, 137-55		46
2131	British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. 1997 , 349, 1838-1839		1
2130	Emerging international consensus for use of antiretroviral therapy. 1997 , 349, 1042		11
2129	Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?. 1997 , 9, 21-36		16
2128	Management of Asymptomatic HIV Infection. 1997 , 1, 105-117		
2127	Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. 1997 , 126, 946-54		1451
2126	Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. 1997 , 13, 737-42		126
2125	Biology of HIV-1 in women and men. 1997 , 24, 731-42		1
2124	Clinical chemistry. 1997 , 69, 165R-229R		77
2123	Current problems and the future of antiretroviral drug trials. <i>Science</i> , 1997 , 276, 548-50	33:3	22
2122	Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. <i>Science</i> , 1997 , 276, 960-4	33:3	524
2121	Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes. <i>Science</i> , 1997 , 278, 1462-4	33:3	59
2120	Serial quantification of the human immunodeficiency virus in an arthroscopic effluent. 1997 , 13, 739-42		6

2119	Women and HIV. Epidemiology and global overview. 1997 , 24, 705-29	34
2118	A novel highly reproducible quantitative competitive RT PCR system. 1997 , 274, 338-52	22
2117	A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. 1997 , 337, 725-33	2231
2116	Candidate antiretroviral agents for use in postexposure prophylaxis. 1997 , 102, 25-31	74
2115	Dermatologic manifestations of human immunodeficiency virus infection. 1997 , 9, 205-242	2
2114	Adherence as a particular issue with protease inhibitors. 1997 , 8 Suppl, 10-7	28
2113	HIV RNA quantitation: marker of HIV infection. 1997 , 8, 31-8	1
2112	HIV plasma viral load in the clinical setting: measurement and interpretation. 1997 , 8, 21-3	
2111	T cell turnover in HIV-1 disease. 1997 , 7, 583-9	105
2110	Current antiretroviral therapy in the treatment of HIV infection. 1997 , 16, 224-34	6
2109	The impact of high-risk patients on the results of clinical trials. 1997 , 50, 1089-98	96
2108	Predicting outcomes in HIV-infected veterans: I. Progression to AIDS. 1997 , 50, 1231-40	7
2107	Predicting outcomes in HIV-infected veterans: II. Survival after AIDS. 1997 , 50, 1241-8	12
2106	Impaired early growth of infants perinatally infected with human immunodeficiency virus: correlation with viral load. 1997 , 130, 915-22	57
2105	Antigenic diversity thresholds and hazard functions. 1997 , 139, 59-68	1
2104	What went right: why is HIV a treatable infection?. 1997 , 3, 714-7	6
2103	British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. 1997 , 349, 1086-1092	192
2102	Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR. 1997 , 350, 256-9	21

2101	HIV-1 viral load, phenotype, and resistance in a subset of drug-naïve participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. 1997 , 350, 983-90	109
2100	Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. 1997 , 337, 1267-74	482
2099	Molecular approaches for the diagnosis of syphilis. 1997 , 17, 35-39	
2098	International expenditure projections for pharmacotherapeutic advances in the treatment of HIV/AIDS. 1997 , 19, 86-95; discussion 84-5	3
2097	Les traitements antirétroviraux. 1997 , 27, 23-30	
2096	Measuring human immunodeficiency virus type 1 RNA viral load. 1997 , 54, 1646-51	1
2095	Resistance, remission, and qualitative differences in HIV chemotherapy. 1997 , 3, 273-83	24
2094	Increased viral load and suicidal ideation in an HIV-infected patient. 1997 , 126, 86-7	1
2093	Polycythemia vera in acromegaly. 1997 , 126, 87	2
2092	In search of a selective antiviral chemotherapy. 1997 , 10, 674-93	209
2091	To screen or not to screen for HIV in pregnant women. Pros and cons of routine screening and use of home test kits. 1997 , 102, 77-8, 83-6, 89-90	2
2090	Prognostic markers and surrogate markers of clinical progression in HIV infection. 1997 , 8, 552-6; quiz 557	3
2089	Cyclophosphamide-induced bladder cancer. 1997 , 126, 86	1
2088	Physicians' attitudes about patients in the persistent vegetative state. 1997 , 126, 89-90	
2087	Elevated serum amylase levels after seizures. 1997 , 126, 89	1
2086	Use of HIV viral load in clinical practice: back to the future. 1997 , 126, 983-5	19
2085	Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. 1997 , 41, 284-91	209
2084	Antiretroviral therapy for HIV infection. Heartening successes mixed with continuing challenges. 1997 , 102, 100-7, 111-3, 119-20	1

2083	Update in general internal medicine. 1997 , 127, 43-51	1
2082	Cyclophosphamide-Induced Bladder Cancer. 1997 , 126, 86	
2081	Dysregulation of Membrane-Bound Tumor Necrosis Factor- α and Tumor Necrosis Factor Receptors on Mononuclear Cells in Human Immunodeficiency Virus Type 1 Infection: Low Percentage of p75-Tumor Necrosis Factor Receptor Positive Cells in Patients With Advanced Disease and High Viral Load. 1997 , 90, 2670-2679	27
2080	Molecular diagnostics of infectious diseases. 1997 , 43, 2021-2038	212
2079	Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. 1997 , 159, 17-29	94
2078	Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. 1997 , 3, 205-11	1041
2077	Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. 1997 , 3, 665-70	28
2076	The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. 1997 , 3, 1160-2	225
2075	Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. 1997 , 75, 389-96	60
2074	AIDS: decline and fall of immune surveillance?. 1997 , 7, R136-40	31
2073	Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. 1997 , 78, 145-58	58
2072	Antiretroviral therapy for pregnant women. 1997 , 176, 478-89	87
2071	Development of a quantitative competitive polymerase chain reaction for human herpesvirus 8. 1997 , 64, 19-26	30
2070	Quantification of HIV-1 viral RNA and proviral DNA by isotopic competitive PCR. 1997 , 66, 269-82	8
2069	Stability of HIV-1 RNA in blood during specimen handling and storage prior to amplification by NASBA-QT. 1997 , 67, 199-207	36
2068	Determination of HCV RNA concentration by direct quantitation of the products from a single RT-PCR. 1997 , 69, 113-24	1
2067	Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies. 1997 , 35, 65-82	5
2066	Methods, interpretation and applications of HIV-1 viral load measurements. 1997 , 19, 1-5	13

2065	Circulating CD8 T cells show increased interferon-gamma mRNA expression in HIV infection. 1997 , 178, 91-8	26
2064	Relationship of plasma HIV-RNA levels and levels of TNF-alpha and immune activation products in HIV infection. 1997 , 84, 36-45	49
2063	Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. 1997 , 85, 21-7	20
2062	Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection. 1997 , 228, 340-9	66
2061	Activity of human immunodeficiency virus type 1 promoter/TAR regions and tat1 genes derived from individuals with different rates of disease progression. 1997 , 232, 319-31	31
2060	Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV(KU-1). 1997 , 234, 328-39	19
2059	Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities. 1997 , 236, 307-15	16
2058	Current antiretroviral therapy: an overview. 1997 , 6, 471-4	21
2057	Virus load and antigenic diversity. 1997 , 59, 881-96	9
2056	[Combination treatment of HIV infection]. 1997 , 38, 1146-53	1
2055	Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. 1997 , 19, 69-83	33
2054	The role of viral dynamics in the pathogenesis of HIV disease and implications for antiviral therapy. 1997 , 18, 267-83	2
2053	Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. 1997 , 18, 305-22	32
2052	HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. 1997 , 18, 341-54	23
2051	Direct quantification of HIV-1 RNA by capillary electrophoresis with laser-induced fluorescence. 1997 , 697, 189-94	22
2050	Baseline HIV type 1 load predicts the long-term clinical outcome of infected patients. The 'positive feedback theory'. 1997 , 55, 123-5	4
2049	Immune correlates of protection from HIV infection and AIDS. 1997 , 18, 4-8	30
2048	Intérêt de l'étude de la charge virale dans l'instauration et la surveillance des traitements anti-VIH. 1997 , 1997, 53-57	

2047	Kinetic investigations by fluorescence correlation spectroscopy: the analytical and diagnostic potential of diffusion studies. 1997 , 66, 211-28	150
2046	Virus load and antigenic diversity. 1997 , 59, 881-896	1
2045	Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals. 1997 , 30, 1-9	19
2044	Reduction of interlaboratory variability in flow cytometric immunophenotyping by standardization of instrument set-up and calibration, and standard list mode data analysis. 1997 , 30, 10-22	27
2043	Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. 1997 , 184, 203-17	203
2042	Frequency and determinants of use of antiretroviral and prophylactic therapies against <i>Pneumocystis carinii</i> Pneumonia (PCP) before AIDS diagnosis in Italy. 1998 , 14, 41-7	6
2041	Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients. 1998 , 18, 235-40	6
2040	[Clinical studies on the use of protease inhibitors in HIV infection. Answers and questions]. 1998 , 39, 927-34	
2039	Proposed CD4(+) T-cell criteria for staging human immunodeficiency virus-infected Chinese adults. 1998 , 89, 11-22	12
2038	A minimally replicative HIV-2 live-virus vaccine protects <i>M. nemestrina</i> from disease after HIV-2(287) challenge. 1998 , 242, 150-60	34
2037	Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. 1998 , 241, 251-9	74
2036	Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells. 1998 , 246, 53-62	7
2035	Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. 1998 , 248, 95-107	53
2034	HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. 1998 , 391, 397-401	854
2033	Early participation in an HIV cohort study slows disease progression and improves survival. 1998 , 244, 479-487	6
2032	Micronutrients and HIV infection: a review. 1998 , 52, 157-63	32
2031	Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. 1998 , 4, 215-21	377
2030	Chemokine genes--beating the odds. 1998 , 4, 275-7	22

2029	Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?. 1998 , 164, 37-51	49
2028	Natural history of SIVmac BK28 and H824 infection in <i>Macaca nemestrina</i> . 1998 , 27, 87-93	4
2027	The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. 1998 , 36, 307-11	18
2026	Detection and analysis of cytokine mRNA in tissues and cell lines. 1998 , 212, 113-23	12
2025	Rationale for immune-based therapies for HIV-1 infection. 1998 , 131, 197-206	6
2024	The comparative pathology of the lentiviruses. 1998 , 119, 333-95	18
2023	Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. 1998 , 37, 1-16	27
2022	Cartesian coordinate analysis of viral burden and CD4+ T-cell count in human immunodeficiency virus type-1 infection. 1998 , 38, 181-94	1
2021	The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. 1998 , 38, 153-79	321
2020	Quantitative reverse transcription strand displacement amplification: quantitation of nucleic acids using an isothermal amplification technique. 1998 , 259, 226-34	43
2019	Target cell limited and immune control models of HIV infection: a comparison. 1998 , 190, 201-14	248
2018	Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. 1998 , 192, 81-98	92
2017	Hepatitis C viral infection in the immunosuppressed patient. 1998 , 27, 2-6	61
2016	Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. 1998 , 28, 1702-6	44
2015	Statistical issues for HIV surrogate endpoints: point/counterpoint. 1998 , 17, 2435-2462	33
2014	Detection of HIV-RNA-positive monocytes in peripheral blood of HIV-positive patients by simultaneous flow cytometric analysis of intracellular HIV RNA and cellular immunophenotype. 1998 , 31, 265-74	39
2013	Longitudinal study of plasma HIV-1 RNA concentrations during the asymptomatic stage of HIV infection measured using AMPLICOR HIV monitor and NASBA HIV-1 RNA QT tests. 1998 , 54, 60-68	2
2012	Role of HIV-1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T-cell count. 1998 , 56, 259-263	12

2011	Human immunodeficiency virus mutation and changes in CD4 T-cell levels during antiretroviral therapy. 1998 , 17, 301-3	2
2010	Plasma HIV-1 load and disease progression in HIV-infected patients in Hungary. 1998 , 4, 52-5	
2009	Development of a DNA biochip: principle and applications1The submitted manuscript has been authored by a contractor of the US Government under contract No. DE-AC05-96OR22464. Accordingly, the US Government retains a nonexclusive royalty-free license to publish or reproduce the published form of this contribution, or allow others to do so, for US Government purposes.1.	37
2008	Cutaneous polyarteritis nodosa: a report of a case associated with melioidosis (Burkholderia pseudomallei). 1998 , 37, 433-6	12
2007	Diagnosing HIV-related disease: using the CD4 count as a guide. 1998 , 13, 131-6	51
2006	Progression of HIV in haemophilia. 1998 , 4, 601-9	5
2005	Antiretroviral therapy for patients with HIV disease. 1998 , 45, 221-8	32
2004	Early increase of CD4+ CD45RA+ and CD4+ CD95- cells with conserved repertoire induced by anti-retroviral therapy in HIV-infected patients. 1998 , 111, 3-11	16
2003	Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. 1998 , 19, 44-8	59
2002	Etude de la mutation au codon 215 chez dix patients progresseurs lents sous zidovudine. 1998 , 28, 652-657	
2001	Opiates as potential cofactors in progression of HIV-1 infections to AIDS. 1998 , 83, 77-87	144
2000	Antiretroviral treatment in 1998. 1998 , 352, 1919-22	75
1999	Surrogacy in HIV-1 clinical trials. 1998 , 351, 536-7	21
1998	Towards an HIV-1 vaccine: lessons from studies in macaque models. 1998 , 16, 904-15	34
1997	[Molecular biology and transfusional viral safety]. 1998 , 5, 22-38	3
1996	[Importance of molecular biology in retrovirus and herpesvirus infections]. 1998 , 5, 39-46	
1995	Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity. 1998 , 1, 21-8	11
1994	Oral mucosal transudate testing for HIV-1 antibodies: a clinical update. 1998 , 9, 68-72	7

1993 La biologie moléculaire en virologie: le bon outil au bon moment. **1998**, 13, 195-199

1992 Human immunodeficiency virus (HIV) in America, 1981 to 1997: epidemiologic and therapeutic considerations. **1998**, 19, 122-7 4

1991 Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. **1998**, 147, 173-205 67

1990 Viral dynamics in HIV-1 infection. **1998**, 93, 665-71 176

1989 THE RELATIONSHIP OF PREGNANCY TO HIV DISEASE. **1998**, 18, 329-344 1

1988 Principles of current adult HIV pharmacotherapy. **1998**, 80, 363-7; quiz 367-8

1987 HIV infection and AIDS. **1998**, 25, 759-74 5

1986 Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. **1998**, 14, 1053-8 21

1985 Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. **1998**, 13, 697-705 22

1984 Acute human immunodeficiency virus type 1 infection. **1998**, 339, 33-9 542

1983 Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. **1998**, 10, 187-94 56

1982 The clinical utility of viral quantitation using molecular methods. **1998**, 10, 25-47 59

1981 Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. *Science*, **1998**, 279, 2103-6 333 1247

1980 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. **1998**, 338, 853-60 7930

1979 Primary HIV Infection/Acute Retroviral Syndrome: An Intervention Opportunity for Correctional Facilities. **1998**, 5, 51-62 1

1978 The predictive value of several markers in the progression to acquired immunodeficiency syndrome. **1998**, 36, 169-73 7

1977 Audit of HIV RNA quantitation measurements in the West Midlands: a preliminary report. Collaborating HIV Physicians. **1998**, 9, 361-3 2

1976 Urinary neopterin as a prognostic index of survival time in HIV-1 infection. **1998**, 9, 326-9 1

1975 Übersicht. **1998**, 22, 6-13

1974	Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. 1998 , 26, 323-9	65
1973	Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. 1998 , 177, 40-7	186
1972	Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. 1998 , 178, 1279-87	106
1971	Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life. 1998 , 32, 525-30	15
1970	Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. 1998 , 134, 940-5	18
1969	A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. 1998 , 339, 1269-76	182
1968	Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: evidence of variabilities in levels of virion-associated RT. 1998 , 177, 1221-9	30
1967	Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. 1998 , 279, 35-40	157
1966	Antiretroviral Drug Development and Information on the Internet. 1998 , 2, 141-151	
1965	Hematologic and virologic effects of lineage-specific and non-lineage-specific recombinant human and rhesus cytokines in a cohort of SIVmac239-infected macaques. 1998 , 14, 651-60	8
1964	Anti-HIV type 1 memory cytotoxic T lymphocyte responses associated with changes in CD4+ T cell numbers in progression of HIV type 1 infection. 1998 , 14, 1423-33	25
1963	Plasma virus load evaluation in relation to disease progression in HIV-infected children. 1998 , 14, 571-7	18
1962	9-Nitrocamptothecin inhibits tumor necrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone. 1998 , 14, 39-49	11
1961	Primary HIV-1 infection: diagnosis and prognostic impact. 1998 , 12, 751-8	7
1960	Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. 1998 , 14, 453-9	59
1959	A genetic and viral load analysis of the simian immunodeficiency virus during the acute phase in macaques inoculated by the vaginal route. 1998 , 14, 171-81	80
1958	Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha. 1998 , 14, 727-34	36

1957	Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. 1998 , 14, 475-81	32
1956	Long-term nonprogression in HIV infection: methodological issues and scientific priorities. Report of an international European community-National Institutes of Health Workshop, The Royal Society, London, England, November 27-29, 1995. Scientific Coordinating Committee. 1998 , 14, 1211-28	15
1955	Can we predict the prognosis of HIV infection? How to use the findings of a prospective study. 1998 , 74, 149-54	3
1954	Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. 1998 , 14, 869-76	130
1953	Coinfection with HTLV-I and HIV: increase in HTLV-I-related outcomes but not accelerated HIV disease progression?. 1998 , 12, 619-23	15
1952	Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. 1998 , 178, 1803-5	27
1951	The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. 1998 , 188, 1159-71	95
1950	HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. 1998 , 187, 1113-22	166
1949	Productive infection of neonatal CD8+ T lymphocytes by HIV-1. 1998 , 187, 1139-44	72
1948	Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/microL. SEROCO & HEMOCO Study Group. 1998 , 27, 897-903	13
1947	The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis. 1998 , 26, 1072-3	38
1946	Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. 1998 , 17, 411-8	28
1945	Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. 1998 , 33, 201-35	41
1944	Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. 1998 , 19, 6-18	70
1943	Antiretroviral drugs and the central nervous system. 1998 , 12, 1941-55	141
1942	The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. 1998 , 12, 1639-43	59
1941	Transforming laboratory test results to improve clinical outcome predictions in HIV patients. Swiss HIV Cohort Study. 1998 , 17, 442-9	6
1940	Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice. 1998 , 12, 865-72	9

1939	Susceptibility of peripheral blood mononuclear cells to apoptosis is correlated to plasma HIV load. 1998 , 17, 419-23	13
1938	Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection. 1998 , 12, 1285-9	15
1937	Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. 1998 , 12, 1483-90	70
1936	Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. 1998 , 19, 238-44	32
1935	Analysis of life-long strategies to prevent <i>Pneumocystis carinii</i> pneumonia in patients with variable HIV progression rates. 1998 , 12, 1317-25	7
1934	Longitudinal HIV-1 RNA levels in a cohort of homosexual men. 1998 , 18, 155-61	50
1933	Pediatric AIDS prognosis using somatic growth velocity. 1998 , 12, 1361-9	28
1932	Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. 1998 , 12, F191-6	29
1931	Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. 1998 , 148, 1117-26	57
1930	Differences in susceptibility to AIDS development: a cohort study of Danish and American homosexual-bisexual men, 1981 to 1995. 1998 , 18, 270-6	1
1929	Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. 1998 , 19, 89-97	20
1928	The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. 1998 , 12, F9-14	158
1927	Stressful events, pessimism, natural killer cell cytotoxicity, and cytotoxic/suppressor T cells in HIV+ black women at risk for cervical cancer. 1998 , 60, 714-22	74
1926	A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. 1998 , 101, 335-43	92
1925	Quantification of viral load: clinical relevance for human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. 1998 , 41, 24-34	40
1924	Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. 1998 , 12, 1745-51	31
1923	Heterosexual HIV-1 transmission and viral load in hemophilic patients. 1998 , 17, 42-5	52
1922	Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis. 1998 , 17, 245-52	50

1921	Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis. 1998 , 18, 126-35	43
1920	HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors. 1998 , 18, 229-33	22
1919	Serum retinol and HIV-1 RNA viral load in rapid and slow progressors. 1998 , 18, 21-6	4
1918	Impact of opportunistic disease on survival in patients with HIV infection. 1998 , 12, 29-33	101
1917	Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. 1998 , 95, 8869-73	645
1916	Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. 1998 , 12, 1267-73	50
1915	Serum retinol and HIV-1 RNA viral load in rapid and slow progressors. 1998 , 18, 401-6	11
1914	Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. 1998 , 12, 1437-49	39
1913	Disease progression and survival following specific AIDS-defining conditions. 1998 , 12, 1007-1013	49
1912	Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. 1998 , 12, 1347-52	25
1911	Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. 1998 , 12, 1581-90	127
1910	Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. 1998 , 12, 2193-202	42
1909	Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naïve patients. NV15355 Study Team. 1998 , 12, F103-9	38
1908	A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. 1998 , 19, 339-49	52
1907	Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. 1998 , 12, F131-5	97
1906	Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. Multicenter Hemophilia Cohort Study. 1998 , 12, 1691-7	29
1905	Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count?. 1998 , 12, F175-9	11
1904	Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. 1998 , 12, 473-80	28

1903	The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study. 1998 , 121, 369-76	12
1902	Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. 1998 , 12, 389-94	90
1901	Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. 1998 , 12, 1027-1032	87
1900	Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. 1998 , 12, 2107-13	66
1899	Quantitation of HIV-1 by real-time amplification and detection. 1998 , 3259, 94	
1898	Acquired Immune Deficiency Syndrome (AIDS). 1998 , 6-13	
1897	From exceptionalism to normalisation: a reappraisal of attitudes and practice around HIV testing. 1998 , 316, 290-3	84
1896	Biological and virologic characteristics of primary HIV infection. 1998 , 128, 613-20	197
1895	Quantitation of HIV-1 RNA viral load using nucleic acid sequence based amplification methodology and comparison with other surrogate markers for disease progression. 1998 , 93, 411-5	2
1894	Quantitative, competitive PCR assay for HIV-1 using a microplate-based detection system. 1998 , 24, 810-6	31
1893	Influence of host genes on HIV-1 disease progression. 1998 , 12, 625-32	62
1892	Elevated Levels of Serum-Soluble CD14 in Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Correlation to Disease Progression and Clinical Events. 1998 , 92, 2084-2092	134
1891	A Rapid, Sensitive, Multiplexed Assay for Detection of Viral Nucleic Acids Using the FlowMetrix System. 1998 , 44, 2054-2056	51
1890	Clinical Evaluation of a New, Miniaturized Biosensor for Self-monitoring of Blood Glucose. 1998 , 44, 2056-2057	12
1889	HIV-Related Hepatic Disease: When and Why to Biopsy. 1998 , 8, 939-962	2
1888	From fate to tragedy: the changing meanings of life, death, and AIDS. 1998 , 129, 899-902	41
1887	A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. The Swiss HIV Cohort Study. 1998 , 158, 247-52	44
1886	Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. 1998 , 54, 291-7	26

1885	Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. 1999 , 159, 1771-6	70
1884	A theoretical model of the evolution of virulence in sexually transmitted HIV/AIDS. 1999 , 33, 329-33	5
1883	HLA and HIV-1 Infection. 1999 , 155-171	1
1882	Flow microsphere immunoassay-based method of virus quantitation. 1999 , 27, 356-61	13
1881	HIV-1 and HIV-2 Molecular Diagnosis. 1999 , 207-222	2
1880	Human Immunodeficiency Viruses. 659-693	
1879	Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. 1999 , 73, 10489-502	790
1878	An Indicator Cell Assay for T-Cell Tropic, Macrophage-Tropic, and Primary Isolates of HIV-1 Based on Green Fluorescent Protein. 1999 , 22, 213	8
1877	Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. 1999 , 52, 607-13	259
1876	The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. 1999 , 13, 2269-79	56
1875	Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team. 1999 , 20, 245-54	13
1874	Plasma RNA Viral Load as Measured by the Branched DNA and Nucleic Acid SequenceBased Amplification Assays of HIV-1 Subtypes A and D in Uganda. 1999 , 22, 208	4
1873	HIV-1 dynamics in children. 1999 , 20, 468-73	27
1872	An indicator cell assay for T-cell tropic, macrophage-tropic, and primary isolates of HIV-1 based on green fluorescent protein. 1999 , 22, 213-20	11
1871	CD4+ and CD8+ lymphocytes and HIV RNA in HIV infection: high baseline counts and in particular rapid decrease of CD8+ lymphocytes predict AIDS. 1999 , 13, 195-201	11
1870	HIV-1 reactivation in resting peripheral blood mononuclear cells of infected adults upon in vitro CD4 cross-linking by ligands of the CDR2-loop in extracellular domain 1. 1999 , 21, 9-19	9
1869	Natural history of HIV infection in the era of combination antiretroviral therapy. 1999 , 13, 1933-42	316
1868	HIV viral load and response to antileishmanial chemotherapy in co-infected patients. 1999 , 13, 1921-5	57

1867	Plasma RNA viral load as measured by the branched DNA and nucleic acid sequence-based amplification assays of HIV-1 subtypes A and D in Uganda. 1999 , 22, 208-9	5
1866	The effects of HIV viral load on the phagocytic activity of monocytes activated with lipopolysaccharide from oral microorganisms. 1999 , 21, 421-38	8
1865	Combined antiviral therapy reduces HIV-1 plasma load and improves CD4 counts but does not interfere with ongoing lymphocyte apoptosis. 1999 , 21, 645-65	3
1864	Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with <i>Pneumocystis carinii</i> pneumonia. 1999 , 160, 2048-55	46
1863	Anti-HIV-1 activity of an ionically modified porous polypropylene membrane determined by filtration of a viral suspension. 1999 , 43, 141-51	4
1862	Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes. 1999 , 31, 37-42	6
1861	Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. 1999 , 341, 1865-73	874
1860	Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy. 1999 , 180, 1851-62	24
1859	Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection. 1999 , 180, 1089-95	68
1858	Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. 1999 , 180, 1338-41	95
1857	Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication. 1999 , 10, 115-9	4
1856	Relationship between nutritional status and histologic findings in small bowel mucosa of children presenting with diarrhoea of more than 14 days' duration. 1999 , 45, 302-4	3
1855	Early dexamethasone treatment in preterm infants treated with surfactant: a double blind controlled trial. 1999 , 45, 304-6	6
1854	Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. 1999 , 180, 695-701	42
1853	The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. 1999 , 179, 527-37	152
1852	Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. 1999 , 180, 1116-21	186
1851	Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort. 1999 , 180, 1790-802	43
1850	Viral dynamics of acute HIV-1 infection. 1999 , 190, 841-50	229

1849	Association between the rate of CD4+ T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV cohort study. 1999 , 180, 1803-8	26
1848	Viral loads in dual infection with HIV-1 and cytomegalovirus. 1999 , 80, 132-6	4
1847	Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. 1999 , 179, 1254-8	171
1846	Evaluation of human immunodeficiency virus (HIV) type 1 load, CD4 T cell level, and clinical class as time-fixed and time-varying markers of disease progression in HIV-1-infected children. 1999 , 180, 1514-20	22
1845	Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. 1999 , 179, 859-70	847
1844	Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. 1999 , 15, 1691-701	87
1843	Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy. 1999 , 179, 345-51	8
1842	Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?. 1999 , 43, 379-88	2
1841	Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. 1999 , 180, 666-72	153
1840	Haematological abnormalities in children with tuberculosis. 1999 , 45, 307-10	12
1839	Longer-term immunologic effects and side effects of successful antiretroviral therapy. 1999 , 29, 12-8	31
1838	Plasma and urine carnitine levels and carnitine supplementation in children with malnutrition. 1999 , 45, 294-6	7
1837	Virus levels in untreated African infants infected with human immunodeficiency virus type 1. 1999 , 180, 1838-43	31
1836	Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection. 1999 , 179, 1405-9	46
1835	Stability of saliva for measuring HIV in the tropics. 1999 , 45, 296-9	2
1834	Surrogate markers of disease progression in HIV-infected children in Rio de Janeiro, Brazil. 1999 , 45, 299-302	5
1833	Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy. 1999 , 179, 361-6	18
1832	Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe. 1999 , 179, 1382-7	36

1831	Assay of plasma samples representing different HIV-1 genetic subtypes: an evaluation of new versions of the amplicor HIV-1 monitor assay. 1999 , 15, 889-94	27
1830	Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. 1999 , 15, 1499-508	74
1829	Impact of HIV type 1 subtype variation on viral RNA quantitation. 1999 , 15, 133-42	111
1828	Long-term pattern of HIV-1 RNA load in perinatally infected children. 1999 , 31, 337-43	11
1827	Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals. 1999 , 15, 1063-71	31
1826	Activation-induced CD4+ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4+ T cell count, and HIV plasma viral copy number. 1999 , 15, 1509-18	44
1825	Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. 1999 , 189, 991-8	1218
1824	Genital HIV shedding in women. 1999 , 13, 695-701	7
1823	Prospective study of CD8+ lymphocyte activation in relation to viral load in HIV-infected patients with > or = 400 CD4+ lymphocytes per microliter. 1999 , 15, 1419-25	16
1822	Virus threshold determines disease in SIVsmmPBj14-infected macaques. 1999 , 15, 183-94	6
1821	Correlation of clinical parameters and immunological function with human immunodeficiency virus plasma viremia in children. 1999 , 12, 139-48	3
1820	Immunologic and viral markers of HIV-1 disease progression: implications for dentistry. 1999 , 130, 1313-22	17
1819	CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy. 1999 , 15, 461-70	25
1818	Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection. 1999 , 15, 223-7	16
1817	Quantitative PCR Protocols. 1999 ,	3
1816	A simple relationship between viral load and survival time in HIV-1 infection. 1999 , 96, 11549-53	36
1815	HIV recent advances in AIDS research: genetics, molecular biology and immunology. 1999 , 11, 449-50	6
1814	Perspectives en biologie moléculaire appliquée au suivi thérapeutique des personnes infectées par le VIH. 1999 , 1999, 141-143	

1813	Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV. 1999 , 66, 53-9	55
1812	Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. 1999 , 66, 121-8	54
1811	Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients. 1999 , 69, 283-9	18
1810	Contribution of zinc to reduce CD4+ risk factor for 'severe' infection relapse in aging: parallelism with HIV. 1999 , 21, 271-81	33
1809	CD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes. 1999 , 115, 477-84	7
1808	Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood. 1999 , 29, 445-52	12
1807	Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation. 1999 , 29, 723-32	32
1806	Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment. 1999 , 49, 539-47	11
1805	HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications. 1999 , 1, 1113-20	38
1804	HIV-1 viral load testing. 1999 , 38, 141-6	11
1803	Equivalent amplification of intrinsically variable nucleic acid sequences by multiple-primer-induced overlapping amplification assay: applications for universal detection and quantitation. 1999 , 5, 1081-5	14
1802	ON THE MARKET. 1999 , 5, 1085-1086	
1801	Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. 1999 , 5, 1270-6	348
1800	HIV's evasion of the cellular immune response. 1999 , 168, 65-74	113
1799	Towards an AIDS vaccine: the role of nonhuman primates. 1999 , 28, 146-53	5
1798	An anti-HIV strategy combining chemotherapy and therapeutic vaccination. 1999 , 28, 195-205	16
1797	Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. 1999 , 5, 211-6	147
1796	Evolution of the fittest ends in tragedy. 1999 , 5, 488-9	8

1795	Thalidomide on the comeback trail. 1999 , 5, 489-90	71
1794	Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. 1999 , 5, 512-7	1681
1793	Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. 1999 , 5, 535-41	169
1792	Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses. 1999 , 256, 15-21	48
1791	Limitation of Tat-associated transcriptional processivity in HIV-infected PBMC. 1999 , 257, 397-405	11
1790	Dissemination of SIV after rectal infection preferentially involves paracolic germinal centers. 1999 , 260, 277-94	25
1789	Localization of HTLV-1 and HIV-1 proviral sequences in chromosomes of persistently infected cells. 1999 , 7, 177-83	7
1788	Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. 1999 , 15, 99-108	9
1787	Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug users. 1999 , 4, 197-202	5
1786	Dynamics of HIV Risk Behavior in HIV-Infected Injection Drug Users. 1999 , 3, 41-57	18
1785	RT-PCR for Amplification of Specific Fragments of HIV-1 Genome. 2000 , 24, 269-82	
1784	Spinal disease in neurologically symptomatic HIV-positive patients. 1999 , 41, 360-8	7
1783	Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections. 1999 , 34, 275-81	10
1782	Human immunodeficiency virus protease inhibitors. 1999 , 19, 35-59	27
1781	HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. 1999 , 19, 281-98	45
1780	An international collaborative study on the detection of an HIV-1 genotype B field isolate by nucleic acid amplification techniques. 1999 , 78, 21-34	7
1779	A quantitative PCR method for the assay of HIV-1 provirus load in peripheral blood mononuclear cells. 1999 , 83, 11-20	11
1778	A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection. 1999 , 41, 21-33	7

1777	Repression of the human immunodeficiency virus type 1 promoter by the human KRAB domain results in inhibition of virus production. 1999 , 1445, 216-23	15
1776	Leishmania-HIV interaction: immunopathogenic mechanisms. 1999 , 15, 182-7	98
1775	Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. 1999 , 54, 26-45	134
1774	Life-steps: Applying cognitive behavioral therapy to HIV medication adherence. 1999 , 6, 332-341	121
1773	Whole body protein turnover in children with human immunodeficiency virus (HIV) infection. 1999 , 15, 189-94	12
1772	Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. 1999 , 15, 865-869	99
1771	Interactions between beta-herpesviruses and human immunodeficiency virus in vivo: evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. 1999 , 57, 278-82	38
1770	Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. 1999 , 58, 256-263	69
1769	Time to consider the concept of a commensal virus?. 1999 , 9, 73-4	37
1768	Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. 1999 , 15, 1219-28	114
1767	Molecular methods of measurement of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection: implications for occupational health practice. 1999 , 56, 730-4	9
1766	Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. 1999 , 282, 771-8	217
1765	Antiviral Methods and Protocols. 1999 ,	
1764	Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression. 1999 , 15, 43-50	11
1763	Increased expression of CD80 and CD86 in in vitro-infected CD3+ cells producing cytoplasmic HIV type 1 p24. 1999 , 15, 173-81	12
1762	Comparison of three commercial assays for the quantification of HIV-1 RNA in plasma from individuals infected with different HIV-1 subtypes. 1999 , 14, 87-94	26
1761	HIV disease treatment in the era of HAART. 1999 , 53, 93-105	22
1760	Prisons and public health: emerging issues in HIV treatment adherence. 1999 , 10, 24-32	15

1759	Oral <i>Candida dubliniensis</i> as a clinically important species in HIV-seropositive patients in the United States. 1999 , 88, 573-80	47
1758	[Contribution of clinical epidemiology to the management of HIV infections]. 1999 , 20, 681-92	
1757	Xenogeneic and allogeneic anti-MHC immune responses induced by plasmid DNA immunization. 1999 , 17, 2479-92	8
1756	Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy. 1999 , 21, 1313-20	3
1755	The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. 1999 , 30, 353-8	27
1754	Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. 1999 , 30, 536-50	63
1753	Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population. 1999 , 30, 557-63	15
1752	The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. 1999 , 90, 238-46	49
1751	Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. 1999 , 134, 597-606	71
1750	As originally published in 1989: human immunodeficiency virus and the cardiac surgeon: a survey of attitudes. Updated in 1999. 1999 , 67, 1203-4	12
1749	Overview of HIV infection. 1999 , 83, 1-5; quiz 6-7	14
1748	Strategies of antiretroviral therapy in adults. 1999 , 26, 809-20, ix-x	6
1747	Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. 1999 , 37, 75-86	84
1746	Stavudine: an update of its use in the treatment of HIV infection. 1999 , 58, 919-49	47
1745	Indinavir: a review of its use in the management of HIV infection. 1999 , 58, 1165-203	65
1744	Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. 1999 , 15, 499-508	51
1743	Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. 1999 , 17, 625-56	449
1742	Monitoring cellular immune function in HIV infection by the delayed hypersensitivity skin test: alternative to the CD4 T-cell count?. 1999 , 103, 26-8	7

1741	Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group. 1999 , 103, 93-8	11
1740	Virus phenotype switching and disease progression in HIV-1 infection. 1999 , 266, 2523-30	23
1739	Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. 1999 , 17, 657-700	1868
1738	Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. 1999 , 91, 283-95	20
1737	Proliferative and regenerative capacities of CD4(+) T cells upon TCR stimulation. 1999 , 93, 16-23	4
1736	Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. 1999 , 189, 1545-54	178
1735	Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection*. 1999 , 97, 707-718	10
1734	Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection. 1999 , 97, 707	3
1733	Viral dynamics during active cytomegalovirus infection and pathology. 1999 , 42, 405-11	21
1732	Oral cavity and oropharyngeal tumors in human immunodeficiency virus-positive patients: acute response to radiation therapy. 1999 , 125, 873-6	26
1731	Viral Load Testing for HIV Beyond the CD4 Count. 1999 , 30, 102-108	
1730	Virologic, Immunologic, and Immune Activation Markers as Predictors of HIV-Associated Weight Loss Prior to AIDS. 1999 , 22, 386	2
1729	Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. 1999 , 13, 381-9	43
1728	Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. 1999 , 13, 447-54	40
1727	The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. 1999 , 13, 487-94	169
1726	Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. 1999 , 13, 669-76	90
1725	Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. 1999 , 13, 951-6	94
1724	The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. 1999 , 13, 1717-26	44

1723	Prognostic value of plasma HIV RNA in the natural history of <i>Pneumocystis carinii</i> pneumonia, cytomegalovirus and <i>Mycobacterium avium</i> complex. Multicenter AIDS Cohort Study. 1999 , 13, 341-9	32
1722	Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. 1999 , 13, 1151-8	49
1721	Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. 1999 , 13, 1461-8	26
1720	HIV-1 RNA levels in an African population-based cohort and their relation to CD4 lymphocyte counts and World Health Organization clinical staging. 1999 , 22, 167-73	1
1719	Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. 1999 , 13, 1035-44	39
1718	The interaction of opportunistic infections and HIV replication. 1999 , 13, 1603-6	9
1717	A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. Medical Outcomes Study HIV Health Survey. 1999 , 13, 1727-35	54
1716	Chemical Characterization of Single Cells and Single Molecules. 1999 , 46, 351-360	2
1715	Natural immunity and HIV disease progression. 1999 , 13, 557-63	36
1714	Both necrosis and apoptosis contribute to HIV-1-induced killing of CD4 cells. 1999 , 13, 1827-39	48
1713	Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. 1999 , 13, 2281-8	19
1712	Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. 1999 , 13, 2075-82	106
1711	HIV-1 RNA Levels in an African Population-Based Cohort and Their Relation to CD4 Lymphocyte Counts and World Health Organization Clinical Staging. 1999 , 22, 167	11
1710	Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group. 1999 , 22, 437-44	18
1709	Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study. 1999 , 21, 317-25	19
1708	Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS. Multicenter AIDS Cohort Study. 1999 , 22, 386-94	13
1707	Comparison of viral load and human leukocyte antigen statistical and neural network predictive models for the rate of HIV-1 disease progression across two cohorts of homosexual men. 1999 , 20, 129-36	10
1706	HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement. 1999 , 22, 19-30	16

1705	Impact of Early HIV-1 RNA and T-Lymphocyte Dynamics During Primary HIV-1 Infection on the Subsequent Course of HIV-1 RNA Levels and CD4+ T-Lymphocyte Counts in the First Year of HIV-1 Infection. 1999 , 22, 437	17
1704	Relation between herpes simplex viruses and human immunodeficiency virus infections. 1999 , 135, 1393-7	50
1703	HIV-1 Nef: a critical factor in viral-induced pathogenesis. 2000 , 48, 299-343	14
1702	HIV therapeutics: Past, present, and future. 2000 , 49, 1-40	
1701	Utility of an HIV-1 RNA Assay in the Diagnosis of Acute Retroviral Syndrome. 2000 , 93, 1004-1006	
1700	Management of Antiretroviral Therapy for HIV Infection: Analyzing When to Change Therapy. 2000 , 46, 1200-1213	8
1699	Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. 2000 , 49, 437-77	81
1698	The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients. 2000 , 44, 405-10	4
1697	Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. 2000 , 130, 1424S-31S	48
1696	Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. 2000 , 25, 36-43	6
1695	Fluctuations in HIV-1 Viral Load Are Correlated to CD4+ T-Lymphocyte Count During the Natural Course of Infection. 2000 , 23, 375-379	3
1694	Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. 2000 , 24, 106-14	56
1693	Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. 2000 , 24, 227-31	22
1692	Dissociation of Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy. 2000 , 23, 314-320	12
1691	Acute Retrovirus Syndrome Among Prospectively Identified Homosexual Men With Incident HIV Infection in Brazil. 2000 , 25, 188-191	5
1690	Dissociation of immunologic and virologic responses to highly active antiretroviral therapy. 2000 , 23, 314-20	19
1689	NF-kappa B and HIV: linking viral and immune activation. 2000 , 48, 161-207	24
1688	Fluctuations in HIV-1 viral load are correlated to CD4+ T-lymphocyte count during the natural course of infection. 2000 , 23, 375-9	8

1687	Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. 2000 , 14, 1921-33	69
1686	Course of viral load throughout HIV-1 infection. 2000 , 23, 172-7	40
1685	Quantification of viral ribonucleic acid in plasma of cats naturally infected with feline immunodeficiency virus. 2000 , 61, 1609-13	10
1684	The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies. 2000 , 74, 573-9	37
1683	Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. 2000 , 14, 821-6	61
1682	Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. 2000 , 14, 1973-8	20
1681	Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. 2000 , 14, 2313-22	93
1680	Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa. 2000 , 14, 339-44	47
1679	Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study. 2000 , 24, 227-231	21
1678	Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. 2000 , 24, 257-63	19
1677	Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. 2000 , 12, 438-44	14
1676	Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. 2000 , 14, 123-31	112
1675	Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. 2000 , 14, 2831-9	15
1674	Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. 2000 , 25, 11-8	18
1673	Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA). 2000 , 14, 971-8	71
1672	Duration of Viral Suppression in Patients on Stable Therapy for HIV-1 Infection Is Predicted by Plasma HIV RNA Level After 1 Month of Treatment. 2000 , 25, 36-43	15
1671	Measuring the effect of clinical guidelines on patient outcomes. 2000 , 16, 1013-23	20
1670	Problems in the interpretation of HIV-1 viral load assays using commercial reagents. 2000 , 61, 187-94	7

1669	Comparative quantification of diverse serotypes of HIV-1 in plasma from a diverse population of patients. 2000 , 62, 445-9	22
1668	Experimental infection of monkeys with Langat virus II. Turnover of circulating virus, 1967. 2000 , 10, 207-15	5
1667	Essential medical facts for mental health practitioners. 2000 , 2000, 3-15	2
1666	Enhanced interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in gingival crevicular fluid from periodontal pockets of patients infected with human immunodeficiency virus 1. 2000 , 15, 67-73	22
1665	Hematopoietic response to lineage-non-specific (rrIL-3) and lineage-specific (rhG-CSF, rhEpo, rhTpo) cytokine administration in SIV-infected rhesus macaques is related to stage of infection. 2000 , 29, 47-56	3
1664	Propagation of Viral-Size Particles in Lymph and Blood after Subcutaneous Inoculation. 2000 , 7, 193-200	14
1663	A critical examination of current HIV therapies. 2000 , 18, 635-52	1
1662	Ethanol enhances TNF-alpha-inducible NFkappaB activation and HIV-1-LTR transcription in CD4+ Jurkat T lymphocytes. 2000 , 136, 333-43	25
1661	Ribozyme therapy for HIV infection. 2000 , 44, 71-8	40
1660	Clinical and laboratory implications of acute HIV-1 infection. 2000 , 22, 33-37	2
1659	Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. 2000 , 86, 145-70	62
1658	Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR. 2000 , 87, 1-12	7
1657	Ultrasensitive in-house reverse transcription-competitive PCR for quantitation of HIV-1 RNA in plasma. 2000 , 87, 91-7	11
1656	Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. 2000 , 88, 81-7	55
1655	Direct detection of infectious HIV-1 in blood using a centrifugation-indicator cell assay. 2000 , 88, 111-5	5
1654	Quantification of HIV-1 group M (subtypes A-G) and group O by the LCx HIV RNA quantitative assay. 2000 , 89, 97-108	41
1653	Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. 2000 , 86, 61-70	78
1652	The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2. IRHAN Study Group. 2000 , 45, 95-9	6

1651	Health-related quality of life and virologic outcomes in an HIV clinic. 2000 , 9, 977-85	87
1650	Human immunodeficiency virus type 1 replication, immune activation, and circulating cytotoxic T cells against uninfected CD4+ T cells. 2000 , 20, 175-86	7
1649	Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients. 2000 , 16, 209-16	2
1648	Implication of the C-terminal domain of nef protein in the reversion to pathogenicity of attenuated SIVmacBK28-41 in macaques. 2000 , 266, 286-98	8
1647	Different immunological requirements for protection against acute versus persistent Friend retrovirus infections. 2000 , 272, 177-82	19
1646	DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles. 2000 , 275, 116-24	22
1645	Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland. 2000 , 28, 287-96	21
1644	Antiretroviral therapy 2000. 2000 , 23, 425-37	4
1643	Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. 2000 , 95, 48-55	14
1642	Flow Cytometry: Principles and Clinical Applications in Hematology. 2000 , 46, 1221-1229	274
1641	Immunopathological factors for vertical transmission of HIV-1. 2000 , 68, 53-67	5
1640	The case for more cautious, patient-focused antiretroviral therapy. 2000 , 132, 306-11	48
1639	Immunocompromised host: from the early events until the impact of acquired immunodeficiency syndrome. 2000 , 95 Suppl 1, 141-4	5
1638	Pathogenesis and treatment of HIV-1 infection: recent developments (Y2K update). 2000 , 5, d30	2
1637	Immunological evaluation of human immunodeficiency virus infected individuals by flow cytometry. 2000 , 95, 393-400	4
1636	Applications of flow cytometry to clinical microbiology. 2000 , 13, 167-95	166
1635	HIV Infection in Children: A New Hope. 2000 , 9, 279-294	
1634	Pathogenesis and treatment of HIV-1 infection: recent developments (Y2K update). 2000 , 5, D30-49	4

1633	Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. 2000 , 284, 2193-202	102
1632	A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. 2000 , 74, 9222-33	209
1631	The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques. 2000 , 74, 5836-44	35
1630	Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. 2000 , 74, 552-5	53
1629	Molecular Pathology Protocols. 2000 ,	
1628	Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. 2000 , 74, 5679-90	113
1627	Applications of Flow Cytometry to Clinical Microbiology. 2000 , 13, 167-195	126
1626	Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. 2000 , 16, 1507-17	20
1625	Relationship of CD4+ T cell counts and HIV type 1 viral loads in untreated, infected adolescents. Adolescent Medicine HIV/AIDS Research Network. 2000 , 16, 959-63	27
1624	CTL escape - progress in identifying therapeutic avenues to control HIV viraemia. 2000 , 4, 297-312	
1623	Differential dynamics of CD4(+) and CD8(+) T-lymphocyte proliferation and activation in acute simian immunodeficiency virus infection. 2000 , 74, 8413-24	60
1622	Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. 2000 , 64, 725-45	10
1621	Effects of negative life events on immune suppression in children and youth infected with human immunodeficiency virus type 1. 2000 , 106, 540-6	45
1620	Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication. 2000 , 74, 9388-95	43
1619	The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children. 2000 , 182, 88-95	32
1618	Discontinuing prophylaxis for opportunistic infection: guiding principles. 2000 , 30 Suppl 1, S66-71	3
1617	Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. 2000 , 14, 1383-1388	12
1616	Evidence for late stage compartmentalization of HIV-1 resistance mutations between lymph node and peripheral blood mononuclear cells. 2000 , 14, 2273-81	29

1615	Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. 2000 , 14, 243-9	54
1614	Physician Experience in the Care of HIV-Infected Persons Is Associated With Earlier Adoption of New Antiretroviral Therapy. 2000 , 24, 106-114	61
1613	Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000. 2000 , 1, 60-110	20
1612	Lipopolysaccharide-induced HIV-1 expression in transgenic mice is mediated by tumor necrosis factor-alpha and interleukin-1, but not by interferon-gamma nor interleukin-6. 2000 , 14, 1299-307	14
1611	Course of Viral Load Throughout HIV-1 Infection. 2000 , 23, 172-177	42
1610	Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. Projecto Pra- Onze Study Group. 2000 , 25, 188-91	5
1609	Antiviral Resistance of Biologic HIV-2 Clones Obtained From Individuals on Nucleoside Reverse Transcriptase Inhibitor Therapy. 2000 , 25, 11-18	31
1608	Lower HIV-2 Plasma Viral Loads May Explain Differences Between the Natural Histories of HIV-1 and HIV-2 Infections. 2000 , 24, 257-263	25
1607	Differential responses of T cell subsets: possible role in the immunopathogenesis of AIDS. 2000 , 14, 1689-700	9
1606	[Anterior segment involvement in HIV-related eye disease after the commencement of highly active antiretroviral therapy (HAART)]. 2000 , 216, 61-7	4
1605	Ultrasensitive Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma by the AMPLICOR and COBAS AMPLICOR HIV-1 MONITOR Tests. 2001 , 49, 389-412	
1604	Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. 2000 , 160, 3286-93	97
1603	Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. 2000 , 160, 1134-40	42
1602	Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. 2000 , 16, 559-67	88
1601	Genetic and metabolic control of the mitochondrial transmembrane potential and reactive oxygen intermediate production in HIV disease. 2000 , 2, 551-73	64
1600	Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. 2000 , 16, 645-53	37
1599	Treatment of HIV disease in the new millennium. 2000 , 12, 140-4	4
1598	Cardiac surgery and the human immunodeficiency virus. 2000 , 12, 145-7	11

1597	CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines. 2000 , 13, 481-95	22
1596	Dependence of CD8+ T-cell-mediated suppression of HIV type 1 on viral phenotypes and mediation of phenotype-dependent suppression by viral envelope gene and not by beta-chemokines. 2000 , 16, 117-24	11
1595	Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load. 2000 , 16, 665-75	36
1594	Monitoring patients with HIV disease. 2000 , 53, 266-72	19
1593	Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication. 2000 , 11, 321-7	15
1592	Molecular techniques for clinical diagnostic virology. 2000 , 53, 502-6	16
1591	Biological considerations in the development of a human immunodeficiency virus vaccine. 2000 , 182, 579-89	39
1590	Application of QuantiGene nucleic acid quantification technology for high throughput screening. 2000 , 5, 343-52	25
1589	Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. 2000 , 181, 1280-8	64
1588	Quantitative molecular virology in patient management. 2000 , 53, 76-83	11
1587	Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. 2000 , 74, 57-64	222
1586	Homozygosity for a conserved Mhc class II DQ-DRB haplotype is associated with rapid disease progression in simian immunodeficiency virus-infected macaques: results from a prospective study. 2000 , 182, 716-24	46
1585	Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. 2000 , 74, 2502-9	134
1584	The natural history of hepatitis C virus infection: host, viral, and environmental factors. 2000 , 284, 450-6	806
1583	Determinants of the quantity of hepatitis C virus RNA. 2000 , 181, 844-51	110
1582	Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. 2000 , 133, 401-10	284
1581	Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. 2000 , 182, 96-103	46
1580	Network-related mechanisms may help explain long-term HIV-1 seroprevalence levels that remain high but do not approach population-group saturation. 2000 , 152, 913-22	92

1579	Interleukin 2 treatment for HIV infection. 2000 , 284, 236-8	5
1578	Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. 2000 , 181, 912-20	129
1577	Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes. 2000 , 74, 5403-11	29
1576	Maternal SDF1 3'A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. 2000 , 74, 5736-9	49
1575	High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. 2000 , 74, 7538-47	144
1574	An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. 2000 , 74, 10882-91	85
1573	Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. 2000 , 74, 1209-23	171
1572	Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. 2000 , 74, 1554-7	113
1571	Direct detection of apoptotic cells in peripheral blood from highly pathogenic SHIV-inoculated monkey. 2000 , 268, 868-74	8
1570	Predictors of operative outcome in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. 2000 , 180, 228-33	47
1569	Effect of recent thymic emigrants on progression of HIV-1 disease. 2000 , 355, 599-604	87
1568	The discriminative ability of the 12-item short form health survey (SF-12) in a sample of persons infected with HIV. 2000 , 22, 1112-20	58
1567	Les multiples aspects de la r�sistance du VIH aux antir�troviraux. 2000 , 30, 551-564	1
1566	Anti-major histocompatibility complex antibody responses in macaques via intradermal DNA immunizations. 2000 , 18, 3152-65	6
1565	Pertussis immunization in HIV-1-infected infants: a model to assess the effects of repeated T cell-dependent antigen administrations on HIV-1 progression. Italian Register for HIV infection in children. 2000 , 18, 1203-9	6
1564	Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva. 2000 , 89, 432-40	33
1563	Natural history of HIV-1 infection. 2000 , 18, 389-99	6
1562	Spontaneous apoptosis and highly active antiretroviral therapy (HAART). 2000 , 54, 16-20	11

1561	Inhibition of needlestick-induced simulated viremia by local measures. 2000 , 70, 229-33	1
1560	Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapy. 2000 , 4, 187-93	9
1559	Determinants of virological response to antiretroviral therapy: implications for long-term strategies. 2000 , 30 Suppl 2, S177-84	86
1558	Analysis of left-censored longitudinal data with application to viral load in HIV infection. 2000 , 1, 355-68	93
1557	Recent advances in diagnosis and therapy of human papillomaviruses. 2000 , 9, 1753-65	4
1556	Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. 2000 , 16, 1123-33	77
1555	Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. 2000 , 16, 1385-94	19
1554	Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects. 2000 , 32, 153-60	14
1553	Significance of HIV-1 genetic subtypes. 2000 , 32, 455-63	19
1552	HIV-1 protease inhibitors. 2000 , 30 Suppl 2, S160-70	51
1551	High-throughput single-molecule DNA screening based on electrophoresis. 2000 , 72, 2879-85	74
1550	Viral and immunopathogenesis of vertical HIV-1 infection. 2000 , 47, 65-78	10
1549	Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection. 2000 , 60, 481-516	25
1548	Enhanced interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by LPS stimulated human monocytes isolated from HIV+ patients. 2000 , 22, 401-21	28
1547	Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. 2000 , 18, 665-708	438
1546	Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management. 2001 , 120, 607-21	39
1545	Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. 2001 , 17, 553-61	69
1544	HIV and Molecular Biology of the Virus-Host Interplay. 1-12	

1543	Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. <i>Science</i> , 2001 , 293, 1503-6	33-3	283
1542	AIDS--the first 20 years. 2001 , 344, 1764-72		287
1541	Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. 2001 , 19, 4121-9		28
1540	Using HIV-1 sequence variability to explore virus biology. 2001 , 76, 137-60		31
1539	Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france. 2001 , 280, 19-30		68
1538	Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. 2001 , 55, 7-15		29
1537	The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. 2001 , 20, 23-30		38
1536	Does plasma HIV RNA predict outcome in a cohort of treated HIV-infected individuals followed over 3 years?. 2001 , 22, 271-8		3
1535	Immunomodulators as adjunctive therapy for HIV-1 infection. 2001 , 22, 289-95		23
1534	Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. 2001 , 358, 1760-5		86
1533	Using standards and controls in molecular assays for infectious diseases. 2001 , 6, 335-45		
1532	NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS*. 2001 , 18, 293-327		1
1531	Clinical utility of viral quantification as a tool for disease monitoring. 2001 , 1, 153-62		28
1530	Elevated plasma stromal cell-derived factor 1 protein level in the progression of HIV type 1 infection/AIDS. 2001 , 17, 587-95		32
1529	HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration. 2001 , 14, 379-89		12
1528	Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. 2001 , 17, 243-51		105
1527	Antiviral activity of 4-benzyl pyridinone derivatives as HIV-1 reverse transcriptase inhibitors. 2001 , 6, 225-38		3
1526	. 2001 ,		

1525	Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. 2001 , 56, 355-61	55
1524	Clinical Prognosis of Patients with Early-Stage Human Immunodeficiency Virus (HIV) Disease: Contribution of HIV-1 RNA and T Lymphocyte Subset Quantitation. 2001 , 166, 571-576	3
1523	Multiple Roles of Cytokines in HIV Infection, Replication, and Therapy. 293-311	
1522	[The role of HIV associated eye changes in the time of HAART (highly active antiretroviral therapy)]. 2001 , 58, 21-7	
1521	Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. 2001 , 91, 1464-73	19
1520	Virologic and regimen termination surrogate end points in AIDS clinical trials. 2001 , 285, 777-84	28
1519	HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. 2001 , 15, 2445-50	55
1518	The public health significance of HIV-1 subtypes. 2001 , 15 Suppl 5, S59-71	41
1517	Primary Care of the HIV-Infected Patient. 2001 , 4, 142-153	
1516	Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. 2001 , 15, 1201-11	31
1515	Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. 2001 , 15, 1379-88	56
1514	CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. 2001 , 15, 1627-34	69
1513	Infection with HIV-2. 2001 , 15 Suppl 5, S35-45	38
1512	Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. 2001 , 15, 1369-77	283
1511	Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. 2001 , 15, 591-9	16
1510	Viral load differences in early infection with two HIV-1 subtypes. 2001 , 15, 683-91	83
1509	Relation Between CD4 Cell Counts and HIV RNA Levels at Onset of Opportunistic Infections. 2001 , 27, 44-48	8
1508	Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996-1998. 2001 , 27, 161-167	10

1507	Progression to AIDS or death as endpoints in HIV clinical trials. 2001 , 2, 330-5	5
1506	Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. 2001 , 2, 160-70	16
1505	HIV-specific effector cytotoxic T lymphocytes and HIV-producing cells colocalize in white pulps and germinal centers from infected patients. 2001 , 97, 2695-701	30
1504	Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. 2001 , 98, 3016-21	295
1503	Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. 2001 , 98, 3739-44	92
1502	Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. 2001 , 135, 782-95	225
1501	Support group participation, HIV viral load and sexual-risk behavior. 2001 , 25, 513-27	15
1500	The Relationship between Vitamin A Deficiency and Hiv Infection: Review of Scientific Studies. 2001 , 22, 235-247	4
1499	Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. 2001 , 91, 1456-63	43
1498	Virologic and immunologic effect of antiretroviral therapy on HIV-1 in gut-associated lymphoid tissue. 2001 , 26, 1-7	29
1497	Pathogenic determinants of the mucosally transmissible CXCR4-specific SHIV(SF33A2) map to env region. 2001 , 27, 222-8	9
1496	Surrogate markers for disease progression in treated HIV infection. 2001 , 28, 226-31	23
1495	HIV-1 RNA levels and development of clinical disease in two different adolescent populations. 2001 , 26, 449-57	
1494	Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. 2001 , 27, 161-7	27
1493	HIV-1 RNA Levels and Development of Clinical Disease in Two Different Adolescent Populations. 2001 , 26, 449-457	3
1492	Relation Between HIV-1 and Hepatitis C Viral Load in Patients With Hemophilia. 2001 , 26, 466-472	18
1491	Long-Term Impact of Highly Active Antiretroviral Therapy on HIV-Related Health Care Costs. 2001 , 27, 14-19	8
1490	Pathogenic Determinants of the Mucosally Transmissible CXCR4-Specific SHIV SF33A2 Map to env Region. 2001 , 27, 222-228	12

1489	Immune Activation Correlates Better Than HIV Plasma Viral Load with CD4 T-Cell Decline During HIV Infection. 2001 , 27, 389-397	25
1488	Viral and Cellular Dynamics in HIV Disease. 2001 , 3, 295-301	3
1487	Where does the lymph flow?. 2001 , 10, 136-141	
1486	Hepatitis C virus infection in HIV-infected patients. 2001 , 3, 469-476	28
1485	On the origin and evolution of the human immunodeficiency virus (HIV). 2001 , 76, 239-54	45
1484	Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. 2001 , 30, 207-14	33
1483	High-throughput single molecule screening of DNA and proteins. 2001 , 1, 123-39	11
1482	Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease. 2001 , 64, 505-512	62
1481	Maximum likelihood inference for left-censored HIV RNA data. 2001 , 20, 33-45	90
1480	TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathology. 2001 , 63, 189-195	43
1479	Quantification of HIV-1 using multiple quantitative polymerase chain reaction standards and bioluminometric detection. 2001 , 288, 28-38	15
1478	Modelling the natural history of HIV infection in individuals and its epidemiological implications. 2001 , 63, 1041-62	18
1477	Single-molecule immunoassay and DNA diagnosis. 2001 , 22, 421-6	19
1476	Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. 2001 , 44, 1998-2008	67
1475	Cervical dysplasia in women infected with the human immunodeficiency virus (HIV): a correlation with HIV viral load and CD4+ count. 2001 , 80, 350-4	38
1474	Characterization of less pathogenic infectious molecular clones derived from acute-pathogenic SHIV-89.6p stock virus. 2001 , 282, 6-13	20
1473	High virus loads in naturally and experimentally SIVagm-infected African green monkeys. 2001 , 283, 324-31	36
1472	Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. 2001 , 21, 227-33	110

1471	Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). 2001 , 10, 517-31	42
1470	Microbial rank. 2001 , 33, 1334-5	1
1469	Change in plasma viral load, and viral DNA and mRNA burdens, in peripheral blood mononuclear cells from patients infected with HIV-1. 2001 , 42, 20-6	1
1468	Evaluation of the new LCx HIV RNA quantitative assay: comparison with the Cobas Amplicor HIV Monitor assay. 2001 , 190, 129-34	7
1467	Determinants of trachoma endemicity using Chlamydia trachomatis ompA DNA sequencing. 2001 , 3, 447-58	20
1466	Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development?. 2001 , 79, 77-84	13
1465	Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. 2001 , 7, 73-9	461
1464	Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. 2001 , 7, 1225-31	68
1463	Biochemical mechanisms of HIV induced T cell apoptosis. 2001 , 8, 127-36	70
1462	Quantitative assay for group M (subtype A-H) and group O HIV-1 RNA detection in plasma. 2001 , 93, 1-14	8
1461	Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma. 2001 , 91, 67-74	19
1460	An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. 2001 , 92, 141-50	77
1459	Antibody masking renders HIV-1 resistant to cationic membrane filtration through alteration of its electrostatic characteristics. 2001 , 94, 15-24	2
1458	A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma. 2001 , 95, 81-92	39
1457	An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. 2001 , 22, 160-75	12
1456	Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods. 2001 , 22, 639-58	19
1455	Differential responses of Equus caballus and Equus asinus to infection with two pathogenic strains of equine infectious anemia virus. 2001 , 79, 93-109	34
1454	The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. 2001 , 21, 41-51	104

1453	Quantification of intrinsic residual viral replication in treated HIV-infected patients. 2001 , 98, 15167-72	22
1452	A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. 2001 , 32, 623-32	64
1451	Longitudinal variability of human immunodeficiency virus type 1 RNA viral load measurements by nucleic acid sequence-based amplification and NucliSens assays in a large multicenter study. 2001 , 39, 3760-3	14
1450	Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0. 2001 , 39, 862-70	51
1449	Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. 2001 , 39, 1378-84	65
1448	Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo. 2001 , 75, 7030-41	15
1447	One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG. 2001 , 39, 1895-902	40
1446	Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. 2001 , 183, 1682-7	39
1445	Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. 2001 , 33, 466-72	43
1444	Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. 2001 , 183, 392-400	29
1443	Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. 2001 , 183, 1574-85	72
1442	Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. 2001 , 15, 1831-6	50
1441	HIV-1 Viral Load Testing. 2001 , 32, 142-152	5
1440	Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. 2001 , 27, 14-9	40
1439	Differences in early virus loads with different phenotypic variants of HIV-1 and SIV(cpz) in chimpanzees. 2001 , 15, 2085-92	22
1438	Novel, live attenuated simian immunodeficiency virus constructs containing major deletions in leader RNA sequences. 2001 , 75, 2776-85	17
1437	Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?. 2001 , 15 Suppl 2, S36-42	18
1436	Virologic and Immunologic Effect of Antiretroviral Therapy on HIV-1 in Gut-Associated Lymphoid Tissue. 2001 , 26, 1-7	38

1435	HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. 2001 , 15, 2251-7	84
1434	Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. 2001 , 26, 466-72	93
1433	Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. 2001 , 27, 44-8	9
1432	Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. 2001 , 27, 389-97	85
1431	Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001. 2001 , 2, 227-306	21
1430	Effect of HCV viral dynamics on treatment design: lessons learned from HIV. 2001 , 96, 2818-28	9
1429	Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. 2001 , 39, 1303-10	117
1428	Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. 2001 , 39, 464-73	53
1427	Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. 2001 , 98, 597-602	34
1426	Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. 2001 , 98, 13288-93	135
1425	Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics. 2001 , 75, 11234-8	48
1424	Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. 2001 , 14, 753-77, table of contents	224
1423	A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. 2001 , 33, 1060-8	27
1422	Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. 2001 , 2, 13-29	51
1421	Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. 2001 , 33, 1901-9	15
1420	In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. 2001 , 75, 278-91	73
1419	Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. 2001 , 75, 5646-55	67
1418	HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. 2001 , 285, 1880-5	55

1417	Human immunodeficiency virus-specific and CD3-redirected cytotoxic T lymphocyte activity in the human female reproductive tract: lack of correlation between mucosa and peripheral blood. 2001 , 183, 977-83	25
1416	The pathogenesis of HIV-1 infection. 2001 , 58, 61-72	26
1415	Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. 2001 , 58, 89-108	33
1414	Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. 2001 , 75, 2262-75	208
1413	Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. 2001 , 98, 5140-5	217
1412	Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. 2001 , 75, 6953-61	187
1411	Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution. 2001 , 12, 573-81	26
1410	Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. 2001 , 183, 589-95	116
1409	Small variations in multiple parameters account for wide variations in HIV-1 set-points: a novel modelling approach. 2001 , 268, 235-42	48
1408	The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. 2001 , 268, 2085-95	33
1407	Human immunodeficiency virus Type 1 (HIV-1) plasma virus load and markers of immune activation among HIV-infected female sex workers with sexually transmitted diseases in Abidjan, Côte d'Ivoire. 2001 , 183, 1405-8	32
1406	Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. 2001 , 193, 181-94	241
1405	Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. 2001 , 286, 2568-77	495
1404	A randomized trial of the discontinuation of primary and secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. 2001 , 344, 159-67	176
1403	Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?. 2001 , 344, 520-2	18
1402	Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. 2001 , 32, 1756-68	32
1401	[Diagnosis of resistance in the treatment of AIDS: clarification of viral and cellular factors]. 2001 , 126, 1249-54	
1400	Making the animal model for AIDS research more precise: the impact of major histocompatibility complex (MHC) genes on pathogenesis and disease progression in SIV-infected monkeys. 2001 , 1, 515-22	28

1399	Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. 2001 , 17, 1333-44	20
1398	Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization. 2001 , 17, 577-86	9
1397	Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?. 2001 , 17, 1099-105	8
1396	Molecular Diagnosis of HIV Infection. 2002 , 138-157	4
1395	Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India. 2002 , 18, 1175-9	30
1394	Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2. 2002 , 18, 491-9	7
1393	Immunologic control of HIV-1. 2002 , 53, 149-72	128
1392	Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies. 2002 , 21, 659-64	17
1391	Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. 2002 , 76, 8276-84	130
1390	CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. 2002 , 18, 403-12	18
1389	Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers. 2002 , 18, 1167-73	61
1388	Calibrated real-time PCR assay for quantitation of human herpesvirus 8 DNA in biological fluids. 2002 , 40, 4652-8	43
1387	Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. 2002 , 76, 2298-305	307
1386	Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virus. 2002 , 76, 10079-83	24
1385	Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?. 2002 , 99, 4-6	35
1384	Clinical trials of HIV vaccines. 2002 , 53, 207-21	86
1383	Reactivation of human herpesvirus 6 infection in an immunocompetent host with chronic encephalopathy. 2002 , 185, 1843; author reply 1843-4	2
1382	The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion. 2002 , 186, 470-6	10

1381	Productive HIV-1 infection of primary CD4+ T cells induces mitochondrial membrane permeabilization leading to a caspase-independent cell death. 2002 , 277, 1477-87	55
1380	Molecular diagnosis of HIV. 2002 , 2, 233-9	12
1379	Contribution of peaks of virus load to simian immunodeficiency virus pathogenesis. 2002 , 76, 2573-8	11
1378	Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. 2002 , 76, 662-72	82
1377	Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life. 2002 , 30, 485-92	83
1376	Underevaluation of HIV-1 plasma viral load by a commercially available assay in a cluster of patients infected with HIV-1 A/G circulating recombinant form (CRF02). 2002 , 31, 488-94	25
1375	Intraocular and plasma HIV-1 RNA in HIV-infected patients with CMV retinitis and HIV-infected controls. 2002 , 34, 742-5	2
1374	Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. 2002 , 16, 1051-8	306
1373	Antiretroviral Therapy in Resource-Limited Settings. 2002 , 322-344	
1372	SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. 2002 , 16, 1489-96	184
1371	Patient-perceived barriers to antiretroviral adherence: associations with race. 2002 , 14, 607-17	43
1370	Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. 2002 , 186, 922-31	102
1369	Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. 2002 , 34, 91-7	84
1368	Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. 2002 , 76, 10099-108	75
1367	Does patient sex affect human immunodeficiency virus levels?. 2002 , 35, 313-22	128
1366	Impact of protease polymorphisms and viral fitness on human immunodeficiency virus (HIV) type 1 viremia in untreated HIV-1 infection. 2002 , 185, 1844-6	2
1365	Identification of the cryptosporidium pig genotype in a human patient. 2002 , 185, 1846-8	86
1364	Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. 2002 , 185, 905-14	116

1363	Highly pathogenic simian immunodeficiency virus mne variants that emerge during the course of infection evolve enhanced infectivity and the ability to downregulate CD4 but not class I major histocompatibility complex antigens. 2002 , 76, 6425-34	31
1362	Mycobacterium avium complex promotes recruitment of monocyte hosts for HIV-1 and bacteria. 2002 , 169, 3854-62	18
1361	Evaluation of drug resistance in HIV infection. 2002 , 58, 157-202	2
1360	Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. 2002 , 99, 15590-5	95
1359	Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. 2002 , 76, 10169-76	40
1358	Detection of dengue virus replication in peripheral blood mononuclear cells from dengue virus type 2-infected patients by a reverse transcription-real-time PCR assay. 2002 , 40, 4472-8	77
1357	Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. 2002 , 99, 13747-52	176
1356	High levels of viral replication contrast with only transient changes in CD4(+) and CD8(+) cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx. 2002 , 76, 10256-63	67
1355	Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. 2002 , 186, 1718-25	170
1354	Inpatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_AG-IbNG infection. 2002 , 76, 10745-55	34
1353	Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. 2002 , 49, 713-21	24
1352	Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. 2002 , 186, 1092-7	63
1351	Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. 2002 , 76, 12845-54	89
1350	Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death. 2002 , 76, 5966-73	64
1349	Through a glass, darkly: cerebrospinal fluid viral load measurements and the pathogenesis of human immunodeficiency virus infection of the central nervous system. 2002 , 59, 909-12	30
1348	Reply. 2002 , 185, 1843-1844	2
1347	Vitamin A deficiency and the acute phase response among HIV-1-infected and -uninfected women in Kenya. 2002 , 31, 243-9	29
1346	Correlates of plasma HIV-1 RNA viral load among HIV-1-seropositive women in Dar es Salaam, Tanzania. 2002 , 30, 316-23	22

1345	Predicting death from HIV/AIDS: a case-control study from Florida public HIV/AIDS clinics. 2002 , 30, 351-8	21
1344	Concordance between HIV source partner identification and molecular confirmation in acute retroviral syndrome. 2002 , 29, 232-43	14
1343	Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. 2002 , 31, 27-37	29
1342	Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection. 2002 ,	1
1341	Cell-associated HIV DNA measured early during infection has prognostic value independent of serum HIV RNA measured concomitantly. 2002 , 34, 529-33	15
1340	Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. 2002 , 16, 21-9	124
1339	The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. 2002 , 30, 421-8	21
1338	Primary HIV-1 subtype C infection in Ethiopia. 2002 , 30, 463-70	30
1337	Gender difference in HIV RNA levels: a meta-analysis of published studies. 2002 , 31, 11-9	92
1336	"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. 2002 , 30, 159-66	30
1335	Role of Sexually Transmitted Diseases in HIV-1 Transmission. 2002 , 231-250	1
1334	Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. 2002 , 137, 381-433	234
1333	HIV update. Diagnostic tests and markers of disease progression and response to therapy. 2002 , 118 Suppl, S26-32	5
1332	The significance of HIV viral load assay precision: a review of the package insert specifications of two commercial kits. 2002 , 1, 134-40	3
1331	The challenge of viral reservoirs in HIV-1 infection. 2002 , 53, 557-93	500
1330	Adaptive changes after human immunodeficiency virus type 1 transmission. 2002 , 18, 545-56	4
1329	New methods for the detection of HIV. 2002 , 22, 573-92, v	4
1328	Serum malondialdehyde correlates with therapeutic efficiency of high activity antiretroviral therapies (HAART) in HIV-1 infected children. 2002 , 36, 341-4	7

1327	AIDS in Africa. 2002,	23
1326	Genetic Amplification Techniques for Diagnosing Infectious Diseases. 2002, 69-81	
1325	Rapid confirmation of HIV infection. 2002, 6, 170-7	8
1324	Human immunodeficiency virus type 1 (HIV-1) disease progression may be due to defects in the expression of the TCR/CD3 complex as well as to a T CD4+ cell deficit. 2002, 58, 519-20	
1323	Current strategies in the treatment of HIV infection. 2002, 48, A3-184	2
1322	A new generation of HIV vaccines. 2002, 8, 489-95	27
1321	Quality control in nucleic acid testing--where do we stand?. 2002, 25 Suppl 3, S13-21	76
1320	Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 2002, 20, 1949-55	64
1319	Viral evolution and challenges in the development of HIV vaccines. 2002, 20 Suppl 4, A66-8	24
1318	CD8+ T-cell immunity to HIV infection. 2002, 22, 773-97	10
1317	HIV-1 reservoirs. 2002, 22, 651-80, vi	1
1316	Prospects for vaccine protection against HIV-1 infection and AIDS. 2002, 20, 73-99	163
1315	Nuevos métodos de evaluación de la eficacia antirretrovírica en ensayos clínicos de tratamiento de la infección vih. 2002, 8, 3815-3820	
1314	Ratio of two successive optical densities from the Roche HIV-1 monitor test as a measure of accuracy of estimates of human immunodeficiency virus RNA concentration. 2002, 40, 1067-8	1
1313	Pathogenesis and Clinical Manifestations of HIV-1 Infection. 2002, 421-440	
1312	Evaluation and management of HIV-infected women. 2002, 136, 228-42	19
1311	Host genetic factors in the clinical course of HIV-1 infection: chemokines and chemokine receptors. 2002, 5, 88-101	4
1310	Combination Antiretroviral Chemotherapy. 2002, 1-31	

1309	Monitoring Viral Load. 2002 , 173-185	1
1308	A New Mathematical Model for Assessing Therapeutic Strategies for HIV Infection. 2002 , 4, 147-155	11
1307	Morbidity and survival in advanced AIDS in Rio de Janeiro, Brazil. 2002 , 44, 179-86	17
1306	Improved detection of simian immunodeficiency virus RNA by in situ hybridization in fixed tissue sections: combined effects of temperatures for tissue fixation and probe hybridization. 2002 , 99, 23-32	37
1305	Real-time PCR methods for independent quantitation of TTV and TLMV. 2002 , 104, 59-67	30
1304	Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. 2002 , 55, 15-25	28
1303	The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. 2002 , 23, 198-220	74
1302	In vitro susceptibility to infection with SIVcpz and HIV-1 is lower in chimpanzee than in human peripheral blood mononuclear cells. 2002 , 67, 301-11	13
1301	The dual role of CD4 T helper cells in the infection dynamics of HIV and their importance for vaccination. 2002 , 214, 633-46	20
1300	The HCV and HIV coinfecting patient: what have we learned about pathophysiology?. 2002 , 4, 15-22	4
1299	Treatment of Primary HIV. 2002 , 4, 81-87	3
1298	Macaque animal model for HIV-induced neurological disease. 2002 , 109, 747-66	32
1297	Early dissemination rates of Friend murine leukaemia virus variants correlate with late pathogenesis. 2002 , 110, 899-912	2
1296	Human retroviruses after 20 years: a perspective from the past and prospects for their future control. 2002 , 185, 236-65	44
1295	Longitudinal follow up of SIVmac pathogenesis in rhesus macaques of Chinese origin: emergence of B cell lymphoma. 2002 , 31, 154-63	20
1294	Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque. 2002 , 31, 171-8	96
1293	Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. 2002 , 31, 5-10	50
1292	Prognostic significance of HIV-associated oral lesions and their relation to therapy. 2002 , 8 Suppl 2, 110-4	28

1291	Clinical relevance of viral dynamics and genotypes in hepatitis B virus. 2002 , 17 Suppl 3, S322-8	19
1290	Molecular diagnosis of influenza. 2002 , 12, 375-89	117
1289	Prediction of survival and opportunistic infections in HIV-infected patients: a comparison of imputation methods of incomplete CD4 counts. 2002 , 21, 1387-408	15
1288	Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. 2002 , 8, 493-9	335
1287	Modelling viral and immune system dynamics. 2002 , 2, 28-36	676
1286	New hope for an AIDS vaccine. 2002 , 2, 239-50	116
1285	Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. 2002 , 301, 176-87	56
1284	SHIV-KB9 infection of rhesus monkeys does not always cause disease-contribution of host immune factors and thymic output. 2002 , 303, 47-57	7
1283	Modulation of apoptosis by HIV protease inhibitors. 2002 , 7, 295-312	23
1282	HIV-1 therapeutic vaccines. 2002 , 44, 152-9	5
1281	T cell signaling and apoptosis in HIV disease. 2003 , 27, 247-60	15
1280	Human immunodeficiency virus-associated dementia: an evolving disease. 2003 , 9, 205-21	329
1279	Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma. 2003 , 5, 176-184	12
1278	Recent evolutionary history of human immunodeficiency virus type 1 subtype B--response. 2003 , 56, 643-4; author reply 645-7	4
1277	Fuzzy epidemics. 2003 , 29, 241-59	30
1276	Modelling emerging HIV epidemics: the role of injecting drug use and sexual transmission in the Russian Federation, China and India. 2003 , 14, 25-43	57
1275	Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo. 2003 , 306, 100-8	19
1274	In vivo inactivation of Nef ITAM motif of chimeric simian/human immunodeficiency virus SHIVsbg-YE correlates with absence of increased virulence in Chinese rhesus macaques. 2003 , 313, 322-34	2

1273	Bispecific monoclonal antibodies against a viral and an enzyme: utilities in ultrasensitive virus ELISA and phage display technology. 2003 , 274, 115-27	9
1272	Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression. 2003 , 71, 483-91	18
1271	The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. 2003 , 65, 263-77	20
1270	Early changes in peripheral blood T cells during primary infection of rhesus macaques with a pathogenic SIV. 2000 , 29, 127-35	17
1269	AIDS and heart disease: is cardiac surgery justified?. 2003 , 12, 193-5	1
1268	On the analysis of viral load endpoints in HIV vaccine trials. 2003 , 22, 2281-98	52
1267	T cells versus HIV-1: fighting exhaustion as well as escape. 2003 , 4, 12-3	7
1266	Checks and balances on developing B cells. 2003 , 4, 13-5	8
1265	HIV-1 pathogenesis. 2003 , 9, 853-60	323
1264	HIV-1 dynamics in vivo: implications for therapy. 2003 , 1, 181-90	117
1263	Hepatitis C in the HIV-infected patient. 2003 , 7, 179-94	48
1262	13. HIV-1 infection. 2003 , 111, S582-92	31
1261	Psychological risk factors for HIV pathogenesis: mediation by the autonomic nervous system. 2003 , 54, 1444-56	90
1260	Lopinavir/ritonavir: a review of its use in the management of HIV infection. 2003 , 63, 769-802	300
1259	Molecular characterization of 39 HIV isolates representing group M (subtypes A-G) and group O: sequence analysis of gag p24, pol integrase, and env gp41. 2003 , 19, 625-9	47
1258	The economic viability of antiretroviral adherence interventions. 2003 , 115, 672-3	11
1257	Glancing behind virus load variation in HIV-1 infection. 2003 , 11, 499-504	51
1256	Intrinsic and extrinsic pathways signaling during HIV-1 mediated cell death. 2003 , 85, 795-811	22

1255	Mitochondria in HIV-1-induced apoptosis. 2003 , 304, 561-74	34
1254	Treatment of antiretroviral-drug-resistant HIV-1 infection. 2003 , 362, 2002-11	165
1253	Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. 2003 , 18, 441-52	518
1252	Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals. 2003 , 26, 101-7	19
1251	Could TCR antagonism explain associations between MHC genes and disease?. 2003 , 9, 139-46	16
1250	CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. 2003 , 108, 234-40	77
1249	Evolution of virulence: adaptive or not?. 2003 , 11, 112-3; author reply 113-4	6
1248	AIDS-related non-Hodgkin's lymphoma: etiology, epidemiology, and impact of highly active antiretroviral therapy. 2003 , 44 Suppl 3, S63-8	8
1247	Can drug resistance mutations influence the measurement of plasma HIV-RNA by different viral load techniques?. 2003 , 17, 321-4	1
1246	Aging is associated with increased human T cell CC chemokine receptor gene expression. 2003 , 23, 575-82	22
1245	Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. 2003 , 188, 1421-5	35
1244	An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. 2003 , 278, 44816-25	42
1243	Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. 2003 , 77, 13146-55	50
1242	Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression. 2003 , 77, 6645-59	27
1241	Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. 2003 , 188, 1181-91	36
1240	What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. 2003 , 188, 179-93	54
1239	Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. 2003 , 77, 12479-93	43
1238	Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. 2003 , 187, 144-8	40

1237	Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. 2003 , 188, 1492-7	139
1236	Overcoming the false dichotomy of curative vs palliative care for late-stage HIV/AIDS: "let me live the way I want to live, until I can't". 2003 , 290, 806-14	51
1235	The relationship between virologic and immunologic responses in AIDS clinical research using mixed-effects varying-coefficient models with measurement error. 2003 , 4, 297-312	75
1234	Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. 2003 , 77, 12430-40	59
1233	Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. 2003 , 37, 551-8	17
1232	Ulcer prophylaxis is unnecessary with short course NSAIDs. 2003 , 79, 42-42	78
1231	New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. 2003 , 41, 4531-6	485
1230	p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection. 2003 , 41, 1016-22	73
1229	The race between initial T-helper expansion and virus growth upon HIV infection influences polyclonality of the response and viral set-point. 2003 , 270, 1349-58	21
1228	Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. 2003 , 77, 9029-40	160
1227	HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. 2003 , 170, 4403-10	54
1226	Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success. 2003 , 132, 196-209	36
1225	Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. 2003 , 77, 6041-9	26
1224	Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children. 2003 , 77, 7492-501	28
1223	Noninvasive detection of new simian immunodeficiency virus lineages in captive sooty mangabeys: ability to amplify virion RNA from fecal samples correlates with viral load in plasma. 2003 , 77, 2214-26	43
1222	Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. 2003 , 77, 2736-40	172
1221	Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms. 2003 , 41, 3361-7	33
1220	Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. 2003 , 77, 10028-36	54

1219	Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progressor macaques: association with CD4-independent usage of CCR5. 2003 , 77, 6405-18	38
1218	HIV-1 fitness and macrophages. 2003 , 74, 657-66	20
1217	Latency in human immunodeficiency virus type 1 infection: no easy answers. 2003 , 77, 1659-65	143
1216	Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. 2003 , 77, 1163-74	40
1215	Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. 2003 , 77, 989-98	74
1214	Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. 2003 , 19, 891-900	29
1213	Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression. 2003 , 19, 293-305	19
1212	The detection of gene-environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement?. 2003 , 32, 51-7	192
1211	HIV viral suppression in the era of antiretroviral therapy. 2003 , 79, 36-42	21
1210	Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. 2003 , 77, 11563-77	82
1209	Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. 2003 , 101, 4653-9	293
1208	The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. 2003 , 97 Suppl 1, 79-98	54
1207	Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. 2003 , 171, 3837-46	101
1206	Commentary: Balancing quantity and quality when designing epidemiological studies. 2003 , 32, 58-9	5
1205	Psychological distress and progression to AIDS in a cohort of injection drug users. 2003 , 32, 429-34	33
1204	Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. 2003 , 17, 1513-20	48
1203	AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination. 2003 , 34, 214-20	16
1202	Grade 4 events are as important as AIDS events in the era of HAART. 2003 , 34, 379-86	90

1201	Macrophage HIV-1 infection and the gastrointestinal tract reservoir. 2003 , 74, 642-9	74
1200	Clinical and immunologic progression in HIV-infected US women before and after the introduction of highly active antiretroviral therapy. 2003 , 33, 614-24	15
1199	Iron, haptoglobin phenotype, and HIV-1 viral load: a cross-sectional study among pregnant Zimbabwean women. 2003 , 33, 74-81	33
1198	HIV vaccines: a global perspective. 2003 , 3, 183-93	38
1197	Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. 2003 , 23, 149-66	22
1196	HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. 2003 , 33, 292-9	35
1195	Distinct cycling CD4(+)- and CD8(+)-T-cell profiles during the asymptomatic phase of simian immunodeficiency virus SIVmac251 infection in rhesus macaques. 2003 , 77, 10047-59	38
1194	synthesis of Functionalised derivatives of Pentaerythritol. 2003 , 2003, 2-3	0
1193	Measurements of HIV viral loads from different levels of the respiratory tract. 2003 , 124, 536-42	14
1192	Diagnostic Molecular Microbiology: Nucleic Acid Probes and Microbes. 2003 , 8, 137-144	
1191	A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. 2003 , 4, 287-300	60
1190	Cytokine therapies in HIV-1 infection: present and future. 2003 , 1, 83-96	16
1189	When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. 2003 , 17, 1863-9	41
1188	Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. 2003 , 17, 2593-601	70
1187	Sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients: a 48-week retrospective multicenter study. 2003 , 4, 248-51	3
1186	Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. 2003 , 4, 137-43	62
1185	Diagnostic Molecular Microbiology: Nucleic Acid Probes and Microbes. 2003 , 8, 137-144	
1184	Diagnosing HIV infection. 2003 , 3, 203-5	1

1183	Psychological distress is associated with decreased memory helper T-cell and B-cell counts in pre-AIDS HIV seropositive men and women but only in those with low viral load. 2003 , 65, 627-35	20
1182	Hepatitis C in the HIV-Infected Person. 2003 , 138, 197-207	299
1181	Polymorphic chemokine receptor and ligand genes in HIV infection. 2003 , 185-220	
1180	An adherence trilogy is essential for long-term HAART success. 2003 , 7, 307-14	10
1179	Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. 2003 , 1, 69-86	81
1178	Structured treatment interruptions in HIV infection: benefit or disappointment?. 2003 , 1, 129-39	9
1177	SIVagm: genetic and biological features associated with replication. 2003 , 8, d1170-85	33
1176	Correlation between cytokine serum levels, number of CD4+ T cells/mm ³ ; and viral load in HIV-1 infected individuals with or without antiretroviral therapy. 2004 , 10, 293	1
1175	The role of the immune response during SIVagm infection of the African green monkey natural host. 2004 , 9, 550-64	23
1174	Diagnostic Approaches. 1-21	
1173	The paradox of simian immunodeficiency virus infection in sooty mangabeys: active viral replication without disease progression. 2004 , 9, 521-39	47
1172	[HIV and lung]. 2004 , 58, 416-27	3
1171	Delayed HIV-1 infection of CD4+ T lymphocytes from therapy-naïve patients demonstrated by quantification of HIV-1 DNA copy numbers. 2004 , 48, 767-72	3
1170	The density of coreceptors at the surface of CD4+ T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death. 2004 , 20, 1230-43	11
1169	Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. 2004 , 78, 275-84	37
1168	Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. 2004 , 200, 761-70	875
1167	Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. 2004 , 199, 905-15	240
1166	Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies. 2004 , 190, 713-21	60

1165	Considerations in clinical trials of combination antifungal therapy. 2004 , 39 Suppl 4, S228-35	13
1164	Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction. 2004 , 190, 2047-54	2
1163	Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. 2004 , 190, 1697-705	52
1162	Does tuberculosis increase HIV load?. 2004 , 190, 1677-84	61
1161	Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy. 2004 , 39, 853-60	36
1160	Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. 2004 , 101, 12266-70	71
1159	Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. 2004 , 200, 1243-56	185
1158	A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. 2004 , 78, 14012-22	85
1157	Immunogenicity and tolerability of a trivalent virosomal influenza vaccine in a cohort of HIV-infected children. 2004 , 32, 492-9	13
1156	Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design?. 2004 , 167, 1047-58	41
1155	Classic AIDS in a sooty mangabey after an 18-year natural infection. 2004 , 78, 8902-8	114
1154	Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. 2004 , 78, 11340-51	51
1153	Direct inoculation of simian immunodeficiency virus from sooty mangabeys in black mangabeys (<i>Lophocebus aterrimus</i>): first evidence of AIDS in a heterologous African species and different pathologic outcomes of experimental infection. 2004 , 78, 11506-18	48
1152	Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study. 2004 , 38, 903-7	49
1151	Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. 2004 , 78, 2780-9	186
1150	Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. 2004 , 189, 303-11	68
1149	Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis. 2004 , 18, 99-108	35
1148	Frequent human leukocyte antigen class I alleles are associated with higher viral load among HIV type 1 seroconverters in Thailand. 2004 , 37, 1318-23	20

1147	Cytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. 2004 , 35, 446-54	34
1146	Highly active antiretroviral therapy improves neurocognitive functioning. 2004 , 36, 562-6	113
1145	Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. 2004 , 18, 51-8	133
1144	Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. 2004 , 37, 1423-30	37
1143	Recent advances in the development of HIV-1 Tat-based vaccines. 2004 , 2, 357-76	37
1142	Low-dose iron supplementation does not increase HIV-1 load. 2004 , 36, 637-8	38
1141	The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. 2004 , 36, 900-14	41
1140	Mycobacterium tuberculosis recall antigens suppress HIV-1 replication in anergic donor cells via CD8+ T cell expansion and increased IL-10 levels. 2004 , 172, 1953-9	19
1139	Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. 2004 , 85, 2407-2419	46
1138	Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. 2004 , 78, 3561-71	34
1137	Leishmania infantum promotes replication of HIV type 1 in human lymphoid tissue cultured ex vivo by inducing secretion of the proinflammatory cytokines TNF-alpha and IL-1 alpha. 2004 , 172, 3086-93	33
1136	Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. 2004 , 78, 10096-103	91
1135	Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort. 2004 , 189, 1988-95	7
1134	Complementary and Alternative Approaches to Biomedicine. 2004 ,	2
1133	HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partners. 2004 , 20, 19-25	51
1132	CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome. 2004 , 18, 189-98	19
1131	Cross-resistance patterns among HIV protease inhibitors. 2004 , 18, 199-208	24
1130	Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. 2004 , 38 Suppl 5, S414-20	17

1129	Outpatient pharmacy care and HIV viral load response among patients on HAART. 2004 , 16, 446-57	22
1128	A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect. 2004 , 78, 4907-13	11
1127	Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. 2004 , 78, 630-41	119
1126	Backfitting Random Varying-Coefficient Models with Time-Dependent Smoothing Covariates. 2004 , 31, 3-19	38
1125	Cognitive reorganization and stigmatization among persons with HIV. 2004 , 47, 510-25	14
1124	Viral load in tissues during the early and chronic phase of non-pathogenic SIVagm infection. 2004 , 33, 83-97	52
1123	A real-time PCR-based method to independently sample single simian immunodeficiency virus genomes from macaques with a range of viral loads. 2004 , 33, 227-35	3
1122	Prevalence of Borna disease virus RNA in populations at high or low risk for blood-borne infections. 2004 , 44, 1396	2
1121	ABO sequence analysis in a family with weak expression of blood group B. 2004 , 44, 1394-5	7
1120	Why do physicians request fresh frozen plasma?. 2004 , 44, 1393-4	54
1119	High frequency of nonprogression 20 years after transfusion-transmitted human immunodeficiency virus type-1 infection. 2004 , 44, 1397-8	1
1118	Validation of pH and glucose determination for bacteria detection screening in platelet concentrates stored in the Terumo Teruflex XT612 platelet container. 2004 , 44, 1395	8
1117	Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. 2004 , 432, 769-75	681
1116	Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients. 2004 , 115, 183-9	53
1115	Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. 2004 , 121, 93-9	9
1114	Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health. 2004 , 15, 133-138	8
1113	Projecting the impact of HAART on the evolution of HIV life history. 2004 , 176, 227-253	10
1112	Plasma RNA viral load is not associated with inpatient quasispecies heterogeneity in HIV-1 infection. 2004 , 149, 1761-71	10

1111	AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. 2004 , 48, 1-12	91
1110	Viral and cellular dynamics in HIV disease. 2004 , 1, 40-6	2
1109	CD8+CD38+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ adolescent population. 2004 , 20, 263-9	41
1108	Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. 2004 , 13, 933-58	29
1107	Incorporating durability information in the comparison of proportions of patients with HIV suppression. 2004 , 14, 741-55	
1106	[Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy]. 2004 , 22, 142-9	6
1105	Molecular Diagnostic Techniques and Other Tests for Direct Detection of HIV. 2004 , 185-193	
1104	Immunodeficiency in HIV-1 Infection. 2004 , 265-283	1
1103	Care of the Adult Patient with HIV Infection. 2004 , 305-370	
1102	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. 2004 , 22, 3258-69	60
1101	Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. 2004 , 20, 293-303	270
1100	Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. 2004 , 29, 282-9	76
1099	Infección por el VIH: tratamiento antirretrovírico de la infección por el VIH en adultos. 2004 , 9, 1461-1480	
1098	Methods for the analysis of continuous biomarker assay data with increased sensitivity. 2004 , 15, 724-32	6
1097	Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. 2004 , 37, 1534-8	30
1096	Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. 2004 , 61, 1687-96	109
1095	HIV-producing T cells in cerebrospinal fluid. 2004 , 37, 1237-44	13
1094	Early correction of cell cycle perturbations predicts the immunological response to therapy in HIV-infected patients. 2004 , 18, 393-402	18

1093	Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. 2004 , 18, 749-55	42
1092	Development of the antibody response in acute HIV-1 infection. 2004 , 18, 371-81	72
1091	Human Immunodeficiency Viruses. 721-757	2
1090	Antiretroviral therapy in drug-naïve patients infected with human immunodeficiency virus. 2004 , 328, 3-9	6
1089	A randomized trial of the efficacy of group therapy in changing viral load and CD4 counts in individuals living with HIV infection. 2005 , 35, 349-62	13
1088	Lung CD4 lymphocytes predict survival in asymptomatic HIV infection. 2005 , 128, 2262-7	4
1087	Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. 2005 , 24, 880-5	14
1086	Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. 2005 , 19, 1145-54	45
1085	Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy. 2005 , 6, 92-102	12
1084	Predictors of death within six months in patients with advanced AIDS. 2005 , 3, 265-72	5
1083	Replication of M-tropic HIV-1 in activated human intestinal lamina propria lymphocytes is the main reason for increased virus load in the intestinal mucosa. 2005 , 38, 23-30	11
1082	Detection of human immunodeficiency virus type 1 DNA sequence using plasmonics nanoprobe. 2005 , 77, 7810-5	201
1081	Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop-outs. 2005 , 54, 405-423	19
1080	Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Cte d'Ivoire. 2005 , 140, 138-48	22
1079	Naturally SIV-infected sooty mangabeys: are we closer to understanding why they do not develop AIDS?. 2005 , 34, 243-52	67
1078	Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. 2005 , 34, 303-12	274
1077	Laboratory markers associated with progression of HIV infection. 2005 , 19, 243-54	4
1076	New estimation method for highly sensitive quantitation of human immunodeficiency virus type 1 DNA and its application. 2005 , 124, 157-65	4

1075	Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. 2005 , 129, 40-6	31
1074	Dynamic HIV/AIDS parameter estimation with application to a vaccine readiness study in southern Africa. 2005 , 52, 784-91	24
1073	Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire. 2005 , 75, 202-8	19
1072	Development of an AIDS vaccine: a daunting epidemiological challenge. 2005 , 20, 123-6	1
1071	Nature and correlates of SF-12 physical and mental quality of life components among low-income HIV adults using an HIV service center. 2005 , 14, 935-44	36
1070	Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. 2005 , 2, 2	1
1069	Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit. 2005 , 24, 211-28	3
1068	Modelling the association between adherence and viral load in HIV-infected patients. 2005 , 24, 2719-31	42
1067	The clinical virology of pediatric HIV disease. 2005 , 59-67	
1066	The natural history of pediatric HIV disease. 2005 , 68-83	1
1065	Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. 2005 , 79, 13239-49	277
1064	Indolyl aryl sulfones (IASs): development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug resistant mutants. 2005 , 11, 3779-806	16
1063	Molecular detection of human immunodeficiency virus: where do we stand? Molekularer Nachweis des humanen Immunschwächevirus: Aktueller Stand. 2005 , 29, 44-49	
1062	Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. 2005 , 43, 857-61	59
1061	Use of stored serum from Uganda for development and evaluation of a human immunodeficiency virus type 1 testing algorithm involving multiple rapid immunoassays. 2005 , 43, 5312-5	19
1060	Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon?. 2005 , 40, 1350-4	34
1059	Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. 2005 , 191, 2053-63	107
1058	Viral dynamics of primary HIV-1 infection in Senegal, West Africa. 2005 , 191, 1460-7	23

1057	Impact of viral factors on very early in vivo replication profiles in simian immunodeficiency virus SIVagm-infected African green monkeys. 2005 , 79, 6249-59	76
1056	Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. 2005 , 40, 853-8	70
1055	Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. 2005 , 79, 2823-30	79
1054	HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. 2005 , 79, 10218-25	63
1053	Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. 2005 , 79, 4043-54	163
1052	Higher frequency of HIV-1-specific T cell immune responses in African American children vertically infected with HIV-1. 2005 , 192, 1772-80	11
1051	Is antimicrobial multiresistance to antibiotics in Cambodian HIV-positive children related to prior antiretroviral or tuberculosis chemotherapy?. 2004 , 36, 779-80	12
1050	Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences. 2005 , 19, 550-62	25
1049	Oral candidosis as a clinical marker of immune failure in patients with HIV/AIDS on HAART. 2005 , 19, 70-7	35
1048	Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. 2005 , 352, 570-85	465
1047	Risky Business: The Market for Unprotected Commercial Sex. 2005 , 113, 518-550	160
1046	Plateau levels of viremia correlate with the degree of CD4+ T-cell loss in simian immunodeficiency virus SIVagm-infected pigtailed macaques: variable pathogenicity of natural SIVagm isolates. 2005 , 79, 5153-62	42
1045	Displacement of SATB1-bound histone deacetylase 1 corepressor by the human immunodeficiency virus type 1 transactivator induces expression of interleukin-2 and its receptor in T cells. 2005 , 25, 1620-33	64
1044	Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children. 2005 , 191, 1451-9	51
1043	Challenges in the study of patients with HIV type 1 seroconversion. 2005 , 40, 1355-7	4
1042	Evaluation of HIV Clinical Consultation Provided by the AIDS Education and Training Centers. 2005 , 4, 97-112	
1041	Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. 2005 , 79, 3243-53	26
1040	Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. 2005 , 192, 46-55	146

1039	Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. 2005 , 79, 6528-31	225
1038	Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline. 2005 , 79, 4908-17	30
1037	Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. 2005 , 102, 4512-7	119
1036	Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. 2005 , 6, 127-35	15
1035	Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. 2005 , 19, 2001-7	68
1034	HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. 2005 , 40, 250-6	21
1033	Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. 2005 , 365, 233-40	183
1032	When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. 2005 , 5, 407-14	46
1031	HIV testing and monitoring. 2005 , 33, 8-10	
1030	The Evaluation of Surrogate Endpoints. 2005 ,	146
1029	Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. 2005 , 21, 285-91	24
1028	Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens. 2005 , 34, 245-52	25
1027	Basics of the virology of HIV-1 and its replication. 2005 , 34, 233-44	86
1026	Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics. 2005 , 26, 166-71	43
1025	HIV chemokine receptor inhibitors as novel anti-HIV drugs. 2005 , 16, 659-77	38
1024	Analysis of IGG and IGG4 in HIV-1 seropositive patients and correlation with biological and genetic markers. 2005 , 59, 38-46	4
1023	Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. 2005 , 112, 771-9	76
1022	SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251. 2006 , 3, 65	5

1021	Virus fitness: concept, quantification, and application to HIV population dynamics. 2006 , 299, 83-140	60
1020	Synthesis of 2-bromomethyl-3-hydroxy-2-hydroxymethyl-propyl pyrimidine and theophylline nucleosides under microwave irradiation. Evaluation of their activity against hepatitis B virus. 2006 , 25, 925-39	9
1019	New Concepts of Antiviral Therapy. 2006 ,	
1018	Economic models of antiretroviral therapy: searching for the optimal strategy. 2006 , 24, 631-42	11
1017	Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. 2006 , 6, 215-25	47
1016	Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. 2006 , 368, 1254-9	92
1015	HIV and skin cancer. 2006 , 24, 521-30, vii	12
1014	Acute retroviral syndrome. 2006 , 24, 431-8, v	7
1013	Human Immunodeficiency Virus (HIV). 2006 ,	
1012	Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. 2006 , 44, 4371-5	20
1011	Nucleic acid testing for viral burden and viral genotyping. 2006 , 363, 197-205	13
1010	On the intra-host dynamics of HIV-1 infections. 2006 , 199, 1-25	19
1009	Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert. 2006 , 24, 532-9	3
1008	Acquired Immunodeficiency Syndrome in the Infant. 2006 , 667-692	3
1007	Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. 2006 , 1, e89	35
1006	Difference of progression to AIDS according to CD4 cell count, plasma HIV RNA level and the use of antiretroviral therapy among HIV patients infected through blood products in Japan. 2006 , 16, 101-6	7
1005	Molecular Diagnostics for HIV-1. 2006 , 453-459	
1004	The scientific basis of pediatric HIV care. 3-77	

1003	The Shifting Locus of Risk-Reduction. 2006 , 42, 112-132	1
1002	Effect of a liquid nutritional supplement on viral load and haematological parameters in HIV-positive/AIDS patients. 2006 , 63, 134-9	8
1001	MODELLING OF HIV INFECTION: VACCINE READINESS, DRUG EFFECTIVENESS AND THERAPEUTICAL FAILURES. 2006 , 39, 485-492	
1000	Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. 2006 , 20, 1117-23	49
999	Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill. 2006 , 20, 1987	1
998	Response to Waters et al. "Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia ...". 2006 , 20, 1991-2	2
997	HIV escape and attenuation by cytotoxic T lymphocytes. 2006 , 1, 34-9	3
996	Stable virulence levels in the HIV epidemic of Switzerland over two decades. 2006 , 20, 889-94	45
995	Drugs should be affordable to India's poor to fight HIV/AIDS. 2006 , 20, 1988-9	
994	The role of tenofovir in the prevention of HIV infections. 2006 , 20, 1990-1	7
993	AIDS/HIV, Molecular and Cell Biology. 2006 ,	
992	[Frontier of AIDS therapy]. 2006 , 95, 2112-7	
991	Semi-parametric accelerated failure time regression analysis with application to interval-censored HIV/AIDS data. 2006 , 25, 3850-63	16
990	Radical prostatectomy in patients infected with human immunodeficiency virus. 2006 , 98, 303-7	17
989	Distribution of brain HIV load in AIDS. 1998 , 8, 277-84	190
988	Rapid characterization of HIV clade C-specific cytotoxic T lymphocyte responses in infected African children and adults. 2000 , 918, 330-45	12
987	Simian immunodeficiency viruses replication dynamics in African non-human primate hosts: common patterns and species-specific differences. 2006 , 35, 194-201	52
986	Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C. 2006 , 13, 482-8	12

985	Micronutrient interventions and HIV infection: a review of current evidence. 2006 , 11, 1849-57	39
984	A schematic age-structured compartment model of the impact of antiretroviral therapy on HIV incidence and prevalence. 2006 , 71, 131-148	2
983	Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR. 2006 , 32, 101-10	7
982	Quality of life in HIV subtype C infection among asymptomatic subjects and its association with CD4 counts and viral loads--a study from South India. 2006 , 15, 1597-605	36
981	Polymorphisms in eight host genes associated with control of HIV replication do not mediate elite control of viral replication in SIV-infected Indian rhesus macaques. 2006 , 58, 1003-9	19
980	Antiretroviral therapy 2006: pharmacology, applications, and special situations. 2006 , 29, 431-58	10
979	DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. 2006 , 348, 200-15	28
978	Interactive association of proviral load and IFN-gamma-secreting T cell responses in HIV-1C infection. 2006 , 349, 142-55	15
977	Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. 2006 , 352, 169-77	72
976	Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate. 2006 , 354, 116-31	5
975	Aspects of successful drug discovery and development. 2006 , 71, 77-89	39
974	Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: Comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays--LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor. 2006 , 131, 134-42	32
973	Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry. 2006 , 131, 134-42	61
972	Development and evaluation of a real-time RT-PCR assay for quantification of cell-free human immunodeficiency virus type 2 using a Brome Mosaic Virus internal control. 2006 , 135, 102-8	37
971	Comparison of the COBAS TAQMAN HIV-1 HPS with VERSANT HIV-1 RNA 3.0 assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes. 2006 , 135, 223-8	13
970	A new Real-Time-RT-PCR for quantitation of human endogenous retroviruses type K (HERV-K) RNA load in plasma samples: increased HERV-K RNA titers in HIV-1 patients with HAART non-suppressive regimens. 2006 , 136, 51-7	47
969	Reverse transcriptase activity for quantitation of HIV-1 subtype C in plasma: relation to RNA copy number and CD4 T-cell count. 2006 , 78, 161-8	16
968	Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials. 2006 , 7, 116-24	2

967	Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings: efficiency related to active case finding. 2006 , 41, 232-7	3
966	Baseline HIV RNA and the when to start question: time to stop asking this question?. 2006 , 20, 1197-8	
965	Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin. 2006 , 20, 1989-90	7
964	The role of Vpr in HIV-1 disease progression is independent of its G2 arrest induction function. 2006 , 5, 2275-80	11
963	Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost. 2006 , 42, 1772-80	9
962	HIV pathogenesis: knowledge gained after two decades of research. 2006 , 19, 10-6	32
961	Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. 2006 , 296, 1498-506	241
960	HIV-1 fitness and disease progression: insights from the SIV-macaque model. 2006 , 4, 65-77	17
959	On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials. 2006 , 2, e64	5
958	Primary simian immunodeficiency virus SIVmnd-2 infection in mandrills (<i>Mandrillus sphinx</i>). 2006 , 80, 3301-9	34
957	Biological and Medical Data Analysis. 2006 ,	1
956	Role of avidity and breadth of the CD4 T cell response in progression to AIDS. 2006 , 273, 1697-704	7
955	APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. 2006 , 80, 2069-72	60
954	Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. 2006 , 43, 1337-46	73
953	Primary HIV. 2006 , 82, 267-8	3
952	Infectious molecular clones from a simian immunodeficiency virus-infected rapid-progressor (RP) macaque: evidence of differential selection of RP-specific envelope mutations in vitro and in vivo. 2006 , 80, 1463-75	24
951	Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. 2006 , 43, 1347-56	80
950	The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. 2006 , 3, 119-32	6

949	Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. 2006 , 80, 5211-8	144
948	Quantification of Feline immunodeficiency virus (FIVpco) in peripheral blood mononuclear cells, lymph nodes and plasma of naturally infected cougars. 2006 , 87, 967-975	8
947	Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. 2006 , 296, 1523-5	14
946	Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. 2006 , 80, 5875-85	217
945	Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. 2006 , 42, 843-52	153
944	The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. 2006 , 58, 1024-30	27
943	Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. <i>Science</i> , 2006 , 312, 1530-3	333 310
942	Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. 2006 , 70, 548-63	149
941	Physical theory of the competition that allows HIV to escape from the immune system. 2006 , 97, 188106	10
940	The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. 2006 , 22, 640-7	40
939	Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. 2006 , 19, 728-62	209
938	Th-1-type cytotoxic CD8+ T-lymphocyte responses to simian immunodeficiency virus (SIV) are a consistent feature of natural SIV infection in sooty mangabeys. 2006 , 80, 2771-83	57
937	Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. 2006 , 80, 6757-63	26
936	CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. 2006 , 42, 709-15	166
935	Is the glass three-quarters full or one-quarter empty?. 2006 , 194, 1628-31	6
934	Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. 2007 , 81, 8838-42	78
933	Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. 2007 , 81, 5759-65	65
932	FoxP3+ CD25+ CD8+ T-cell induction during primary simian immunodeficiency virus infection in cynomolgus macaques correlates with low CD4+ T-cell activation and high viral load. 2007 , 81, 13444-55	45

931	Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of human immunodeficiency virus type 1 burden. 2007 , 45, 891-6	39
930	Genetic and biological characterization of recombinant HIV type 1 with Env derived from long-term nonprogressor (LTNP) viruses. 2007 , 23, 1377-86	3
929	Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. 2007 , 179, 3035-46	222
928	Impact of antiretroviral treatment on gene expression in peripheral blood mononuclear cells from SIVmac251-infected macaques. 2007 , 196, 384-93	3
927	Optimal timing and duration of induction therapy for HIV-1 infection. 2007 , 3, e133	8
926	The relation between symptoms, viral load, and viral load set point in primary HIV infection. 2007 , 45, 445-8	64
925	Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. 2007 , 44, 478-83	28
924	Virus immunocapture provides evidence of CD8 lymphocyte-derived HIV-1 in vivo. 2007 , 21, 1507-13	7
923	When to initiate HIV antiretroviral therapy: do benefits other than survival deserve greater attention?. 2007 , 45, 131-2	6
922	Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial. 2007 , 8, 68-76	2
921	Antiretroviral treatment of HIV infection: Swedish recommendations 2007. 2007 , 39, 486-507	16
920	Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?. 2007 , 6, 289-91	2
919	An ultrasensitive young interferometer handheld sensor for rapid virus detection. 2007 , 4, 447-54	11
918	Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. 2007 , 19, 637-45	30
917	Contribution of monocytes to viral replication in macaques during acute infection with simian immunodeficiency virus. 2007 , 23, 372-80	10
916	Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. 2007 , 297, 2349-50	104
915	Real-time quantitative RT-PCR and PCR assays for a novel European field isolate of equine infectious anaemia virus based on sequence determination of the gag gene. 2007 , 160, 611-8	31
914	Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. 2007 , 81, 5325-30	79

913	Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex. 2007 , 85, 261-300	21
912	Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay. 2007 , 45, 3616-9	33
911	Long-term inpatient viral evolution during HIV-2 infection. 2007 , 195, 726-33	31
910	Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. 2007 , 195, 1452-60	115
909	Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. 2007 , 166, 219-27	48
908	Papers in this week's Veterinary Record. 2007 , 160, 610-610	1
907	Virus subtype-specific features of natural simian immunodeficiency virus SIVsmm infection in sooty mangabeys. 2007 , 81, 7913-23	58
906	Impact of the COBAS AmpliPrep/COBAS AMPLICOR HIV-1 MONITOR Test, Version 1.5, on clinical laboratory operations. 2007 , 45, 3101-4	4
905	Neurological sequelae of primary HIV infection. 2007 , 85, 69-77	1
904	Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. 2007 , 104, 17441-6	306
903	Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. 2007 , 81, 5024-35	66
902	Dynamics of T-cell responses and memory T cells during primary simian immunodeficiency virus infection in cynomolgus macaques. 2007 , 81, 13456-68	42
901	Correlates of preserved CD4(+) T cell homeostasis during natural, nonpathogenic simian immunodeficiency virus infection of sooty mangabeys: implications for AIDS pathogenesis. 2007 , 178, 1680-91	97
900	Comparison of the Roche COBAS Amplicor Monitor, Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Test assays for quantification of hepatitis C virus and HIV RNA. 2007 , 45, 917-22	18
899	Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes. 2007 , 81, 406-10	39
898	Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. 2007 ,	1
897	Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. 2007 , CD006517	5
896	The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase. 2007 , 21, 2015-23	27

895	Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfecting patients. 2007 , 2, 489-95	
894	Treatment interruption to boost specific HIV immunity in acute infection. 2007 , 2, 21-5	5
893	Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. 2007 , 204, 2171-85	235
892	Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. 2007 , 21, 565-74	58
891	Analytic insights into the population level impact of imperfect prophylactic HIV vaccines. 2007 , 45, 454-67	16
890	Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review. 2007 , 104, 455-60	22
889	Does preserving memory correlate with surviving HIV?. 2007 , 15, 1-3	1
888	Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. 2007 , 11, 413-6	41
887	Viral dynamics in transplant patients: implications for disease. 2007 , 7, 460-72	54
886	Advances in Statistical Methods for the Health Sciences. 2007 ,	4
885	CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. 2007 , 81, 2440-8	126
884	Molecular Pathology in Clinical Practice. 2007 ,	3
883	Toll-like receptor signaling in HIV-1 infection: a potential target for therapy?. 2007 , 5, 323-6	9
882	An HIV vaccine--evolving concepts. 2007 , 356, 2073-81	220
881	Primary care issues for HIV-infected patients. 2007 , 21, 49-70, viii	4
880	HIV testing and monitoring. 2007 , 3, 126-128	
879	Psychobiology of HIV Infection. 2007 , 1053-1076	6
878	Analysis of relation between virologic responses and immunologic responses, patient's factors in AIDS clinical trials using a semiparametric mixed-effects model. 2007 , 49, 406-15	

877	Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART). 2007 , 46, 359-70	12
876	Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load . 2007 , 79, 1440-5	10
875	Modelling of HIV infection: Vaccine readiness, drug effectiveness and therapeutical failures. 2007 , 17, 253-260	20
874	Understanding the mechanisms and limitations of immune control of HIV. 2007 , 216, 164-75	43
873	CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. 2007 , 8, 1324-36	130
872	CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. 2007 , 13, 46-53	824
871	Is HIV-1 evolving to a less virulent form in humans?. 2007 , 5, 141-51	142
870	Acutely dysregulated, chronically disabled by the enemy within: T-cell responses to HIV-1 infection. 2007 , 85, 6-15	41
869	Dynamics of CD4+ T cells in HIV-1 infection. 2007 , 85, 287-94	18
868	A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. 2007 , 261, 123-31	19
867	Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. 2007 , 8, 511-9	41
866	HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. 2007 , 8, 536-46	33
865	Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins. 2007 , 36, 195-205	9
864	Epidemiology, pathogenesis, and management of human immunodeficiency virus infection in patients with periodontal disease. 2007 , 44, 55-81	23
863	Immunophenotypic alterations in acute and early HIV infection. 2007 , 125, 299-308	10
862	Efficient repeated low-dose intravaginal infection with X4 and R5 SHIVs in rhesus macaque: implications for HIV-1 transmission in humans. 2007 , 362, 207-16	19
861	Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys. 2007 , 367, 390-7	8
860	Clinical performance of an in-house real-time RT-PCR assay using a fluorogenic LUX primer for quantitation of human immunodeficiency virus type-1 (HIV-1). 2007 , 146, 14-21	7

859	Fast, ultrasensitive virus detection using a Young interferometer sensor. 2007 , 7, 394-7	224
858	The Interaction between HIV and malaria in Africa. 2007 , 9, 47-54	24
857	Hepatitis C virus infection in HIV-infected patients. 2007 , 3, 469-76	9
856	Liver transplant in patients with HIV: infection risk associated with HIV and post-transplant immunosuppression. 2008 , 10, 74-81	2
855	Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. 2008 , 40, 271-86	7
854	A comparison of methods for determining HIV viral set point. 2008 , 27, 121-39	13
853	Cervical cancer in patients infected with the human immunodeficiency virus. 2008 , 112, 2683-9	15
852	Affordable CD4 T-cell enumeration for resource-limited regions: a status report for 2008. 2008 , 74 Suppl 1, S27-39	36
851	Synthesis and antiviral evaluation of novel 2,3-dihydroxypropyl nucleosides from 2- and 4-thiouracils. 2008 , 27, 1257-71	9
850	Association of HIV viral load with oral diseases. 1999 , 5, 294-8	29
849	Immune alteration fends off AIDS. 2008 , 14, 1016-8	3
848	Autoantibodies vex the vasculature. 2008 , 14, 1018-9	12
847	The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. 2008 , 65 Suppl 1, 47-53	17
846	Connectivity and HIV-1 Infection: Role of CD4+ T-Cell Counts and HIV-1 RNA Copy Number. 2008 , 52, 618-627	
845	Changes in simian immunodeficiency virus reverse transcriptase alleles that appear during infection of macaques enhance infectivity and replication in CD4+ T cells. 2008 , 370, 184-93	7
844	AIDS pathogenesis: a tale of two monkeys. 2008 , 37 Suppl 2, 6-12	27
843	Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays. 2008 , 8, 369-77	10
842	Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-biphosphate in membrane targeting. 2008 , 382, 434-47	80

841	The molecular biology and evolution of feline immunodeficiency viruses of cougars. 2008 , 123, 154-8	5
840	Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease. 2008 , 22, 676-89	63
839	HIV-1 at 25. 2008 , 133, 561-5	24
838	Disease progression patterns of SHIV-KB9 in rhesus macaques of Chinese origin in comparison with Indian macaques. 2008 , 21, 302-7	6
837	AIDS: Overview. 2008 , 90-98	
836	Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. 2008 , 197, 1394-401	48
835	Immunopharmacology. 2008 ,	5
834	PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples. 2008 , 6, 49-58	22
833	Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. 2008 , 48, 263-71	39
832	MULTI-AGENT SIMULATIONS OF THE IMMUNE RESPONSE TO HIV DURING THE ACUTE STAGE OF INFECTION. 2008 , 19, 15-32	3
831	Real-time quantitative polymerase chain reaction for virus infection diagnostics. 2008 , 2, 1155-71	6
830	Early divergence in lymphoid tissue apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates. 2008 , 82, 1175-84	70
829	The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. 2008 , 283, 31289-93	71
828	Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples. 2008 , 181, 2626-35	41
827	Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. 2008 , 82, 5501-9	76
826	Use of viral loads in blood and nasopharyngeal secretions for the diagnosis of EHV-1 infection in field cases. 2008 , 162, 728-9	18
825	Rapid disease progression to AIDS due to Simian immunodeficiency virus infection of macaques: host and viral factors. 2008 , 56, 369-98	6
824	Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. 2008 , 198, 486-92	37

823	Hormonal contraception and HIV disease progression. 2008 , 47, 945-51	22
822	Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. 2008 , 82, 3725-35	70
821	Assays for the determination of HIV-1 load in semen: a review of indications, methods and performance in vitro. 2008 , 6, 182-8	3
820	On methods to utilize HIV-RNA data measured by two different PCR assays. 2008 , 18, 724-36	1
819	Targeting of a CD8 T cell env epitope presented by HLA-B*5802 is associated with markers of HIV disease progression and lack of selection pressure. 2008 , 24, 72-82	52
818	Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. 2008 , 22, 2179-85	93
817	Immune activation and AIDS pathogenesis. 2008 , 22, 439-46	181
816	Cytotoxic T lymphocyte responses in HIV-1-infected long-term nonprogressors: lessons for vaccine design. 2008 , 2, 351-361	1
815	Different disease progression rate according to HIV-1 subtype. 2008 , 2, 319-322	1
814	Psychosocial influences on HIV-1 disease progression: neural, endocrine, and virologic mechanisms. 2008 , 70, 562-8	60
813	Immunology of SIV infection in natural hosts: implications for HIV pathogenesis. 2008 , 2, 603-611	
812	The helminth HIV connection: time to act. 2008 , 22, 1611-4	8
811	Primary HIV infection: to treat or not to treat?. 2008 , 21, 4-10	22
810	Humans with chimpanzee-like major histocompatibility complex-specificities control HIV-1 infection. 2008 , 22, 1299-303	7
809	Host factors associated with outcome from primary human immunodeficiency virus-1 infection. 2008 , 3, 28-35	7
808	Role of the gastrointestinal tract in establishing infection in primates and humans. 2008 , 3, 22-7	25
807	HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. 2008 , 48, 350-4	37
806	Assessment of cytokine values in serum by RT-PCR in HIV-1 infected individuals with and without highly active anti-retroviral therapy (HAART). 2008 , 14, 685-702	2

805	Prevalence of resistance-associated mutations in human immunodeficiency virus type 1-positive individuals failing HAART in Rio de Janeiro, Brazil. 2008 , 12, 380-4	6
804	Factors influencing the natural history of HIV-1 infection. 2008 , 121, 2613-2621	2
803	[HIV controllers: a new evolutionary entity of HIV infection?]. 2008 , 24, 7-9	0
802	Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. 2008 , 3, e3907	144
801	The Role of the APOBEC3 Family of Cytidine Deaminases in Innate Immunity, G-to-A Hypermutation, and Evolution of Retroviruses. 2008 , 183-205	4
800	Intra-host Dynamics and Evolution of HIV Infection. 2008 , 279-301	4
799	Cost-effectiveness of HIV screening in patients older than 55 years of age. 2008 , 148, 889-903	50
798	Lentiviruses in Their Natural Hosts. 77-118	
797	. 2009 ,	10
796	Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV?. 2009 , 20, e1-7	16
795	Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. 2009 , 200, 1714-23	210
794	Beneficial effects of a combination of Korean red ginseng and highly active antiretroviral therapy in human immunodeficiency virus type 1-infected patients. 2009 , 16, 1127-31	35
793	Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. 2009 , 47, 889-95	38
792	Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. 2009 , 106, 9403-8	337
791	Armored long RNA controls or standards for branched DNA assay for detection of human immunodeficiency virus type 1. 2009 , 47, 2571-6	38
790	Evaluation of a highly sensitive qualitative human immunodeficiency virus type 1 (HIV-1) RNA assay for detection of HIV-1 suppression. 2009 , 47, 833-6	8
789	Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. 2009 , 183, 706-17	32
788	Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. 2009 , 83, 7641-8	153

787	Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis. 2009 , 206, 1575-88	60
786	Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo. 2009 , 83, 2349-56	7
785	Rapid, ultrasensitive detection of microorganisms based on interferometry and lab-on-a-chip nanotechnology. 2009 ,	2
784	Comparison of four methods to quantify Equid herpesvirus 1 load by real-time polymerase chain reaction in nasal secretions of experimentally and naturally infected horses. 2009 , 21, 836-40	17
783	Epidemiologically linked transmission of HIV-1 illustrates the impact of host genetics on virological outcome. 2009 , 23, 259-62	3
782	Phenotypic and functional characterization of HIV-1-specific CD4+CD8+ double-positive T cells in early and chronic HIV-1 infection. 2009 , 50, 444-56	24
781	United Kingdom acquisition of HIV infection in African residents in London: more than previously thought. 2009 , 23, 262-6	26
780	AIDS in african nonhuman primate hosts of SIVs: a new paradigm of SIV infection. 2009 , 7, 57-72	76
779	Clinical implications of new findings in HIV basic research. 2009 , 3, 351-360	1
778	Update on HIV viral-load assays: new technologies and testing in resource-limited settings. 2009 , 4, 423-430	5
777	Development and assessment of a multiplex real-time PCR assay for quantification of human immunodeficiency virus type 1 DNA. 2009 , 47, 2194-9	18
776	Increasing clinical virulence in two decades of the Italian HIV epidemic. 2009 , 5, e1000454	30
775	Inhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys. 2009 , 5, e1000691	33
774	HLA-mediated control of HIV and HIV adaptation to HLA. 2009 , 68, 1-20	7
773	Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. 2009 , 5, e1000296	111
772	Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. 2009 , 83, 470-8	54
771	Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. 2009 , 83, 3719-33	537
770	Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. 2009 , 182, 7131-45	72

769	High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. 2009 , 83, 3288-97	85
768	HIV testing and monitoring. 2009 , 37, 326-329	1
767	The changing profile of mental health problems in people with HIV. 2009 , 8, 216-222	2
766	Quantitation of HIV-1 group M proviral DNA using TaqMan MGB real-time PCR. 2009 , 157, 141-6	15
765	Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study. 2009 , 159, 93-7	16
764	HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load. 2009 , 131, 277-87	18
763	Modeling HIV persistence, the latent reservoir, and viral blips. 2009 , 260, 308-31	164
762	Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection. 2009 , 259, 751-9	61
761	Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease. 2009 , 15, 25-35	6
760	Genomic Medicine and AIDS. 2009 , 1324-1339	
759	Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART). 2009 , 99, 96-104	8
758	Brazilian HIV-infected population: assessment of the needs of endodontic treatment in the post-highly active antiretroviral therapy era. 2009 , 35, 1178-81	7
757	[Aviremic HIV infection: "elite controller" patients]. 2009 , 209, 260-1	
756	Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques. 2009 , 6, 106	33
755	The co-receptor signaling model of HIV-1 pathogenesis in peripheral CD4 T cells. 2009 , 6, 41	8
754	Nef gene evolution from a single transmitted strain in acute SIV infection. 2009 , 6, 57	5
753	Lessons learned from the natural hosts of HIV-related viruses. 2009 , 60, 485-95	88
752	The ABC of HIV Clinical Trials. 2009 , 23, 201-211	

751	Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. 2009 , 23, 19-28	72
750	Defining treatment failure in resource-rich settings. 2009 , 4, 459-66	30
749	Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. 2009 , 23, 266-8	14
748	Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative. 2009 , 23 Suppl 1, S69-77	27
747	Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. 2009 , 23, 268-72	20
746	Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. 2009 , 50, 19-26	28
745	Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. 2009 , 23, 257-9	21
744	An optimized sensitive method for quantitation of DNA/RNA viruses in heparinized and cryopreserved plasma. 2011 , 176, 1-8	11
743	A multiplex calibrated real-time PCR assay for quantitation of DNA of EBV-1 and 2. 2011 , 178, 98-105	10
742	Pathogenic mechanisms of HIV disease. 2011 , 6, 223-48	229
741	Using the Millon Behavioral Medicine Diagnostic (MBMD) to evaluate the need for mental health services in association with biomarkers of disease status among HIV positive men and women. 2011 , 18, 30-8	5
740	Increased APOBEC3G and APOBEC3F expression is associated with low viral load and prolonged survival in simian immunodeficiency virus infected rhesus monkeys. 2011 , 8, 77	23
739	Treatment as prevention: preparing the way. 2011 , 14 Suppl 1, S6	25
738	Individual differences in emotionality: social temperament and health. 2011 , 73, 507-15	32
737	Empirical likelihood for semiparametric regression model with missing response data. 2011 , 102, 723-740	25
736	Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. 2011 , 6, 1251-60	27
735	Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. 2011 , 8, 1035-46	38
734	Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. 2011 , 49, 118-24	47

733	Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. 2011 , 85, 7523-34	69
732	Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses. 2011 , 85, 4618-22	16
731	Viremia copy-years predicts mortality among treatment-naïve HIV-infected patients initiating antiretroviral therapy. 2011 , 53, 927-35	103
730	Extended high vireemics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. 2011 , 25, 1515-22	51
729	Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. 2011 , 108, 2420-5	88
728	Comparison of the Abbott m2000 HIV-1 Real-Time and Roche AMPLICOR Monitor v1.5 HIV-1 assays on plasma specimens from Rakai, Uganda. 2011 , 22, 373-5	13
727	Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models. 2011 , 28, 1605-16	37
726	The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point?. 2011 , 7, e1002055	62
725	Autonomous targeting of infectious superspreaders using engineered transmissible therapies. 2011 , 7, e1002015	37
724	Modelling the spread of HIV immune escape mutants in a vaccinated population. 2011 , 7, e1002289	7
723	Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion. 2011 , 7, e1002170	66
722	A strong case for viral genetic factors in HIV virulence. 2011 , 3, 204-16	21
721	Transmission selects for HIV-1 strains of intermediate virulence: a modelling approach. 2011 , 7, e1002185	30
720	Examining the relationship between urogenital schistosomiasis and HIV infection. 2011 , 5, e1396	124
719	A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. 2011 , 8, e1000422	85
718	Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). 2011 , 53, 1024-34	42
717	HIV pathogenesis: the host. 2012 , 2, a007005	55
716	Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. 2012 , 8, e1003041	70

715	Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. 2012 , 8, e1002529	270
714	HIV-1 dynamics: a reappraisal of host and viral factors, as well as methodological issues. 2012 , 4, 2080-96	10
713	The impact of HIV-1 infection and exposure on natural killer (NK) cell phenotype in Kenyan infants during the first year of life. 2012 , 3, 399	28
712	Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. 2012 , 8, e1002506	86
711	Administration of Fozivudine tidoxil as a single-agent therapeutic during acute feline immunodeficiency virus infection does not alter chronic infection. 2012 , 4, 954-62	3
710	Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. 2012 , 206, 552-61	67
709	The dynamics of HIV-1 adaptation in early infection. 2012 , 190, 1087-99	14
708	Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120. 2012 , 92, 1093-102	19
707	Using HIV viral load to guide treatment-for-prevention interventions. 2012 , 7, 117-24	27
706	Rheonix CARD() Technology: An Innovative and Fully Automated Molecular Diagnostic Device. 2012 , 11, 42-51	15
705	HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. 2012 , 4, 123ra25	187
704	Anal human papillomavirus infection in a street-based sample of drug using HIV-positive men. 2012 , 23, 195-200	14
703	Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naïve and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects. 2012 , 8, 479-85	7
702	Interleukin-7 biology in HIV disease and the path to immune reconstitution. 2012 , 10, 341-7	5
701	Size-selective detection in integrated optical interferometric biosensors. 2012 , 20, 20934-50	21
700	The T-cell response to HIV. 2012 , 2,	114
699	Multiple NF- κ B sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. 2012 , 287, 44714-35	56
698	Antiretroviral agents effectively block HIV replication after cell-to-cell transfer. 2012 , 86, 8773-80	32

697	Host factor transcriptional regulation contributes to preferential expression of HIV type 1 in IL-4-producing CD4 T cells. 2012 , 189, 2746-57	17
696	The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. 2012 , 26, 1231-41	95
695	Ten years of external quality assessment of human immunodeficiency virus type 1 RNA quantification. 2012 , 50, 3614-9	17
694	Human serum protein enhances HIV-1 replication and up-regulates the transcription factor AP-1. 2012 , 109, 17639-44	5
693	Transcriptional network predicts viral set point during acute HIV-1 infection. 2012 , 19, 1103-9	9
692	Disease Progression in HIV-1-Infected Viremic Controllers. 2012 , 61, 407-16	24
691	The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. 2012 , 17, 1291-300	8
690	Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. 2012 , 26, F31-7	116
689	Structural brain alterations can be detected early in HIV infection. 2012 , 79, 2328-34	74
688	Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. 2012 , 12, 441-8	39
687	The origin of genetic diversity in HIV-1. 2012 , 169, 415-29	89
686	Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. 2012 , 188, 2158-64	23
685	Impact of HIV type 1 DNA levels on spontaneous disease progression: a meta-analysis. 2012 , 28, 366-73	15
684	A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. 2012 , 30, 4465-75	36
683	Analysis of host genetic diversity and viral entry as sources of between-host variation in viral load. 2012 , 165, 71-80	15
682	Preoperative CD4 count or CD4/CD8 ratio as a useful indicator for postoperative sepsis in HIV-infected patients undergoing abdominal operations. 2012 , 174, e25-30	26
681	A model of HIV-1 infection with two time delays: mathematical analysis and comparison with patient data. 2012 , 235, 98-109	115
680	Human Immunodeficiency Virus Infection : from Biological Observations to Mechanistic Mathematical Modelling. 2012 , 7, 78-104	35

679	Developing strategies for HIV-1 eradication. 2012 , 33, 554-62	77
678	Agent-based and phylogenetic analyses reveal how HIV-1 moves between risk groups: injecting drug users sustain the heterosexual epidemic in Latvia. 2012 , 4, 104-16	26
677	Viral population dynamics and virulence thresholds. 2012 , 15, 525-30	17
676	Pediatric HIV Infection. 2012 , 59, 9-26	6
675	The immune response to HIV. 2012 , 45-57	
674	Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. 2012 , 7, e33715	34
673	Immune Responses Associated to Viral Control. 2012 , 273-291	
672	Immunovirological parameters and cytokines in HIV infection. 2012 , 45, 663-9	13
671	Routine viral load monitoring versus standard care for reducing morbidity and mortality in adolescent and adult patients living with HIV on antiretroviral therapy (ART). 2012 ,	
670	Implications for Therapy. 2012 , 81-132	2
669	Skew-normal/independent linear mixed models for censored responses with applications to HIV viral loads. 2012 , 54, 405-25	29
668	Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. 2012 , 109, 9523-8	170
667	Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. 2012 , 56, 4154-60	21
666	Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations. 2012 , 157, 433-40	1
665	Cell-associated HIV RNA: a dynamic biomarker of viral persistence. 2013 , 10, 41	83
664	An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. 2013 , 10, 52	33
663	Effect of malaria on HIV/AIDS transmission and progression. 2013 , 6, 18	68
662	Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia. 2013 , 202, 67-75	23

661	Primates, Pathogens, and Evolution. 2013 ,	3
660	Epidemiology and interactions of Human Immunodeficiency Virus - 1 and Schistosoma mansoni in sub-Saharan Africa. 2013 , 2, 2	27
659	War in the Body. 2013 ,	2
658	Development of the First AIDS Drugs: AZT and Other Dideoxynueosides. 2013 , 1-20	
657	HIV virology, testing and monitoring. 2013 , 41, 420-424	3
656	On the role of resonance in drug failure under HIV treatment interruption. 2013 , 10, 44	1
655	Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013. 2013 , 10, 93	9
654	SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans. 2013 , 10, 89	39
653	HIV-Associated Infections. 2013 , 1441-1472	4
652	Molecular Diagnosis of HIV-1 Infections: Current State of the Art. 2013 , 785-812	
651	Management of human immunodeficiency virus in primary care. 2013 , 40, 589-617	3
650	Virus-induced target cell activation reconciles set-point viral load heritability and within-host evolution. 2013 , 5, 174-80	6
649	[Host's genetics in HIV disease]. 2013 , 61, 17-20	0
648	Comparison of the NucliSENS EasyQ HIV-1 v2.0 with Abbott m2000rt RealTime HIV-1 assay for plasma RNA quantitation in different HIV-1 subtypes. 2013 , 193, 18-22	11
647	Validation of dilution of plasma samples with phosphate buffered saline to eliminate the problem of small volumes associated with children infected with HIV-1 for viral load testing using Cobas AmpliPrep/COBAS TaqMan HIV-1 test, version 2.0 (CAP CTM HIV v2.0). 2013 , 194, 217-21	2
646	A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns. 2013 , 7, 11	11
645	Empirical likelihood semiparametric nonlinear regression analysis for longitudinal data with responses missing at random. 2013 , 65, 639-665	7
644	Human immunodeficiency virus-related retinal microangiopathy and systemic cytomegalovirus disease association. 2013 , 57, 372-8	5

643	Molecular HIV screening. 2013 , 13, 693-705	7
642	Efficient mucosal transmissibility but limited pathogenicity of R5 SHIV SF162P3N in Chinese-origin rhesus macaques. 2013 , 62, 496-504	7
641	CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa. 2013 , 63, 34-41	21
640	Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. 2013 , 57, 448-57	9
639	A novel PCR assay for quantification of HIV-1 RNA. 2013 , 87, 6521-5	64
638	The Evolution of SIV in Primates and the Emergence of the Pathogen of AIDS. 2013 , 291-327	
637	SIVagm infection in wild African green monkeys from South Africa: epidemiology, natural history, and evolutionary considerations. 2013 , 9, e1003011	82
636	Kinetics of myeloid dendritic cell trafficking and activation: impact on progressive, nonprogressive and controlled SIV infections. 2013 , 9, e1003600	25
635	Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. 2013 , 9, e1003798	59
634	Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. 2013 , 207, 1195-205	42
633	Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy. 2013 , 8, 87-92	22
632	HIV pathogenesis: dynamics and genetics of viral populations and infected cells. 2013 , 3, a012526	76
631	How effectively can HIV phylogenies be used to measure heritability?. 2013 , 2013, 209-24	16
630	Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. 2013 , 87, 3952-65	43
629	Pressure from TRIM5 α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles. 2013 , 87, 10368-80	23
628	HLA-B*44 is associated with a lower viral set point and slow CD4 decline in a cohort of Chinese homosexual men acutely infected with HIV-1. 2013 , 20, 1048-54	8
627	HLA Genetic Polymorphisms: Role in HIV-1 Susceptibility, Disease Progression and Treatment Outcomes. 2013 , 1	1
626	Human Immunodeficiency Virus Reverse Transcriptase. 2013 ,	

625	Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters. 2013 , 29, 164-71	18
624	Is HIV short-sighted? Insights from a multistrain nested model. 2013 , 67, 2769-82	39
623	Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing. 2013 , 2, e137	42
622	Impact of pre-therapy viral load on virological response to modern first-line HAART. 2013 , 18, 867-76	31
621	Disparities in community viral load among HIV-infected persons in New York City. 2013 , 27, 2129-39	15
620	Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. 2013 , 27, 1119-28	2
619	Acute human immunodeficiency virus infection. 2013 , 345, 136-42	26
618	Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection. 2013 , 27, 313-23	2
617	EVOLUTION OF PATIENTS WITH AIDS AFTER cART: CLINICAL AND LABORATORY EVOLUTION OF PATIENTS WITH AIDS AFTER 48 WEEKS OF ANTIRETROVIRAL TREATMENT. 2013 , 55, 267-273	2
616	High Rate of Non-detectable HIV-1 RNA Among Antiretroviral Drug Naive HIV Positive Individuals in Nigeria. 2013 , 4, 35-40	3
615	Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testing. 2013 , 8, e62928	11
614	A stochastic multi-scale model of HIV-1 transmission for decision-making: application to a MSM population. 2013 , 8, e70578	6
613	Gastrointestinal viral load and enteroendocrine cell number are associated with altered survival in HIV-1 infected individuals. 2013 , 8, e75967	4
612	The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature. 2013 , 2013, 176459	27
611	Introduction to Human Immunodeficiency Virus. 2013 , 1-17	
610	Evaluation of the NucliSens EasyQ v2.0 assay in comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in quantification of C-clade HIV-1 in plasma. 2014 , 9, e103983	10
609	A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression. 2014 , 9, e114111	12
608	Patients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression. 2014 , 9, e114441	18

607 HIV to AIDS—the Dynamics of HIV Infection. **2014**, 03,

606 Simian Immunodeficiency Virus Infections in the Wild. **2014**, 37-67

1

605 Bibliography. 219-244

604 Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. **2014**, 52, 3944-51

70

603 Factors associated with simian immunodeficiency virus transmission in a natural African nonhuman primate host in the wild. **2014**, 88, 5687-705

62

602 Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?. **2014**, 369, 20130436

18

601 The contribution of viral genotype to plasma viral set-point in HIV infection. **2014**, 10, e1004112

33

600 Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. **2014**, 111, E5393-400

65

599 Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. **2014**, 44, 2925-37

41

598 Single-copy quantification of HIV-1 in clinical samples. **2014**, 1087, 251-60

2

597 Role of Fc-mediated antibody function in protective immunity against HIV-1. **2014**, 142, 46-57

59

596 CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads. **2014**, 209, 922-30

8

595 In vivo HIV-1 hypermutation and viral loads among antiretroviral-naïve Brazilian patients. **2014**, 30, 867-80

6

594 Pathogenic features associated with increased virulence upon Simian immunodeficiency virus cross-species transmission from natural hosts. **2014**, 88, 6778-92

25

593 Does this adult patient have early HIV infection?: The Rational Clinical Examination systematic review. **2014**, 312, 278-85

22

592 Human Immunodeficiency Viruses Types 1 and 2. **2014**, 1001-1062

591 Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control. **2014**, 88, 7357-66

35

590 Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. *Science*, **2014**, 343, 124372733.3 163

589	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. 2014 , 14, 281-90	345
588	Design and expression of a short peptide as an HIV detection probe. 2014 , 443, 308-12	22
587	Human Retroviruses. 2014 ,	
586	Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. 2014 , 30, 1027-40	14
585	Viral suppression in HIV studies: combining times to suppression and rebound. 2014 , 70, 441-8	6
584	Bayesian Analysis of Nonlinear Reproductive Dispersion Mixed Models for Longitudinal Data with Nonignorable Missing Covariates. 2014 , 43, 1265-1287	4
583	Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing. 2014 , 30, 806-11	2
582	Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-term disease outcome. 2014 , 88, 12793-801	27
581	The Different Modes of Resistance to AIDS: Lessons from HIV/SIV Controllers and SIV Natural Hosts. 2014 , 287-352	1
580	Cellular HIV type 1 DNA levels are equivalent among drug-sensitive and drug-resistant strains in newly diagnosed and antiretroviral naive patients. 2014 , 30, 266-71	4
579	Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections. 2014 , 111, 12187-92	56
578	Laboratory diagnosis of viral infection. 2014 , 123, 123-47	14
577	Attenuation of immune activation in an open-label clinical trial for HIV-AIDS using a polyherbal formulation. 2014 , 25, 302-13	
576	How Helminths Alter Immunity to Infection. 2014 ,	1
575	Infección por el VIH (I). 2014 , 11, 2893-2901	
574	Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. 2014 , 409, 117-30	29
573	End of the debate about antiretroviral treatment initiation. 2014 , 14, 258-9	11
572	Virus-induced target cell activation reconciles set-point viral load heritability and within-host evolution. 2014 , 7, 36-42	0

571	Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. 2014 , 17, 18651	31
570	Determinants of HIV-induced brain changes in three different periods of the early clinical course: A data mining analysis. 2015 , 9, 75-82	13
569	HIV/AIDS. 2015 , 501-581	
568	Simultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolution. 2015 , 6, 67-82	15
567	HIV infection. 2015 , 1, 15035	162
566	HIV transmission law in the age of treatment-as-prevention. 2015 , 41, 982-6	8
565	Pandemic HIV-1 Vpu overcomes intrinsic herd immunity mediated by tetherin. 2015 , 5, 12256	9
564	CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time. 2015 , 29, 2435-46	28
563	Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in Ghana. 2016 , 16, 58	14
562	The need for treatment interruption studies and biomarker identification in the search for an HIV cure. 2015 , 29, 1429-32	47
561	Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution. 2015 , 29, 1549-56	13
560	Management of HIV/AIDS in older patients-drug/drug interactions and adherence to antiretroviral therapy. 2015 , 7, 251-64	24
559	Hepatitis C. 2015 , 1904-1927.e9	4
558	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. 2015 , 7, 5443-75	20
557	Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure. 2015 , 6, 474	11
556	High frequency of transmitted HIV-1 Gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection. 2015 , 10, e0119886	9
555	Extremely High Mutation Rate of HIV-1 In Vivo. 2015 , 13, e1002251	206
554	Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients. 2015 , 10, e0137281	7

553	PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. 2015 , 11, e1005270	31
552	Changes in B-Cell Counts and Percentages during Primary HIV Infection Associated with Disease Progression in HIV-Infected Men Who Have Sex with Men: A Preliminary Study. 2015 , 2015, 468194	2
551	General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases). 2015 , 1541-1557.e5 ²	
550	HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective. 2015 , 13, 250-7	27
549	Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. 2015 , 13, 414-25	120
548	Brain alterations within the first 100 days of HIV infection. 2015 , 2, 12-21	62
547	Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses. 2015 , 16, 95-104	16
546	Interferon-inducible protein 10 (IP-10) is associated with viremia of early HIV-1 infection in Korean patients. 2015 , 87, 782-9	11
545	Detection of viruses by counting single fluorescent genetically biotinylated reporter immunophage using a lateral flow assay. 2015 , 7, 2891-8	16
544	Host genetic and viral determinants of HIV-1 RNA set point among HIV-1 seroconverters from sub-saharan Africa. 2015 , 89, 2104-11	19
543	Contribution of HIV-1 genomes that do not integrate to the basic reproductive ratio of the virus. 2015 , 367, 222-229	3
542	Promoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription. 2015 , 4, e222	17
541	The recombinant maize ribosome-inactivating protein transiently reduces viral load in SHIV89.6 infected Chinese Rhesus Macaques. 2015 , 7, 156-69	10
540	Risk factors for developing active tuberculosis after the treatment of latent tuberculosis in adults infected with human immunodeficiency virus. 2015 , 2, ofu120	19
539	Crossing the scale from within-host infection dynamics to between-host transmission fitness: a discussion of current assumptions and knowledge. 2015 , 370,	63
538	Efficacy of generic highly active antiretroviral therapy in HIV-1 infected individuals in Nigeria. 2015 , 36, 464-77	4
537	High heritability is compatible with the broad distribution of set point viral load in HIV carriers. 2015 , 11, e1004634	18
536	Optimizing an HIV testing program using a system dynamics model of the continuum of care. 2015 , 18, 334-62	22

535	Brief report: HIV-1 transmissions during asymptomatic infection: exploring the impact of changes in HIV-1 viral load due to coinfections. 2015 , 68, 594-8	7
534	HIV-1 replication capacity: Setting the pace of disease. 2015 , 112, 3591-2	
533	In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice. 2015 , 89, 6264-74	59
532	HIV-1 Disease Progression and Survival in an Adult Population in Zimbabwe: Is There an Effect of the Mannose Binding Lectin Deficiency?. 2015 , 19, 542-52	4
531	A lower viral set point but little immunological impact after early treatment during primary HIV infection. 2015 , 28, 134-44	2
530	Biomedical applications of high gradient magnetic separation: progress towards therapeutic haemofiltration. 2015 , 60, 393-404	4
529	Short communication: feasibility and acceptability of developing a multisite clinical cohort of transgender people with HIV infection. 2015 , 31, 870-2	5
528	Low CD1c + myeloid dendritic cell counts correlated with a high risk of rapid disease progression during early HIV-1 infection. 2015 , 15, 342	2
527	Quantitative nucleic acid amplification methods for viral infections. 2015 , 61, 72-8	52
526	Antiretroviral Agent. 2016 , 169-214	0
525	Role of HLA Adaptation in HIV Evolution. 2015 , 6, 665	26
524	Immunological Biomarkers for Patient Stratification. 2016 , 327-361	
523	Effect of Chocolate and Yerba Mate Phenolic Compounds on Inflammatory and Oxidative Biomarkers in HIV/AIDS Individuals. 2016 , 8,	11
522	Higher HIV RNA Viral Load in Recent Patients with Symptomatic Acute HIV Infection in Lyon University Hospitals. 2016 , 11, e0146978	1
521	Detection of rotavirus in clinical specimens using an immunosensor based on the principle of fluorescence fluctuation spectroscopy. 2016 ,	0
520	Molecular Detection and Characterization of Human Immunodeficiency Virus Type 1. 2016 , 417-429	
519	Molecular Diagnostics for Use in HIV/AIDS Care and Treatment in Resource-Limited Settings. 2016 , 580-588	
518	Human Immunodeficiency Viruses and Human T-lymphotropic Viruses. 2016 , 527-544	

517	Divergent Annexin A1 expression in periphery and gut is associated with systemic immune activation and impaired gut immune response during SIV infection. 2016 , 6, 31157	5
516	Potential Pitfalls in Estimating Viral Load Heritability. 2016 , 24, 687-698	7
515	CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo. 2016 , 90, 8954-67	8
514	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. 2016 , 128, 1050-8	61
513	HIV. 2016 , 21-74	
512	Cell-to-Cell Spread of HIV and Viral Pathogenesis. 2016 , 95, 43-85	20
511	Double-stranded-RNA-specific adenosine deaminase 1 (ADAR1) is proposed to contribute to the adaptation of equine infectious anemia virus from horses to donkeys. 2016 , 161, 2667-72	6
510	Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa. 2016 , 13, 305-314	52
509	Pathogen Epidemiology. 2016 , 225-231	
508	Viral Evolution and Cytotoxic T Cell Restricted Selection in Acute Infant HIV-1 Infection. 2016 , 6, 29536	9
507	Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0. 2016 , 13, 176	12
506	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. 2016 , 95, e5094	19
505	SIV Infection Impairs the Central Nervous System in Chinese Rhesus Macaques. 2016 , 11, 592-600	7
504	Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. 2016 , 36, 377-87	4
503	Immunopharmacology. 2016 ,	3
502	Aptima HIV-1 Quant Dx--A fully automated assay for both diagnosis and quantification of HIV-1. 2016 , 77, 46-54	24
501	A comparative investigation of methods for longitudinal data with limits of detection through a case study. 2016 , 25, 153-66	9
500	Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. 2016 , 214, 379-89	4

499	Prognostic Value of HIV-1 RNA on CD4 Trajectories and Disease Progression Among Antiretroviral-Naive HIV-Infected Adults in Botswana: A Joint Modeling Analysis. 2016 , 32, 573-8	9
498	Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. 2016 , 90, 4005-4016	16
497	Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. 2016 , 3, e119-27	199
496	Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals. 2016 , 18, 346-53	0
495	HIV-1 Eradication: Early Trials (and Tribulations). 2016 , 22, 10-27	79
494	Use of broadly neutralizing antibodies for HIV-1 prevention. 2017 , 275, 296-312	101
493	Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxis. 2017 , 10, 297-309	8
492	Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria. 2017 , 23, 474-482	12
491	Demographics and natural history of HIV-1-infected spontaneous controllers of viremia. 2017 , 31, 1091-1098	19
490	The impact of dark chocolate intake on arterial elasticity in individuals with HIV/AIDS undergoing ART: a randomized, double-blind, crossover trial. 2017 , 8, 2212-2219	5
489	Cognitive function in early HIV infection. 2017 , 23, 273-282	9
488	Invited Commentary: A Landmark Study Launched in a Public Health Maelstrom. 2017 , 185, 1157-1160	3
487	Short-Sighted Virus Evolution and a Germline Hypothesis for Chronic Viral Infections. 2017 , 25, 336-348	31
486	Health-related quality of life (HRQoL) and its correlates among community-recruited children living with HIV and uninfected children born to HIV-infected parents in West Bengal, India. 2017 , 26, 2171-2180	7
485	Current diagnostic methods for HIV. 2017 , 12, 141-155	9
484	Droplet-Based Multivolume Digital Polymerase Chain Reaction by a Surface-Assisted Multifactor Fluid Segmentation Approach. 2017 , 89, 822-829	47
483	Consolidation of molecular testing in clinical virology. 2017 , 15, 387-400	10
482	Human immunodeficiency virus care cascade among sub-populations in Rakai, Uganda: an observational study. 2017 , 20, 21590	18

481	A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study. 2017 , 7, 13658	11
480	Molecular mechanisms of HIV-1 genetic diversity. 2017 , 51, 483-495	1
479	Thirty-year Perspective of the Long-term Survival, CD4 Percentage and Social Achievements of Perinatally HIV-infected Children as a Function of Their Birth Era. 2017 , 36, 198-201	5
478	Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. 2017 , 74, 126-133	21
477	Management of Newly Diagnosed HIV Infection. 2017 , 167, ITC1-ITC16	5
476	Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup. 2017 , 14, 33	8
475	Broadly neutralizing antibodies: An approach to control HIV-1 infection. 2017 , 36, 31-40	8
474	Very low level viraemia and risk of virological failure in treated HIV-1-infected patients. 2017 , 18, 196-203	11
473	Primary HIV Infection. 2017 , 846-849.e1	
472	Principles of Management of HIV in the Industrialized World. 2017 , 912-917.e2	1
471	Detection of rotavirus in clinical specimens using an immunosensor prototype based on the photon burst counting technique. 2017 , 8, 3383-3394	2
470	CD4 T Follicular Helper Cells and HIV Infection: Friends or Enemies?. 2017 , 8, 135	11
469	Effects of schistosomiasis on susceptibility to HIV-1 infection and HIV-1 viral load at HIV-1 seroconversion: A nested case-control study. 2017 , 11, e0005968	49
468	Influence of HIV virus in the hospital stay and the occurrence of postoperative complications classified according to the Clavien-Dindo classification and in comparison with the Charlson Comorbidity Index in patients subjected to urologic and general surgery operations. Our preliminary results. 2017 , 83, 125-129	4
467	Oral manifestations and their correlation to baseline CD4 count of HIV/AIDS patients in Ghana. 2017 , 43, 29-36	13
466	Molecular Testing for Human Immunodeficiency Virus. 2017 , 49-61	
465	Novel HLA class I associations with HIV-1 control in a unique genetically admixed population. 2018 , 8, 6111	17
464	Viral Characteristics Associated with the Clinical Nonprogressor Phenotype Are Inherited by Viruses from a Cluster of HIV-1 Elite Controllers. 2018 , 9,	25

463	Mechanisms of CD8 T'cell-mediated suppression of HIV/SIV replication. 2018 , 48, 898-914	40
462	Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms. 2018 , 39, 36-78	74
461	The impact of HIV-1 within-host evolution on transmission dynamics. 2018 , 28, 92-101	25
460	Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations. 2018 , 79, 166-171	1
459	Endogenous LINE-1 (Long Interspersed Nuclear Element-1) Reverse Transcriptase Activity in Platelets Controls Translational Events Through RNA-DNA Hybrids. 2018 , 38, 801-815	17
458	Discrimination of patients with different serological evolution of HIV and co-infection with HCV using metabolic fingerprinting based on Fourier transform infrared. 2018 , 11, e201700035	13
457	Immunopathogenesis of HIV-1 Infection. 2018 , 665-667.e2	
456	Remission of HIV-related naïve and high-risk Burkitt's lymphoma treated by autologous stem cell transplantation plus cART. 2018 , 9, 353	1
455	SD-chip enabled quantitative detection of HIV RNA using digital nucleic acid sequence-based amplification (dNASBA). 2018 , 18, 3501-3506	20
454	Laboratory Diagnosis of HIV-1 Infections: State of the Art. 2018 , 445-473	1
453	Relational concurrency, stages of infection, and the evolution of HIV set point viral load. 2018 , 4, vey032	5
452	Fc-gamma receptor IIA and IIIA variants in two African cohorts: Lack of consistent impact on heterosexual HIV acquisition, viral control, and disease progression. 2018 , 525, 132-142	2
451	Comparison of a new in-house HIV-1 TaqMan real-time PCR and three commercial HIV-1 RNA quantitative assays. 2018 , 59, 1-7	1
450	p24 revisited: a landscape review of antigen detection for early HIV diagnosis. 2018 , 32, 2089-2102	21
449	Molecular Microbiology. 2018 , 87-124	
448	Effect of Delayed Immune Response on the Dynamics of HIV Infection Under Multidrug Treatment. 2018 , 1	
447	CD8 Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection. 2018 , 31, 525-536	2
446	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. 2018 , 35, 27-37	19

445	Plasma HIV RNA level is associated with neurocognitive function among HIV-1-infected patients in Nigeria. 2018 , 24, 712-719	4
444	A Practical Guide to Estimating the Heritability of Pathogen Traits. 2018 , 35, 756-772	12
443	Neurologic sequelae of primary HIV infection. 2018 , 152, 65-74	7
442	Trends in Racial/Ethnic Disparities Among Patients Living with HIV in Texas, 1996 to 2013. 2018 , 5, 1023-1032	
441	Targeting the Latent Reservoir for HIV-1. 2018 , 48, 872-895	166
440	Impact of schistosome infection on long-term HIV/AIDS outcomes. 2018 , 12, e0006613	14
439	Circumcision status at HIV infection is not associated with plasma viral load in men: analysis of specimens from a randomized controlled trial. 2018 , 18, 350	
438	Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells. 2018 , 9, 811	13
437	Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC CD4 cell levels: a surrogate marker candidate of HIV-induced intestinal damage. 2018 , 21, e25144	13
436	Competing subsistence needs are associated with retention in care and detectable viral load among people living with HIV. 2018 , 17, 163-179	8
435	Contradictory results of serological confirmatory test and real-time PCR assays in diagnosis a patient of HIV-1 infection. 2018 , 74, 38-40	1
434	Non-AIDS Mortality Is Higher Among Successfully Treated People Living with HIV Compared with Matched HIV-Negative Control Persons: A 15-Year Follow-Up Cohort Study in Sweden. 2018 , 32, 297-305	19
433	Virological failure on first-line antiretroviral therapy; associated factors and a pragmatic approach for switching to second line therapy-evidence from a prospective cohort study in rural South-Western Uganda, 2004-2011. 2018 , 29, 191	13
432	Lessons learned from HIV antiretroviral treatment interruption trials. 2018 , 13, 416-421	27
431	Microfluidic-Based Nucleic Acid Amplification Systems in Microbiology. 2019 , 10,	24
430	Synergistic fungicidal activity with low doses of eugenol and amphotericin B against <i>Candida albicans</i> . 2019 , 518, 459-464	7
429	HIV-2 as a model to identify a functional HIV cure. 2019 , 16, 24	7
428	Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model. 2019 , 10,	9

427	Chagas Disease. 2019 ,	6
426	Population Structure and Implications on the Genetic Architecture of HIV-1 Phenotypes Within Southern Africa. 2019 , 10, 905	7
425	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. 2019 , 220, 1325-1334	11
424	The role of CD4 T cells in immune system activation and viral reproduction in a simple model for HIV infection. 2019 , 75, 210-222	5
423	Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. 2019 , 11,	31
422	Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen. 2019 , 30, 680-688	3
421	Introduction. 2019 , 3-15	
420	Biological Resources for Genomic Investigation in the Vervet Monkey (<i>Chlorocebus</i>). 2019 , 16-28	3
419	Savanna Monkey Taxonomy. 2019 , 31-54	1
418	The Promise of Vervet Genomics. 2019 , 55-59	
417	African Green Monkeys as a Natural Host of SIV. 2019 , 60-70	
416	The Vervet Microbiome. 2019 , 71-78	
415	Population Genetics and Savanna Monkeys. 2019 , 81-100	
414	Population Genetic Structure of Vervet Monkeys in South Africa. 2019 , 101-106	
413	Behavioral Ecology of Savanna Monkeys. 2019 , 109-126	0
412	Socioecology of Vervet Monkeys. 2019 , 127-132	
411	Biological Complexity in Primate Sociality and Health. 2019 , 133-140	
410	Predation and Food Competition in Vervet Monkeys (<i>Chlorocebus pygerythrus</i>). 2019 , 141-151	

409 Vervet Monkeys Social Learning Abilities. **2019**, 152-160

408 Life History of Savanna Monkeys. **2019**, 163-198

1

407 The Social and Thermal Competence of Wild Vervet Monkeys. **2019**, 199-207

1

406 Novelty-Seeking in Vervets: Developmental, Genetic, and Environmental Influences. **2019**, 208-216

405 Measurement of Novelty-Seeking in Wild Vervet Monkeys. **2019**, 217-223

404 Causes of Variation in the Static Allometry of Morphological Structures: A Case Study with Vervet Monkeys. **2019**, 224-232

403 Ethnoprimateology and Savanna Monkeys. **2019**, 235-243

1

402 Exploring Caribbean Green Monkeys (*Chlorocebus sabaues*) through an Ethnoprimateological Lens. **2019**, 244-254

401 Vervet Monkeys (*Chlorocebus pygerythrus*), Chimpanzees (*Pan troglodytes*), and Humans (*Homo sapiens*): Studying Interactions Using Stable Isotope Analysis. **2019**, 255-262

400 Index. **2019**, 333-342

399 Preface. **2019**, xv-xviii

398 Interaction of the Host and Viral Genome and Their Influence on HIV Disease. **2018**, 9, 720

15

397 Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis. **2019**, 15, e1006740

8

396 Nucleic acid testing and molecular characterization of HIV infections. **2019**, 38, 829-842

15

395 Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients. **2019**, 6, ofz003

22

394 Quantification of Viral RNA and DNA Positive Cells in Tissues From Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus Infected Controller and Progressor Rhesus Macaques. **2019**, 10, 2933

4

393 Schistosomiasis was not associated with higher HIV-1 plasma or genital set point viral loads among HIV seroconverters from four cohort studies. **2019**, 13, e0007886

2

392 Copy-Years Viremia and Risk of Virological Failure in Long-Term-Treated HIV Patients. **2019**, 80, 423-428

2

391	[Physiopathology of HIV-2 infection]. 2019 , 23, 277-291	1
390	Dimorphism in the T-cell receptor constant region affects T-cell function, phenotype and HIV outcome. 2019 , 33, 1421-1429	2
389	Sexual role and HIV-1 set point viral load among men who have sex with men. 2019 , 26, 68-76	3
388	HIV peptidome-wide association study reveals patient-specific epitope repertoires associated with HIV control. 2019 , 116, 944-949	12
387	Modern Human Immunodeficiency Virus Therapy: Progress and Prospects. 2019 , 105, 61-70	9
386	A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy. 2019 , 57,	18
385	Multidrug Therapy for HIV Infection: Dynamics of Immune System. 2019 , 67, 129-147	
384	Spectrophotometric ellipsometry based Tat-protein RNA-aptasensor for HIV-1 diagnosis. 2020 , 227, 117748	17
383	Scientific Advances in the Diagnosis of Emerging and Reemerging Viral Human Pathogens. 2020 , 93-120	2
382	HLA Heterozygote Advantage against HIV-1 Is Driven by Quantitative and Qualitative Differences in HLA Allele-Specific Peptide Presentation. 2020 , 37, 639-650	26
381	A packaged intervention to improve viral load monitoring within a deeply rural health district of South Africa. 2020 , 20, 836	3
380	SARS-CoV-2 viral load is associated with increased disease severity and mortality. 2020 , 11, 5493	360
379	Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in Blood of Patients With Coronavirus Disease 2019 (COVID-19): What Does It Mean?. 2021 , 73, e2898-e2900	8
378	HSV-2 Infection as a Potential Cofactor for HIV Disease Progression and Selection of Drug Resistance Mutations in Adults under WHO-Recommended First-Line Antiretroviral Therapy: A Multicentric, Cross-Sectional Study in Cameroon, Central African Republic, Chad, and Gabon. 2020 ,	1
377	Delineation of Homeostatic Immune Signatures Defining Viremic Non-progression in HIV-1 Infection. 2020 , 11, 182	4
376	Protein Arginine -methyltransferases 5 and 7 Promote HIV-1 Production. 2020 , 12,	6
375	Koala retrovirus viral load and disease burden in distinct northern and southern koala populations. 2020 , 10, 263	16
374	Development and application of multiscale models of acute viral infections in intervention research. 2020 , 43, 3280-3306	3

373	Systemic Expression of a Viral RdRP Protects against Retrovirus Infection and Disease. 2020 , 94,	4
372	Resource utilization across the continuum of HIV care: An emergency department-based cohort study. 2021 , 43, 164-169	
371	Biomarkers for the clinical development of antiviral therapies. 2021 , 100, 19-32	
370	Correlation between Cepheid GeneXpert and Abbott M2000 assays for HIV viral load measurements. 2021 , 32, 444-448	0
369	. 2021 , 9, 104405-104417	6
368	Necrotizing periodontal diseases in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: A review. 2021 , 67, 101168	0
367	An assessment of the reproducibility of reverse transcription digital PCR quantification of HIV-1. 2021 ,	6
366	Multi-omics analyses reveal that HIV-1 alters CD4 T cell immunometabolism to fuel virus replication. 2021 , 22, 423-433	16
365	HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana. 2021 , 13,	0
364	Characteristics of the MACS/WIHS Combined Cohort Study: Opportunities for Research on Aging With HIV in the Longest US Observational Study of HIV. 2021 , 190, 1457-1475	12
363	HIV Care Prioritization Using Phylogenetic Branch Length. 2021 , 86, 626-637	3
362	Contribution of the classical polymerase chain reaction in the diagnosis of a HIV-1 infected patient in Benin: a case report. 2021 , 18, 18	
361	Psychosocial Stress Alters the Immune Response and Results in Higher Viral Load During Acute SIV Infection in a Pigtailed Macaque Model of HIV. 2021 ,	3
360	CD8 T-Cell Mediated Control of HIV-1 in a Unique Cohort With Low Viral Loads. 2021 , 12, 670016	1
359	A retrospective analysis of neglected HIV-1 patients with middle-level viremia in Central China based on current policy. 2021 , 16, 347-351	0
358	Biosensing strategies for the electrochemical detection of viruses and viral diseases - A review. 2021 , 1159, 338384	13
357	Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection. 2021 , 95, e0001621	2
356	REGEN-COV Antibody Cocktail in Outpatients with Covid-19.	8

355	Lessons from a local effort to screen for SARS-CoV-2. 2021 , 118,	1
354	Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse. 2021 , 4, 664	3
353	Influence of NKG2C Genotypes on HIV Susceptibility and Viral Load Set Point. 2021 , 95, e0041721	1
352	SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR. 2021 , 23, 907-919	6
351	TRIM22 genotype is not associated with markers of disease progression in children with HIV-1 infection. 2021 , 35, 2445-2450	
350	Encyclopedia of Medical Anthropology. 2004 , 23-30	20
349	A Fast and Sensitive Integrated Young Interferometer Biosensor. 2009 , 265-295	2
348	Nucleic Acid Amplification Assays for Sexually Transmitted Diseases. 1997 , 201-232	2
347	Branched DNA (bDNA) Technology for Direct Quantification of Nucleic Acids: Design and Performance. 1998 , 205-223	1
346	COBAS [®] AmpliPrep/COBAS [®] TaqMan [®] HIV-1 Test, Version 2.0. 2012 , 123-140	1
345	HIV viral load monitoring. 1999 , 458, 199-212	2
344	Antiretroviral therapy in primary HIV. 1999 , 458, 223-7	1
343	Remarks on Modeling Host-Viral Dynamics and Treatment. 2002 , 287-308	4
342	Complementary and alternative medicine during HIV infection. 2004 , 546, 105-10	1
341	Immune system modulation by helminth infections: potential impact on HIV transmission and disease progression. 2014 , 828, 131-49	1
340	Human Immunodeficiency Virus Infection. 2008 , 307-339	3
339	Overview of molecular biological methods for the detection of pathogens causing sexually transmitted infections. 2012 , 903, 1-20	1
338	Mathematical Modeling of HIV-1 Infection and Drug Therapy. 2008 , 87-131	5

337	The Clinical Spectrum of HIV Infection. 2001 , 19-25	1
336	Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection. 2010 , 1635-1661	1
335	General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including the Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases). 2010 , 1705-1725	2
334	Hepatitis C. 2010 , 2157-2185	4
333	HIV Dynamics. 1999 , 59-74	2
332	Quantitative Science. 2005 , 58-89	1
331	The Evolution of Comprehensive AIDS Clinical Care. 2005 , 261-285	1
330	HIV VACCINES: MILESTONES AND NEW INSIGHTS. 2000 , 421-457	2
329	Human immunodeficiency virus vaccines. 2008 , 1213-1251	1
328	Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in the Infant. 2011 , 622-660	3
327	Diseases of the Immune System. 2010 , 183-257	4
326	Savanna Monkeys: The Genus <i>Chlorocebus</i> . 2019 ,	6
325	Connectivity and HIV-1 infection: role of CD4(+) T-cell counts and HIV-1 RNA copy number. 2000 , 52, 618-27	10
324	Eruption of human immunodeficiency virus seroconversion. 1998 , 37, 436-8	2
323	Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. 2001 , 98, 597-602	21
322	Human immunodeficiency virus-associated dementia: An evolving disease. 2003 , 9, 205	20
321	Kaposi's sarcoma-associated herpesvirus and sexual transmission of cancer risk. 1999 , 11, 508-15	17
320	Comparison of three commercial assays for the quantification of plasma HIV-1 RNA from individuals with low viral loads. 1999 , 13, 1977-8	9

319	Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 x 10(6)/l. 2001 , 15, 131-3	7
318	Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. 2001 , 15, 1181-3	704
317	Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. 2002 , 16, 791-3	22
316	Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. 2000 , 38, 404-10	80
315	Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. 1997 , 16, 205-11	17
314	Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. 1998 , 17, 18-23	27
313	Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. 1998 , 17, 495-9	38
312	Effect of superimposed infections on viral replication in human immunodeficiency virus type 1-infected children. 1998 , 17, 755-7	11
311	Growth hormone exerts potent anabolic effects in an adolescent with human immunodeficiency virus wasting. 1999 , 18, 167-9	9
310	Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children. 1999 , 18, 512-6	17
309	Detection of low HIV-1 RNA levels in plasma. 1997 , 14, 179-83	127
308	CD4+ T-lymphocyte counts in HIV infection: are European standards applicable to African patients?. 1997 , 14, 361-7	45
307	Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline. 1997 , 14, 408-14	11
306	Survival after AIDS-defining events in patients with 1997, 14, 459-64	1
305	Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. 1997 , 15, 49-53	13
304	A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease. 1997 , 15, 283-8	8
303	HIV viral load and CD4+ lymphocyte counts in subjects coinfectd with HTLV-I and HIV-1. 1997 , 15, 308-11	33
302	Survival after AIDS diagnosis in a cohort of hemophilia patients. Multicenter Hemophilia Cohort Study. 1997 , 15, 363-9	8

301	HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. 1997 , 16, 10-4	37
300	HIV-2 genetic variation and DNA load in asymptomatic carriers and AIDS cases in Guinea-Bissau. 1997 , 16, 31-8	27
299	Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. 1997 , 16, 93-9	38
298	Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. 1997 , 16, 318-26	61
297	Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2. 2021 , 16, 3-10	1
296	Specific passage of simian immunodeficiency virus from end-stage disease results in accelerated progression to AIDS in rhesus macaques. 1999 , 80 (Pt 12), 3089-3097	22
295	The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus. 1999 , 80 (Pt 9), 2375-2382	5
294	Effects of recombinant ovine interferon-tau on ovine lentivirus replication and progression of disease. 2000 , 81, 525-32	12
293	The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques. 2000 , 81, 1719-26	13
292	Destruction of primary CD4(+) T cells by cell-cell interaction in human immunodeficiency virus type 1 infection in vitro. 2000 , 81, 1907-1911	12
291	A complex human immunodeficiency virus type 1 A/G/J recombinant virus isolated from a seronegative patient with AIDS from Benin, West Africa. 2001 , 82, 1095-1106	17
290	Gender-related differences in susceptibility, early virus dissemination and immunosuppression in mice infected with Friend murine leukaemia virus variant FIS-2. 2001 , 82, 1821-1827	12
289	In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo. 2001 , 82, 2225-2234	21
288	Curtailing the AIDS pandemic. <i>Science</i> , 1997 , 276, 1955-7	33.3 4
287	Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine. <i>Science</i> , 2001 , 292, 69-74	33.3 90
286	Molecular Microbiology. 54-90	4
285	Human Immunodeficiency Viruses. 1436-1457	2
284	A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. 1998 , 42, 269-76	226

283	Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. 1998 , 42, 358-61	12
282	Immunological markers of disease progression in patients infected with the human immunodeficiency virus. 1997 , 4, 474-7	11
281	Variables that affect assays for plasma cytokines and soluble activation markers. 1999 , 6, 89-95	118
280	Current concepts in human immunodeficiency virus infection and AIDS. 1999 , 6, 295-305	11
279	Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. 1999 , 67, 5258-64	32
278	Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay. 1997 , 35, 2740-4	21
277	Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. 1998 , 36, 2964-9	105
276	Evaluation of the Nuclisens HIV-1 QT assay for quantitation of human immunodeficiency virus type 1 RNA levels in plasma. 1998 , 36, 3372-4	25
275	Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy. 1998 , 36, 3392-5	31
274	Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups. 1998 , 36, 3647-52	14
273	Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. 1998 , 36, 493-8	32
272	Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. 1998 , 36, 716-20	69
271	Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma. 1998 , 36, 835-9	39
270	Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. 1998 , 36, 1056-63	6
269	Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. 1998 , 36, 1070-3	39
268	Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics. 1998 , 36, 1471-9	63
267	Use of multiple competitors for quantification of human immunodeficiency virus type 1 RNA in plasma. 1998 , 36, 1864-70	7
266	Quantification of human immunodeficiency virus type 1 RNA levels in plasma by using small-volume-format branched-DNA assays. 1998 , 36, 2096-8	11

265	Comparison of NucliSens and Amplicor monitor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Côte d'Ivoire. 1998 , 36, 2495-8	35
264	Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1. 1999 , 37, 110-6	101
263	Detection of human immunodeficiency virus type 1 nucleocapsid protein p7 in vitro and in vivo. 1999 , 37, 63-7	6
262	Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. 1999 , 37, 333-8	9
261	Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay. 1999 , 37, 453-6	23
260	Reproducibility and performance of the second-generation branched-DNA assay in routine quantification of human immunodeficiency virus type 1 RNA in plasma. 1999 , 37, 812-4	13
259	Comparison of cytomegalovirus loads in plasma and leukocytes of patients with cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. 1999 , 37, 1431-5	21
258	Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target. 1999 , 37, 1813-8	31
257	Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. 1999 , 37, 2557-63	110
256	Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. 2000 , 38, 323-6	27
255	Quality of human immunodeficiency virus viral load testing in Australia. 2000 , 38, 4015-20	16
254	Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. 2000 , 38, 4034-41	80
253	Comparative evaluation of two branched-DNA human immunodeficiency virus type 1 RNA quantification assays with lower detection limits of 50 and 500 copies per milliliter. 2000 , 38, 914-7	8
252	Simultaneous detection of multiplex-amplified human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA using a flow cytometer microsphere-based hybridization assay. 2000 , 38, 1066-71	46
251	Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. 2000 , 38, 1247-9	51
250	Quantitative molecular analysis of virus expression and replication. 2000 , 38, 2030-6	30
249	Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. 2000 , 38, 2688-95	122
248	Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. 2000 , 38, 2837-45	41

247	Fluorescence-based quantitative methods for detecting human immunodeficiency virus type 1-induced syncytia. 2000 , 38, 3055-60	18
246	Quantitative competitive reverse transcription-PCR for quantification of dengue virus RNA. 2000 , 38, 3306-10	36
245	Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. 1996 , 70, 7285-9	22
244	Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. 1996 , 70, 7603-13	64
243	Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. 1996 , 70, 9035-40	26
242	Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. 1997 , 71, 284-90	187
241	Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. 1997 , 71, 7478-87	495
240	Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. 1997 , 71, 7498-508	146
239	Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. 1997 , 71, 7518-25	226
238	Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. 1997 , 71, 8141-8	94
237	The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. 1997 , 71, 9508-14	196
236	Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. 1997 , 71, 1911-21	116
235	The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable. 1997 , 71, 3641-51	34
234	Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. 1997 , 71, 4284-95	107
233	Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. 1997 , 71, 4479-84	106
232	Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease. 1997 , 71, 4694-706	33
231	High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. 1997 , 71, 6271-5	182
230	A lymph node-derived cytopathic simian immunodeficiency virus Mne variant replicates in nonstimulated peripheral blood mononuclear cells. 1998 , 72, 245-56	26

229	Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. 1998 , 72, 7772-84	63
228	Mortality among human immunodeficiency virus type 2-positive villagers in rural Guinea-Bissau is correlated with viral genotype. 1998 , 72, 7895-9	17
227	A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. 1998 , 72, 10281-5	134
226	Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. 1998 , 72, 1552-76	166
225	Extensive diversification of human immunodeficiency virus type 1 subtype B strains during dual infection of a chimpanzee that progressed to AIDS. 1998 , 72, 3005-17	37
224	Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. 1998 , 72, 3872-86	204
223	Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia. 1998 , 72, 6482-9	14
222	Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. 1999 , 73, 362-7	67
221	Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. 1999 , 73, 618-30	42
220	Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats. 1999 , 73, 1518-27	19
219	Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. 1999 , 73, 4393-403	172
218	Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. 1999 , 73, 4829-39	103
217	Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. 1999 , 73, 7027-30	88
216	Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART. 2020 , 5,	24
215	Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. 1998 , 101, 497-502	157
214	The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. 1997 , 99, 1546-54	199
213	Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo. 1997 , 99, 2565-7	60
212	Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. 2004 , 113, 836-45	32

211	Turnover of lymphocytes and conceptual paradigms in HIV infection. 2003 , 112, 821-4	98
210	Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. 2004 , 113, 836-845	39
209	Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. 1998 , 101, 2559-66	130
208	Understanding the benign nature of SIV infection in natural hosts. 2007 , 117, 3148-54	157
207	Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. 2009 , 119, 3556-72	312
206	HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. 1999 , 104, R13-8	179
205	Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. 2000 , 105, 777-82	27
204	Elevated Levels of Serum-Soluble CD14 in Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Correlation to Disease Progression and Clinical Events. 1998 , 92, 2084-2092	49
203	Rapid Telomere Shortening in Children. 1999 , 93, 2824-2830	119
202	Rapid Telomere Shortening in Children. 1999 , 93, 2824-2830	32
201	Micronutrient Interventions and the Hiv Pandemic. 2001 , 219-245	1
200	Large Variations in HIV-1 Viral Load Explained by Shifting-Mosaic Metapopulation Dynamics. 2016 , 14, e1002567	11
199	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. 2017 , 15, e2001855	21
198	Effect of the Latent Reservoir on the Evolution of HIV at the Within- and Between-Host Levels. 2017 , 13, e1005228	14
197	HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. 2008 , 3, e3636	65
196	HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. 2010 , 5, e10148	39
195	Recent HIV-1 infection: identification of individuals with high viral load setpoint in a voluntary counselling and testing centre in rural Mozambique. 2012 , 7, e31859	5
194	Identification of a cluster of HIV-1 controllers infected with low replicating viruses. 2013 , 8, e77663	15

193	CD4 and viral load dynamics in antiretroviral-naïve HIV-infected adults from Soweto, South Africa: a prospective cohort. 2014 , 9, e96369	16
192	Rapid HIV-1 Disease Progression in Individuals Infected with a Virus Adapted to Its Host Population. 2016 , 11, e0150397	11
191	Altered Immune Cytokine Expression Associated with KoRV B Infection and Season in Captive Koalas. 2016 , 11, e0163780	27
190	Cigarette smoking is associated with high HIV viral load among adults presenting for antiretroviral therapy in Vietnam. 2017 , 12, e0173534	11
189	Mother-to-child transmission of HIV-1: the role of HIV-1 variability and the placental barrier. 2001 , 48, 545-73	5
188	Primate models for human immunodeficiency virus infection. Evolution of receptor use during pathogenesis. 2004 , 51, 1-29	4
187	Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naïve HIV-infected individuals with CD4 cell counts between 50 and 250/mm ³ . 2000 , 42, 27-36	7
186	Asymptomatic oral carriage of <i>Candida</i> species in HIV-infected patients in the highly active antiretroviral therapy era. 2006 , 48, 257-61	31
185	Immune response in cervical dysplasia induced by human papillomavirus: the influence of human immunodeficiency virus-1 co-infection -- review. 2005 , 100, 1-12	22
184	Preparation and Evaluation of Ribonuclease-Resistant Viral HIV RNA Standards Based on Armored RNA Technology. 2018 , 22, 394-400	2
183	Low-cost assays for monitoring HIV infected individuals in resource-limited settings. 2011 , 134, 823-34	12
182	Oral lesions: A true clinical indicator in human immunodeficiency virus. 2011 , 2, 145-50	15
181	Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus Type 1 Infection. 2007 , 50, 316	2
180	Impact of viral load testing on patient care. 1999 , 123, 1011-4	4
179	Diagnosing emerging and reemerging infectious diseases: the pivotal role of the pathologist. 2011 , 135, 83-91	20
178	HIV-1 DNA predicts disease progression and post-treatment virological control. 2014 , 3, e03821	210
177	Two-sample functional linear models with functional responses. 2022 , 218, 85-105	
176	Long-Term Non-Progressive HIV Infection. 2000 , 65-75	

175 The Identification of Genes for Complex Genetic Diseases. **2000**, 35-41

174 Effekte verschiedener antiretroviraler Therapien [Ergebnisse einer Langzeitübersicht bei 843 AIDS-Patienten der Jahre 1987-1998. **2000**, 240-246

173 The Role of Cytokines and Chemokines in HIV Disease at the Verge of the New Millennium. **2000**, 29-35

172 Considerations in the Management of HIV Infection in Patients Undergoing Antineoplastic Chemotherapy. **2000**, 281-330

171 HIV Viral Load. **2000**, 261-272

170 Prognostic Markers and Immunological Reconstitution During HIV-1 Infection. **2000**, 243-259

169 Simultaneous Quantification and Localization of HIV gag-pol Expression Using Ultrasensitive Fluorescence In Situ Hybridization. **2000**, 135-142

168 HIV Infection, Immunity and Cancer. **2000**, 11-23

167 Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. **2000**, 95, 48-55

166 Biological Variability of HIV-1. **2000**, 41-54

165 Die antiretrovirale Therapie des HIV-infizierten Kindes. **2000**, 283-288

164 Antioxidants in Human AIDS. **2000**, 15-22

163 Nutrition and HIV Infection/AIDS in Sub-Saharan Africa. **2000**, 175-192

162 Compositional specificity of human T-cell leukemia virus type I and human immunodeficiency virus type 1 integration into the human genome. **2000**, 16, 547-558

161 Host Response. **2001**, 44-67

160 Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. **2001**, 85-100

159 Virus population dynamics, fitness variations and the control of viral disease: an update. **2001**, 57, 77-115

29

158 HIV in America, 1981 to 2000: Therapeutic and Epidemiologic Considerations. **2001**, 9-17

- 157 Rationale and Strategies for Antiretroviral Therapy in HIV-1 Infection. **2001**, 295-315
- 156 Therapie. **2001**, 29-93
- 155 HIV Infection in Women. **2001**, 185-202 0
- 154 Viral load test reports: a description of content from a sample of US laboratories. **2001**, 125, 1546-54
- 153 Human immunodeficiency virus. **2002**, 251-260
- 152 AIDS/HIV and Neurological Disease. **2003**, 66-76
- 151 Immunology and Infection in Space.
- 150 Results of a physician survey on ordering viral load testing. Opportunity for laboratory consultation. **2003**, 127, 446-50 1
- 149 Understanding the cause of AIDS [The biology of viruses. **2003**, 31-36
- 148 Comparison Of Viral Trajectories In Aids Studies By Using Nonparametric Mixed-Effects Models. **2003**, 2, 443-450
- 147 LABORATORY MARKERS ASSOCIATED WITH PROGRESSION OF HIV INFECTION. **2004**, 22, 7-15 3
- 146 Sex and Gender-Specific Issues in HIV Pathogenesis. **2004**, 923-930 1
- 145 Antiinfektive Therapie. **2004**, 75-207
- 144 Highly active antiretroviral treatment (HAART) of pediatric HIV-1 infection. **2004**, 141-157
- 143 Treating primary HIV infection--is your HAART in it?. **2004**, 1, 131-5
- 142 Erworbenes Immunschw chesyndrom (Aids). **2004**, 542-604
- 141 HIV-1 and HIV-2: Molecular Diagnosis. **2004**, 661-665
- 140 Mucosal Immunity and Vaccines Against Simian Immunodeficiency Virus and Human Immunodeficiency Virus. **2005**, 937-957 1

139 Immunobiology of Mucosal HIV-1 Infection * *This work was supported by National Institutes of Health grants DK-47322, HD-41361, and DK-64400 and the Research Service of the Department of Veterans Affairs.. **2005**, 1199-1211

138 Viral Responses HIV-1. **2005**, 578-586

137 Virology. **2005**, 13-35

136 Correlations between Apoptosis and HIV Disease Progression. **2005**, 355-379

135 Impairment of HIV-Specific Immune Effector Cell Function. **2005**, 185-203

134 Lentiviral Biology and Cell Death. **2005**, 3-19

133 HIV-1 Reservoirs and Residual Viral Replication during Highly Active Antiretroviral Therapy. **2005**, 457-474

132 HIV and AIDS. **2006**, 969-990

131 HIV and AIDS. **2006**, 969-990

130 Retinal Disease in HIV-infected Patients. **2006**, 1625-1672

129 HLA and HIV Infection Progression: Application of the Minimum Description Length Principle to Statistical Genetics. **2006**, 1-12

128 Human Immunodeficiency Virus Type 1. **2007**, 399-410

127 Infections of the Nervous System. **2008**, 1529-1553

126 Acquired Immune Deficiency Syndrome. **2008**, 171-201

125 Future of HIV/AIDS Care in Low- and Middle- Income Countries. **2008**, 41-69

124 Neurocognitive Changes in AIDS: Evolution of Treatment of HIV Infection. **2009**, 1-8

123 Human Immunodeficiency Virus. **2009**, 47-68

122 VIRAL LABORATORY DIAGNOSIS. **2009**, 3526-3546

121 Human Immunodeficiency Virus Type 1. **2009**, 41-52

120 HIV/AIDS and Opportunistic Illnesses. **2009**, 373-401

o

119 HIV and the acquired immunodeficiency syndrome. **2009**, 701-708

118 Interpreting the Results of Clinical Trials of Antimicrobial Agents. **2010**, 687-698

117 The immunopathogenesis of HIV-1 infection. **2010**, 944-953

116 Primary HIV infection. **2010**, 954-957

115 Principles of management of HIV in the developed world. **2010**, 1026-1032

114 Molecular Microbiology. **2011**, 27-59

7

113 Human Immunodeficiency Viruses *. **2011**, 1302-1322

112 Chapter 12:Managing the HIV Epidemic in the Developing World [Progress and Challenges. **2011**, 322-365

111 Molecular Detection and Characterization of HIV-1. **2011**, 541-556

110 Litigations for HIV Related Complications. **2011**, 233-247

109 T Cell Responses During Human Immunodeficiency Virus (HIV)-1 Infection. **2012**, 141-169

108 Infektionen. **2012**, 483-550

107 Guidelines for the quantification of HIV and HCV in small volume whole blood samples. **2012**, 903, 35-50

106 Urologic Aspects of AIDS and HIV Infection. **2012**, 417-435.e5

o

105 Care of the Adult HIV-Infected Patient. **2012**, 248-260

104 Immunopathogenesis of HIV-1 Infection. **2012**, 648-650.e2

103 Molecular Methods in Diagnosis and Monitoring of Infectious Diseases. **2012**, 1309-1337

102 Introduction. **2013**, 1-36

101 HIV Population Dynamics. **2013**, 305-325

100 To the Barricades: the Molecular Revolution. **2013**, 293-338

99 Current Topics in Sexually Transmitted Infections. **2013**, 72, 146-149

98 Diversity of trends of viremia and T-cell markers in experimental acute feline immunodeficiency virus infection. **2013**, 8, e56135

97 The Development of Unconventional Extrathymic Activated CD4+CD8+ T Cells in Chagas Disease. **2013**, 2013, 1-11

96 HIV and acquired immunodeficiency syndrome. **2014**, 710-715.e1

95 HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. **1997**, 89-102

94 The role of viral dynamics in the pathogenesis of HIV disease and implications for antiviral therapy. **1997**, 15-31

93 Human immunodeficiency virus (HIV) RNA quantitation using the Amplicor HIV-1 Monitor test: not all yellow-top tubes are suitable for blood collection. **1997**, 35, 1040

92 Dysregulation of Membrane-Bound Tumor Necrosis Factor- α and Tumor Necrosis Factor Receptors on Mononuclear Cells in Human Immunodeficiency Virus Type 1 Infection: Low Percentage of p75-Tumor Necrosis Factor Receptor Positive Cells in Patients With Advanced Disease and High Viral Load. **1997**, 20, 2670-2678

91 Aids und HIV-Infektion [internistische Therapie und Diagnostik]. **1998**, 1-70

90 HIV Gene Therapy: Current Status and Its Role in Therapy. **1998**, 91-101

89 G. **1998**, 331-439

88 Branched DNA (bDNA) Technology for Direct Quantification of Nucleic Acids: Research and Clinical Applications. **1998**, 327-342

87 Die kindliche HIV-Infektion. **1998**, 126-154

86 Therapie. **1998**, 25-53

- 85 Update der antiretroviralen Therapie der HIV-Infektion. **1998**, 24-29
- 84 Strategies of Antiretroviral Therapy in Adults. **1998**, 3, 111-118
- 83 Current Surgical Management of the Immunocompromised Patient. **1998**, 10, 445-455
- 82 Strategies for second-line antiretroviral therapy in adults with HIV infection. **1999**, 458, 239-66 2
- 81 Estimating and Predicting the Number of Free HIV and T Cells by Nonlinear Kalman Filter. **1999**, 115-143
- 80 HIV-Infektion als Beispiel einer erworbenen Immunmangelerkrankung. **1999**, 3-39
- 79 Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients. **1999**, 6, 369-76
- 78 References. 443-629
- 77 Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection. **2015**, 1483-1502.e8
- 76 Infektionen. **2015**, 505-575
- 75 Hematopoietic cell transplantation for HIV-related lymphomas. 217-232
- 74 Acquired Immune Deficiency Syndrome. **2016**, 293-330
- 73 Molecular Methods for Identification of Cultured Microorganisms. 12.3.1.1-12.3.13.6
- 72 The Role of Early Life Programming in Vulnerability and Resilience in Relation to HIV. **2017**, 229-256
- 71 Human Immunodeficiency Virus (HIV). 1-10 1
- 70 Current diagnostic methods for HIV. fvl-2016-9999
- 69 Care of HIV Patients. **2018**, 97-116
- 68 Futuristic Methods for Determining HIV Co-receptor Use. **2019**, 625-663

- 67 Chagas Disease in Immunosuppressed Patients. **2019**, 265-296
- 66 Relationships Between HIV-Mediated Chemokine Coreceptor Signaling, Cofilin Hyperactivation, Viral Tropism Switch and HIV-Mediated CD4 Depletion. **2019**, 17, 388-396 1
- 65 Single Nucleotide Polymorphisms in Tumor Necrosis Factor- β and Susceptibility to HIV Infection in Local Population of Lahore Pakistan. **2020**, 41-47
- 64 The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. **2021**, 35, 783-789 0
- 63 Providing Universal Access While Avoiding Antiretroviral Resistance: Ethical Tensions in HIV Treatment. **2020**, 37-54 1
- 62 HIV-1 Vaccine Testing, Trial Design, and Ethics. **2002**, 612-630
- 61 HIV-Infektion. **2006**, 301-315
- 60 Assessing Drug Resistance in HIV Infection Using Viral Load Using Segmented Regression. **2007**, 289-304
- 59 HIV and the Mucosa: No Safe Haven. **2008**, 459-481
- 58 Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. **2003**, 169, 656-61 117
- 57 The new antiretroviral "cocktails": is the stage set for HIV-positive women to benefit?. **1998**, 158, 339-41
- 56 Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group. **1998**, 158, 496-505 10
- 55 Determining the number of copies of HIV-1 RNA in plasma: applying this new test to management of patients. **1997**, 167, 35
- 54 Combination therapy for HIV disease. **1997**, 167, 346-7
- 53 A randomized double-blind study of the effect of distant healing in a population with advanced AIDS. Report of a small scale study. **1998**, 169, 356-63 74
- 52 Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study. **2010**, 7, 11 4
- 51 Profile of candidiasis in HIV infected patients. **2012**, 4, 204-9 39
- 50 Alcohol's role in HIV transmission and disease progression. **2010**, 33, 203-18 57

49	Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers. 2017 , 90, 245-259	35
48	A multi-center study comparing the analytical sensitivity and clinical concordance of three HIV-1 viral load assays. 2021 , 300, 114373	0
47	So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.. 2022 , 14,	0
46	Cure and Long-Term Remission Strategies.. 2022 , 2407, 391-428	1
45	HIV vaccines: progress to date. 2011 , 71, 387-414	35
44	Sympathetic Nerves and Innate Immune System in the Spleen: Implications of Impairment in HIV-1 and Relevant Models.. 2022 , 11,	
43	The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.. 2022 , 13, 763039	2
42	Clinical and Laboratory Outcomes in HIV-1 and HTLV-1/2 Coinfection: A Systematic Review.. 2022 , 10, 820727	0
41	Does HIV-1 virulence matter in the ART era?. 2022 , 3, 217-219	
40	An HIV-1 Positive Woman Without Usual Immunodeficiency. 2021 , 16,	
39	Data_Sheet_1.pdf. 2020 ,	
38	Table_1.docx. 2019 ,	
37	Data_Sheet_1.PDF. 2019 ,	
36	image_1.PDF. 2018 ,	
35	Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies.. 2022 , 13, 862270	3
34	Innate immune surveillance of the circulation: A review on the removal of circulating virions from the bloodstream.. 2022 , 18, e1010474	1
33	Primary HIV Infection. 1999 , 4, 13-18	4
32	Management of Antiretroviral Therapy for HIV Infection: Modelling when to Change Therapy. 1998 , 3, 147-158	11

31	A Rational Approach to the Selection and Sequencing of Nucleoside/Nucleotide Analogues: A New Paradigm. 2001 , 6, 45-54	9
30	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. 2003 , 8, 127-136	18
29	Shifts in Cell-Associated HIV-1 Rna but Not in Episomal HIV-1 Dna Correlate with New Cycles of HIV-1 Infection in vivo. 2003 , 8, 97-104	14
28	Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings. 2003 , 8, 379-384	6
27	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. 2006 , 11, 305-314	5
26	Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. 2009 , 14, 433-442	30
25	Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. 2005 , 10, 41-52	8
24	Natural Killer Cells in Antibody Independent and Antibody Dependent HIV Control. 2022 , 13,	1
23	Accelerated aging with HIV begins at the time of initial HIV infection. 2022 , 25, 104488	0
22	Molecular Diagnostics. 2010 ,	
21	The COVID misinfodemic: not new, never more lethal. 2022 ,	1
20	The performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis. 2022 , 19, e1004076	0
19	Immune restoration affects 10-year survival in people living with HIV / AIDS.	1
18	Using Standards and Controls in Molecular Assays for Infectious Diseases. 2001 , 6, 335-345	0
17	Functional cure of a chronic virus infection by shifting the virus - host equilibrium state. 13,	1
16	Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression. 2022 , 10, 2172	0
15	ANTIRETROVIRAL THERAPY. 1997 , 24, 531-560	0
14	HIV/AIDS. 1997 , 24, 479-496	0

- 13 Pathophysiology of HIV and strategies to eliminate AIDS as a public health threat. **2023**, 339-376 o
- 12 To the BarricadesTHE MOLECULAR REVOLUTION. **2022**, 245-283 o
- 11 Immunopathogenesis of HIV-1 Infection. **2023**, 684-686.e2 o
- 10 Accidental Injuries by HIV-Contaminated Instruments in Health Provider or Research Environments: Can Seroconversion be Prevented?. **2000**, 66, 14-21 2
- 9 A large population sample of African HIV genomes from the 1980s reveals a reduction in subtype D over time associated with propensity for CXCR4 tropism. **2022**, 19, o
- 8 Norepinephrine Accelerates HIV Replication Via Protein Kinase A-Dependent Effects on Cytokine Production. **1998**, 161, 610-616 3o
- 7 Conserved CTL Epitopes Shared Between HIV-Infected Human Long-Term Survivors and Chimpanzees. **1999**, 162, 2308-2314 6
- 6 Signaling Through the Lymphotoxin- α Receptor Stimulates HIV-1 Replication Alone and in Cooperation with Soluble or Membrane-Bound TNF- α **1999**, 162, 6016-6023 2
- 5 Deep-sequencing of viral genomes from a large and diverse cohort of treatment-naïve HIV-infected persons shows associations between intrahost genetic diversity and viral load. **2023**, 19, e1010756 o
- 4 Changing roles of CD3+CD8low T cells in combating HIV-1 infection. Publish Ahead of Print, o
- 3 Roadmap for Achieving Universal Antiretroviral Treatment. **2023**, 63, 99-117 o
- 2 Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies. **2023**, 97, o
- 1 The Multifaceted Role of Annexin A1 in Viral Infections. **2023**, 12, 1131 o